Bicyclic heteroaryl sulfane diimine derivatives as inhibitors of the ectonucleotide pyrophosphatase phosphodiesterase 1
By developing bicyclic heteroarylthione diimine derivative compounds to inhibit ENPP1 enzyme activity, the problem of poor inhibition effect of ENPP1 enzyme activity in the prior art has been solved, and effective treatment of cancer, inflammatory diseases and metabolic diseases has been achieved.
Patent Information
- Application Number
- CN202580025229.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-03-25
- Filing Date
- 2025-03-24
- Publication Date
- 2026-11-17
AI Technical Summary
Existing technologies are unable to effectively inhibit the activity of exonucleotide pyrophosphatase 1 (ENPP1), resulting in poor treatment outcomes for related diseases such as cancer, inflammatory diseases, metabolic diseases, and viral infections.
A class of bicyclic heteroarylthione diimine derivatives were developed, which can be used to prepare pharmaceutical compositions for the treatment of related diseases by inhibiting ENPP1 enzyme activity.
It enhances the immune response to cancer cells and viral infections, alleviates viral infections, and effectively treats ENPP1-related diseases, including cancer, inflammatory diseases, and metabolic diseases.
Smart Images

Figure SMS_1 
Figure SMS_3 
Figure SMS_5
Abstract
Description
Cross Reference to Related Applications
[0001] This application claims priority to U.S. Provisional Application No. 63 / 569,614, filed March 25, 2024, which is hereby incorporated by reference in its entirety for all purposes.
[0002] Statement as to Federally Sponsored Research and Development Not Applicable Reference to “Sequence Listing,” Table, or Computer Program Attached as an Electronic Fi le Not Applicable TECHNICAL FIELD
[0003] The present disclosure provides certain bicyclic heteroarylsulfane diimine compounds that inhibit the ectonucleotide pyrophosphatase / phosphodiesterase 1 (ENPP1) enzyme activity and are therefore useful in the treatment of diseases treatable by inhibition of ENPP1. Also provided are pharmaceutical compositions containing such compounds and methods for preparing such compounds. BACKGROUND
[0004] ENPP1 is an enzyme found in a wide range of tissues and cell types, including lymphocytes, macrophages, liver, brain, heart, kidney, vascular smooth muscle cells, and chondrocytes. ENPP1 hydrolyzes ATP and other nucleosides triphosphates, releasing AMP or other nucleosides monophosphates and nucleosides pyrophosphate (PPi) (Kato K et al., 2012 PNAS 109:16876-16881; Hessle L et al., 2002 PNAS 99:9445-9449). This enzyme can also hydrolyze other nucleoside monophosphates (Kato K et al., 2012 PNAS 109:16876-16881). ENPP1 has been identified as a major 2'-3'-cGAMP hydrolase in cultured cells, tissue extracts, and blood (Li L et al., 2014 Nat Chem Biol [Nature Chemical Biology] 10:1043-1048). Tissues and blood from ENPP1 knockout mice lack 2'-3'-cGAMP hydrolase activity. Elevated ENPP1 levels are associated with calcific aortic valve disease (CAVD) and calcium pyrophosphate deposition disease (CPPD) (an inflammatory disease caused by CPPD crystal deposits in joints and surrounding tissues) (Cote N et al., 2012 Eur J Pharmacol [European Journal of Pharmacology] 689:139-146; Johnson K et al., 2001 Arthritis Rheum [Arthritis and Rheumatology] 44:1071). ENPP1 expression is upregulated in certain hepatocellular carcinomas, glioblastomas, melanomas, testicular cancers, pancreatic cancers, thyroid cancers, and breast cancers, and is associated with tolerance to chemotherapy (see Lau WM et al., 2013 PLoS One 8:5; Bageritz J et al., 2014 Mol Cell Oncology 1:3; Bageritz J et al., 2014 Cell Death, Differentiation 21:929-940; Umar A et al., 2009 Mol Cell Proteomics 8:1278-1294).Upregulation of ENPP1 and its variants are also associated with insulin resistance and type 2 diabetes (Meyre D et al., 2005 NatGenet [Nature Genetics] 37:863-867; Maddux BA et al., 1995 Nature [Nature] 373:448-451; Rey D et al., 2012 Mol Biol Rep [Molecular Biology Reports] 39:7687-7693), and it has been reported that inhibition of insulin receptor signaling requires enzymatic activity of ENPP1 (Chin CN et al., 2009 Eur J Pharmacol [European Journal of Pharmacology] 606:17-24).
[0005] Circular GMP-AMP synthase (cGAS) is a pattern recognition receptor that synthesizes the endogenous messenger molecule cGAMP from ATP and GTP in response to the presence of DNA derived from viruses, bacteria, damaged mitochondria, or cancer cells. Then, the cGAMP molecule binds to the interferon gene-stimulating factor (STING) protein, which initiates a signaling response that activates the innate immune system and leads to the production of type I interferon, antiviral agents, and immunostimulatory cytokines (Sun L et al., 2013 Science 339:786-791; Wu J et al., 2013 Science 339:826-830; Gao D et al., 2013 Science 341:903-906; Li X et al., 2013 Science 341:1390-1394; Schoggins JW et al., 2014 Nature 505:691-695; Wassermann R et al., 2015 Cell Host Microbe 17:799-810; Watson RO et al., 2015 Cell Host Microbe). 17:811-819; Collins A et al., 2015 Cell Host Microbe 17:820-828; West A et al., 2015 Nature 520:533-557; Woo SR et al., 2014 Immunity 41:830-842; Deng L et al., 2014 Immunity 41:843-852; Chen Q et al., 2016 NatImmunol 17:1142-1148). cGAS enzyme, cGAMP messenger, and STING are also involved in host defense against RNA viruses and immune control of tumor development (Aguirre S et al., 2012 PLoS Pathog [PLOS Pathogens] 8: e1002934; Barber GN 2015 Nat Rev Immunol [Nature Immunology Review] 15:760-770). ENPP1 has been identified as a naturally occurring enzyme that hydrolyzes cGAMP, and thus counteracts the innate immune response to infectious agents, damaged cells, and cancer cells (Li L et al., 2014 Nat Chem Biol [Nature Chemical Biology] 10:1043-1048).Non-hydrolyzable cGAMP analogues are more effective than naturally hydrolyzable cGAMPs in inducing functional immune responses (Li L et al., 2014 Nat Chem Biol 10:1043-1048; Corrales L et al., 2015 Cell Reports 11:1018-1030). ENPP1 overexpression has been shown to promote viral infection, while ENPP1 silencing has been shown to reduce viral infection (Wang J et al., 2018 Mol Immunol 95:56-63).
[0006] Therefore, cGAMP hydrolysis inhibitors can be used to enhance the effectiveness of immune responses against cancer cells and tumors, as well as against infections caused by RNA or DNA viruses or bacteria. ENPP1 inhibitors and cGAMP or nucleoside triphosphate hydrolysis inhibitors can also be used to treat inflammatory diseases associated with elevated nucleoside levels, decreased nucleoside triphosphate levels, decreased cGAMP levels, or decreased nucleoside monophosphate levels, or diseases associated with elevated nucleoside or nucleoside monophosphate levels. For these reasons, ENPP1 is an attractive therapeutic target for treating these diseases.
[0007] This disclosure addresses these needs and also provides related advantages. Summary of the Invention
[0008] In a first aspect, a compound having formula (I) or a pharmaceutically acceptable salt thereof is provided: (I) in: X is N, CH, or when attached to R 1 When, it is C; a, b, d, and e are each independently CH, or when attached to R. 4 R 5 Or R 6 If any of the following is true, then it is C; or one or two of a, b, d, and e are N, and the remaining terms of a, b, d, and e are each independently CH, or when attached to R 4 R 5 Or R 6 For any one of the options, it is C; Z represents a bond, NH, O, S, SO, or SO2; m and n are each 0 or 1 independently; alk is an alkylene group substituted with 0 to 3 halogroups; alk 1It is an alkylene group, wherein one carbon atom in the alkylene chain is optionally replaced by oxygen, and further wherein the alkylene group is substituted with 0 to 3 halogroups; Ar is an arylene, heteroarylene, cycloalkyl, cyclic amino, fused cyclic amino, bridged cyclic amino, or spirocyclic cyclic amino; R 1 It does not exist; alkyl, alkoxy, halogroup, haloalkyl, haloalkoxy, amino, alkylamino, dialkylamino, hydroxyalkyl, alkoxyalkyl, hydroxyalkoxy, alkoxyalkoxy, hydroxyalkylamino, alkoxyalkylamino, aminoalkyl, aminoalkoxy, aminoalkylamino, diaminoalkyl, diaminoalkoxy, diaminoalkylamino or cyano. R 2 and R 3 Each of the following is independent of the following: methyl, ethyl, methoxy, fluorine, trifluoromethyl, trifluoromethoxy, or cyano. R 4 R 5 and R 6 One of them is absent, alkyl, hydroxy, alkoxy, halogroup, haloalkyl, haloalkoxy, cyano, amino, alkylamino, dialkylamino, alkylsulfonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, carboxyl, or alkoxycarbonyl; and R 4 R 5 and R 6 The remaining two are independently absent: alkyl, alkoxy, hydroxy, halogroup, haloalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, hydroxyalkoxy, alkoxyalkoxy, hydroxyalkylamino, alkoxyalkylamino, aminoalkyl, aminoalkoxy, aminoalkylamino, heterocyclic, heterocyclic oxy, heterocyclic amino (wherein the heterocyclic group is substituted by 0 to 3 substituents alone or as part of the heterocyclic oxy and heterocyclic amino groups, each independently selected from alkyl, halogroup, hydroxy, alkoxy, hydroxyalkyl, alkoxyalkyl, and aminoalkyl). Heterocyclic alkyl, heterocyclic alkyloxy, heterocyclic alkylamino (wherein the heterocyclic ring in the heterocyclic alkyl, heterocyclic alkyloxy, and heterocyclic alkylamino is substituted by 0 to 3 substituents, each independently selected from alkyl, haloyl, hydroxy, alkoxy, hydroxyalkyl, alkoxyalkyl, and aminoalkyl), cycloalkyloxy, phenyloxy, or heteroaryloxy (wherein the phenyl in the phenyloxy and the heteroaryl in the heteroaryloxy are substituted by 0 to 3 substituents, each independently selected from alkyl, hydroxy, alkoxy, haloyl, haloalkyl, haloalkoxy, and cyano); R 7It is an alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, aminocarbonylalkyl, carbonylaminoalkyl, carboxyaminoalkyl, cyanoalkyl, cycloalkyl, cycloalkylalkyl, aryl, fused aryl, heteroaryl, fused heteroaryl, heterocyclic, aralkyl, heteroarylalkyl, aryloxyalkyl, heteroaryloxyalkyl, fused aralkyl, fused heteroarylalkyl, or heterocyclic alkyl, wherein the cycloalkyl, aryl, fused aryl, heteroaryl, fused heteroaryl, heterocyclic, and the cycloalkylalkyl, arylalkyl, heteroarylalkyl, aryloxyalkyl, heteroaryloxyalkyl, fused aralkyl, fused heteroarylalkyl, or heterocyclic alkyl ring portion is substituted by one, two, or three substituents, each independently selected from hydrogen, alkyl, haloalkyl, haloalkyl, haloalkoxy, hydroxy, alkoxy, cyano, alkylcarbonyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocyclic; R 8 and R 9 Each is independently selected from hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, aminocarbonylalkyl, carbonylaminoalkyl, carboxyaminoalkyl, cyanoalkyl, cycloalkyl, cycloalkylalkyl, aryl, fused aryl, heteroaryl, fused heteroaryl, heterocyclic, aralkyl, heteroarylalkyl, aryloxyalkyl, heteroaryloxyalkyl, fused aralkyl, fused heteroarylalkyl, or heterocyclic alkyl, wherein the cyclic portion of the cycloalkyl, aryl, fused aryl, heteroaryl, fused heteroaryl, heterocyclic, and cycloalkylalkyl, arylalkyl, heteroarylalkyl, aryloxyalkyl, heteroaryloxyalkyl, fused aralkyl, fused heteroarylalkyl, or heterocyclic alkyl is substituted with one, two, or three substituents, each independently selected from hydrogen, alkyl, haloalkyl, haloalkyl, haloalkoxy, hydroxyl, alkoxy, cyano, alkylcarbonyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocyclic; or Its pharmaceutically acceptable salt.
[0009] In a second aspect, a pharmaceutical composition is provided comprising a compound having formula (I) (or any of the embodiments described herein) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
[0010] In a third aspect, a method is provided for treating an ENPP1-mediated disease in a patient, preferably in a patient deemed to require such treatment, the method comprising administering to the patient in a therapeutically effective amount a compound having formula (I) (or any of the embodiments thereof described herein) or a pharmaceutically acceptable salt thereof. In one embodiment, the disease is cancer. In a second embodiment, the disease is a cancer selected from: hepatocellular carcinoma, glioblastoma, melanoma, testicular cancer, pancreatic cancer, thyroid cancer, cervical cancer, ovarian cancer, bladder cancer, colon cancer, lung cancer, breast cancer, multiple myeloma, acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, hairy cell leukemia, large granular lymphoblastic leukemia, T-cell prolymphocytic leukemia, prolymphocytic leukemia, Hodgkin lymphoma, non-Hodgkin's lymphoma. Lymphoma, diffuse large B-cell lymphoma, low-grade glioma, colorectal cancer, gastric and gastrointestinal cancer, esophageal cancer, anal cancer, appendix cancer, kidney cancer, skin cancer, uterine cancer, brain cancer, adrenal cancer, bile duct cancer, bone cancer, fallopian tube cancer, sarcoma, germ cell tumors, head and neck cancer, neuroblastoma, pheochromocytoma and paraganglioma, bile duct cancer, peritoneal cancer, retinoblastoma, liver cancer, thymoma, urethral cancer, prostate cancer, uveal melanoma, adenoid cystic carcinoma, and vaginal and vulvar cancer. In the third embodiment, the disease is selected from the following cancers: hepatocellular carcinoma, glioblastoma, melanoma, testicular cancer, pancreatic cancer, thyroid cancer, cervical cancer, ovarian cancer, bladder cancer, colon cancer, and lung cancer.
[0011] In a fourth embodiment, the disease is cancer, such as hepatocellular carcinoma, glioblastoma, melanoma, testicular cancer, pancreatic cancer, thyroid cancer, and breast cancer. In another embodiment, the disease is an inflammatory disease, such as calcifying aortic valve disease, osteoarthritis, and calcium pyrophosphate dihydrate disease. In yet another embodiment, the disease is a metabolic disease, such as type 2 diabetes, or a viral infection, such as DNA virus infection, HIV, herpes simplex virus infection, human papillomavirus infection, RNA virus infection, and HBV.
[0012] In another embodiment, the disease is an inflammatory disease, such as calcific aortic valve disease and calcium pyrophosphate deposition disease (CPPD). In yet another embodiment, the disease is a metabolic disease (such as type 2 diabetes) or a viral infection.
[0013] In a fourth aspect, a compound having formula (I) (or any of the embodiments described herein) or a pharmaceutically acceptable salt thereof is provided for use as a pharmaceutical agent. In a second embodiment, the disease is selected from the following cancers: hepatocellular carcinoma, glioblastoma, melanoma, testicular cancer, pancreatic cancer, thyroid cancer, cervical cancer, ovarian cancer, bladder cancer, colon cancer, lung cancer, breast cancer, multiple myeloma, acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, hairy cell leukemia, large granular lymphoblastic leukemia, T-cell prolymphocytic leukemia, prolymphocytic leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma. Lymphoma, diffuse large B-cell lymphoma, low-grade glioma, colorectal cancer, gastric and gastrointestinal cancer, esophageal cancer, anal cancer, appendix cancer, kidney cancer, skin cancer, uterine cancer, brain cancer, adrenal cancer, bile duct cancer, bone cancer, fallopian tube cancer, sarcoma, germ cell tumors, head and neck cancer, neuroblastoma, pheochromocytoma and paraganglioma, bile duct cancer, peritoneal cancer, retinoblastoma, liver cancer, thymoma, urethral cancer, prostate cancer, uveal melanoma, adenoid cystic carcinoma, and vaginal and vulvar cancer. In the third embodiment, the disease is selected from the following cancers: hepatocellular carcinoma, glioblastoma, melanoma, testicular cancer, pancreatic cancer, thyroid cancer, cervical cancer, ovarian cancer, bladder cancer, colon cancer, and lung cancer.
[0014] In another embodiment, the disease is an inflammatory disease, such as calcific aortic valve disease, osteoarthritis, and calcium pyrophosphate dihydrate disease. In yet another embodiment, the disease is a metabolic disease, such as type 2 diabetes, or a viral infection, such as DNA virus infection, HIV, herpes simplex virus infection, human papillomavirus infection, RNA virus infection, and HBV.
[0015] In one embodiment, the agent is used to treat cancers such as hepatocellular carcinoma, glioblastoma, melanoma, testicular cancer, pancreatic cancer, thyroid cancer, and breast cancer. In another embodiment, the agent is used to treat inflammatory diseases such as calcifying aortic valve disease and calcium pyrophosphate deposition disease (CPPD). In yet another embodiment, the agent is used to treat metabolic diseases such as type 2 diabetes or viral infections.
[0016] In a fifth aspect, the use of a compound having formula (I) or a pharmaceutically acceptable salt thereof (and any embodiments thereof disclosed herein) in the manufacture of a medicament for treating a disease in which the activity of ENPP1 promotes the pathology and / or symptoms of the disease in a patient is provided. In one embodiment, the disease is cancer.
[0017] In the second embodiment, the disease is selected from the following cancers: hepatocellular carcinoma, glioblastoma, melanoma, testicular cancer, pancreatic cancer, thyroid cancer, cervical cancer, ovarian cancer, bladder cancer, colon cancer, lung cancer, breast cancer, multiple myeloma, acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, hairy cell leukemia, large granular lymphoblastic leukemia, T-cell prolymphoblastic leukemia, prolymphoblastic leukemia, Hodgkin's lymphoma, and non-Hodgkin's lymphoma. Lymphoma, diffuse large B-cell lymphoma, low-grade glioma, colorectal cancer, gastric and gastrointestinal cancer, esophageal cancer, anal cancer, appendix cancer, kidney cancer, skin cancer, uterine cancer, brain cancer, adrenal cancer, bile duct cancer, bone cancer, fallopian tube cancer, sarcoma, germ cell tumors, head and neck cancer, neuroblastoma, pheochromocytoma and paraganglioma, bile duct cancer, peritoneal cancer, retinoblastoma, liver cancer, thymoma, urethral cancer, prostate cancer, uveal melanoma, adenoid cystic carcinoma, and vaginal and vulvar cancer. In the third embodiment, the disease is selected from the following cancers: hepatocellular carcinoma, glioblastoma, melanoma, testicular cancer, pancreatic cancer, thyroid cancer, cervical cancer, ovarian cancer, bladder cancer, colon cancer, and lung cancer.
[0018] In another embodiment, the disease is an inflammatory disease, such as calcific aortic valve disease, osteoarthritis, and calcium pyrophosphate dihydrate disease. In yet another embodiment, the disease is a metabolic disease, such as type 2 diabetes, or a viral infection, such as DNA virus infection, HIV, herpes simplex virus infection, human papillomavirus infection, RNA virus infection, and HBV.
[0019] In one embodiment, the disease is cancer, such as hepatocellular carcinoma, glioblastoma, melanoma, testicular cancer, pancreatic cancer, thyroid cancer, and breast cancer. In another embodiment, the disease is an inflammatory disease, such as calcifying aortic valve disease and calcium pyrophosphate deposition disease (CPPD). In yet another embodiment, the disease is a metabolic disease (such as type 2 diabetes) or a viral disease.
[0020] In a sixth aspect, a compound having formula (I) (or any of the embodiments thereof described herein) or a pharmaceutically acceptable salt thereof is provided for treating cancer, metabolic disorders, viral infections, or inflammatory diseases. In one embodiment, the disease is cancer.
[0021] In the second embodiment, the disease is selected from the following cancers: hepatocellular carcinoma, glioblastoma, melanoma, testicular cancer, pancreatic cancer, thyroid cancer, cervical cancer, ovarian cancer, bladder cancer, colon cancer, lung cancer, breast cancer, multiple myeloma, acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, hairy cell leukemia, large granular lymphoblastic leukemia, T-cell prolymphoblastic leukemia, prolymphoblastic leukemia, Hodgkin's lymphoma, and non-Hodgkin's lymphoma. Lymphoma, diffuse large B-cell lymphoma, low-grade glioma, colorectal cancer, gastric and gastrointestinal cancer, esophageal cancer, anal cancer, appendix cancer, kidney cancer, skin cancer, uterine cancer, brain cancer, adrenal cancer, bile duct cancer, bone cancer, fallopian tube cancer, sarcoma, germ cell tumors, head and neck cancer, neuroblastoma, pheochromocytoma and paraganglioma, bile duct cancer, peritoneal cancer, retinoblastoma, liver cancer, thymoma, urethral cancer, prostate cancer, uveal melanoma, adenoid cystic carcinoma, and vaginal and vulvar cancer. In the third embodiment, the disease is selected from the following cancers: hepatocellular carcinoma, glioblastoma, melanoma, testicular cancer, pancreatic cancer, thyroid cancer, cervical cancer, ovarian cancer, bladder cancer, colon cancer, and lung cancer.
[0022] In another embodiment, the disease is an inflammatory disease, such as calcific aortic valve disease, osteoarthritis, and calcium pyrophosphate dihydrate disease. In yet another embodiment, the disease is a metabolic disease, such as type 2 diabetes, or a viral infection, such as DNA virus infection, HIV, herpes simplex virus infection, human papillomavirus infection, RNA virus infection, and HBV.
[0023] In a seventh aspect, a method for increasing the activity of immune cells is provided, the method comprising contacting the immune cells with a compound having formula (I) or a pharmaceutically acceptable salt thereof (and any of the embodiments disclosed herein).
[0024] In an eighth aspect, a method for increasing the activity of immune cells in a subject is provided, the method comprising administering to a subject in need a therapeutically effective amount of a compound having formula (I) or a pharmaceutically acceptable salt thereof (and any embodiments thereof disclosed herein). In one embodiment of the seventh aspect, the activity of immune cells is increased in a subject suffering from cancer or a viral disease.
[0025] In the second embodiment, the disease is selected from the following cancers: hepatocellular carcinoma, glioblastoma, melanoma, testicular cancer, pancreatic cancer, thyroid cancer, cervical cancer, ovarian cancer, bladder cancer, colon cancer, lung cancer, breast cancer, multiple myeloma, acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, hairy cell leukemia, large granular lymphoblastic leukemia, T-cell prolymphoblastic leukemia, prolymphoblastic leukemia, Hodgkin's lymphoma, and non-Hodgkin's lymphoma. Lymphoma, diffuse large B-cell lymphoma, low-grade glioma, colorectal cancer, gastric and gastrointestinal cancer, esophageal cancer, anal cancer, appendix cancer, kidney cancer, skin cancer, uterine cancer, brain cancer, adrenal cancer, bile duct cancer, bone cancer, fallopian tube cancer, sarcoma, germ cell tumors, head and neck cancer, neuroblastoma, pheochromocytoma and paraganglioma, bile duct cancer, peritoneal cancer, retinoblastoma, liver cancer, thymoma, urethral cancer, prostate cancer, uveal melanoma, adenoid cystic carcinoma, and vaginal and vulvar cancer. In the third embodiment, the disease is selected from the following cancers: hepatocellular carcinoma, glioblastoma, melanoma, testicular cancer, pancreatic cancer, thyroid cancer, cervical cancer, ovarian cancer, bladder cancer, colon cancer, and lung cancer.
[0026] In yet another embodiment, the disease is a viral infection, such as DNA virus infection, HIV, herpes virus infection, papillomavirus infection, RNA virus infection, and HBV.
[0027] In a ninth aspect, a compound having formula (I) or a pharmaceutically acceptable salt thereof (and any of the embodiments disclosed herein) is provided for treating the following: 1. Cancer; 2. Inflammatory diseases; 3. Metabolic diseases; or 4. Viral diseases.
[0028] In the first embodiment, the disease is cancer. In the second embodiment, the disease is a cancer selected from the following: hepatocellular carcinoma, glioblastoma, melanoma, testicular cancer, pancreatic cancer, thyroid cancer, cervical cancer, ovarian cancer, bladder cancer, colon cancer, lung cancer, breast cancer, multiple myeloma, acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, hairy cell leukemia, large granular lymphoblastic leukemia, T-cell prolymphocytic leukemia, prolymphocytic leukemia, Hodgkin's lymphoma, and non-Hodgkin's lymphoma. Lymphoma, diffuse large B-cell lymphoma, low-grade glioma, colorectal cancer, gastric and gastrointestinal cancer, esophageal cancer, anal cancer, appendix cancer, kidney cancer, skin cancer, uterine cancer, brain cancer, adrenal cancer, bile duct cancer, bone cancer, fallopian tube cancer, sarcoma, germ cell tumors, head and neck cancer, neuroblastoma, pheochromocytoma and paraganglioma, bile duct cancer, peritoneal cancer, retinoblastoma, liver cancer, thymoma, urethral cancer, prostate cancer, uveal melanoma, adenoid cystic carcinoma, and vaginal and vulvar cancer. In the third embodiment, the disease is selected from the following cancers: hepatocellular carcinoma, glioblastoma, melanoma, testicular cancer, pancreatic cancer, thyroid cancer, cervical cancer, ovarian cancer, bladder cancer, colon cancer, and lung cancer.
[0029] In another embodiment, the disease is an inflammatory disease, such as calcific aortic valve disease, osteoarthritis, and calcium pyrophosphate dihydrate disease. In yet another embodiment, the disease is a metabolic disease, such as type 2 diabetes, or a viral infection, such as DNA virus infection, HIV, herpes simplex virus infection, human papillomavirus infection, RNA virus infection, and HBV.
[0030] In one embodiment, the treatment is for cancers such as hepatocellular carcinoma, glioblastoma, melanoma, testicular cancer, pancreatic cancer, thyroid cancer, and breast cancer. In another embodiment, the use is for treating inflammatory diseases such as calcifying aortic valve disease and calcium pyrophosphate deposition disease (CPPD). In yet another embodiment, the agent is used to treat metabolic diseases such as type 2 diabetes or viral infections.
[0031] In any of the foregoing aspects of cancer treatment, additional embodiments include the administration of a compound having formula (I) or a pharmaceutically acceptable salt thereof (or any of the embodiments disclosed herein) in combination with at least one other anticancer agent. When using combination therapy, these agents may be administered simultaneously or sequentially. Detailed Implementation
[0032] definition: Unless otherwise stated, the following terms used in this specification and claims are defined for the purposes of this application and have the following meanings: "alkyl" refers to a straight-chain saturated monovalent hydrocarbon group having one to six carbon atoms or a branched saturated monovalent hydrocarbon group having three to six carbon atoms, such as methyl, ethyl, propyl, 2-propyl, butyl, pentyl, etc. When an alkyl group has one to three carbon atoms, it is also referred to herein as C14. 1-3 alkyl.
[0033] Unless otherwise stated, "alkylene" means a straight-chain saturated divalent hydrocarbon group having one to six carbon atoms or a branched saturated divalent hydrocarbon group having three to six carbon atoms, such as methylene, ethylene, propylene, 1-methylpropylene, 2-methylpropylene, butylene, pentylene, etc.
[0034] "alkylsulfonyl" refers to the -SO2R group (where R is an alkyl group as defined above), such as methylsulfonyl, ethylsulfonyl, etc.
[0035] "Alkyl carbonyl" refers to a -COR group (where R is an alkyl group as defined above), such as methyl carbonyl, ethyl carbonyl, propyl carbonyl, etc.
[0036] "Amino" refers to -NH2.
[0037] "Amino carbonyl" refers to -CONH2.
[0038] "alkylaminocarbonyl" refers to the -CONHR group (where R is an alkyl group as defined above), such as methylaminocarbonyl, ethylaminocarbonyl, etc.
[0039] "Aminocarbonylalkyl" means -(alkylene)-CONRR' group, wherein R is hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, or aminoalkyl, and R' is hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, optionally substituted phenyl, optionally substituted heteroaryl, or optionally substituted heterocyclic group; or R and R' together with the nitrogen atom to which they are attached form an optionally substituted cyclic amino group, each term as defined herein, such as methylaminocarbonyl-ethyl, ethylaminocarbonylethyl, 2-[(HOCH2CH2)2NC(O)]ethyl, etc.
[0040] "alkylamino" refers to the -NHR group (where R is an alkyl group as defined above), such as methylamino, ethylamino, propylamino, or 2-propylamino.
[0041] "Aminoalkyl" refers to a straight-chain monovalent hydrocarbon group having one to six carbon atoms or a branched monovalent hydrocarbon group having three to six carbon atoms that is substituted with -NR'R'' (where R' and R'' are each independently hydrogen or an alkyl group as defined above), such as aminomethyl, aminoethyl, methylaminomethyl, aminopropyl, methylaminopropyl, etc.
[0042] "Aminoalkylamino" refers to -NRa R b Group (where R) a It is hydrogen or alkyl and R b It is an aminoalkyl group as defined above, such as aminoethylamino, dimethylaminoethylamino, diethylaminoethylamino, dimethylaminopropylamino, diethylaminopropylamino, etc.
[0043] "Aminoalkyloxy" or "aminoalkoxy" refers to -OR a Group (where R) a It is an aminoalkyl group as defined above, such as aminoethyloxy, dimethylaminoethyloxy, diethylaminoethyloxy, dimethylaminopropyloxy, diethylaminopropyloxy, etc.
[0044] "Alkoxy" refers to the -OR group (where R is an alkyl group as defined above), such as methoxy, ethoxy, propoxy, or 2-propoxy, n-butoxy, isobutoxy, or tert-butoxy, etc.
[0045] "Alkoxycarbonyl" refers to the -C(O)OR group (where R is an alkyl group as defined above), such as methoxycarbonyl, ethoxycarbonyl, etc.
[0046] "Alkoxyalkyl" means a straight-chain monovalent hydrocarbon group having one to six carbon atoms or a branched monovalent hydrocarbon group having three to six carbon atoms that is substituted by at least one alkoxy group as defined above (such as one or two alkoxy groups), such as 2-methoxyethyl, 1-methoxypropyl, 2-methoxypropyl, or 3-methoxypropyl, 2-ethoxyethyl, etc.
[0047] "Alkoxyalkylamino" refers to the -NRR' group (where R is hydrogen or alkyl and R' is an alkoxyalkyl group as defined above), such as methoxyethylamino, ethoxyethylamino, propoxypropylamino, ethoxypropylamino, etc.
[0048] "Alkoxyalkyloxy" or "alkoxyalkyloxy" refers to the -(O)R group (where R is an alkoxyalkyl group as defined above), such as methoxyethoxy, ethoxyethoxy, etc.
[0049] "Aryl" refers to a monovalent monocyclic or bicyclic aromatic hydrocarbon group with 6 to 10 ring atoms, such as phenyl or naphthyl.
[0050] "Arylalkyl" or "arylalkyl" means -(alkylene)-R (where R is an aryl group as defined above), such as benzyl.
[0051] "Aromatyl" refers to a divalent monocyclic or bicyclic aromatic hydrocarbon group having 6 to 10 ring atoms, such as phenylene or naphthylene.
[0052] "Aryloxy" refers to an -OR group (where R is an aryl group as defined above), such as phenyloxy or naphthyloxy. When the aryl group is phenyl, the group is also referred to herein as phenyloxy or phenoxy.
[0053] "Aryloxyalkyl" refers to an alkylene-OR group (where R is an aryl group as defined above), such as phenyloxymethyl, phenyloxyethyl, phenyloxypropyl, etc.
[0054] "Bridging cyclic amino group" refers to a saturated divalent bicycle with 5 to 7 ring carbon atoms, where two non-adjacent ring atoms are connected by a (CR) group. z R z ') n Group linkage, where n is an integer selected from 1 to 3, and R z and R z Each is independently either H or methyl (also referred to herein as a "bridging" group), and further wherein one of the ring carbon atoms is N and the other ring carbon atoms are selected from N, O, and S(O). n The heteroatom substitutions, where n is an integer selected from 0 to 2 (inclusive). N, O, and S(O) n It can exist in bridging groups. Examples include, but are not limited to, 3,8-diazabicyclo[3.2.1]octyl-3,8-diyl, etc.
[0055] "Cycloalkyl" refers to a cyclic saturated monovalent hydrocarbon group having three to ten carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
[0056] "Cycloalkylene" refers to a cyclic saturated divalent hydrocarbon group having three to ten carbon atoms, such as 1,3-cyclobutylene, 1,3-cyclopentylene, or 1,3- or 1,4-cyclohexylene, etc.
[0057] "Cycloalkylalkyl" refers to a -(alkylene)-R group (where R is a cycloalkyl group as defined above), such as cyclopropylmethyl, cyclobutylethyl, etc.
[0058] "Cycloalkyloxy" refers to an -OR group (where R is a cycloalkyl group as defined above (including specific heterocyclic rings)), such as cyclopropyloxy.
[0059] "Carboxyl group" refers to -COOH.
[0060] "Biodecanamine" refers to a saturated divalent monocyclic ring with 4 to 8 ring atoms, one of which is nitrogen, and the other ring atoms can be nitrogen, O, or S(O)n (where n is 0, 1, or 2), and the remaining ring atom is carbon. Representative examples of cyclicamines include, but are not limited to, 1,3- or 1,4-piperidinediyl, 1,4-piperazindiyl, 1,3-azacyclobutadiyl, and 1,3-morpholindiyl.
[0061] "Carbonylaminoalkyl" means -(alkylene)-NRCOR' group, where R is hydrogen or alkyl and R' is hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, optionally substituted phenyl, optionally substituted heteroaryl, or optionally substituted heterocyclic group; each term as defined herein, for example methylcarbonylaminomethyl, ethylcarbonylaminoethyl, 2-(HOCH2C(O)amino)ethyl, etc.
[0062] "Carboxyaminoalkyl" means -(alkylene)-NRC(O)OR' group, where R' is hydrogen, alkyl, optionally substituted phenyl, optionally substituted heteroaryl, or optionally substituted heterocyclic group; each term as defined herein, such as methoxycarbonylaminomethyl, ethyloxycarbonylaminoethyl, phenoxycarbonylethyl, etc.
[0063] "Cyanoalkyl" refers to a straight-chain monovalent hydrocarbon group with one to six carbon atoms that has been replaced by a cyano group, or a branched monovalent hydrocarbon group with three to six carbon atoms, such as cyanomethyl, cyanoethyl, cyanopropyl, etc.
[0064] "Dialkylaminocarbonyl" means -CONRR' (where R and R' are each independently an alkyl group as defined above), such as dimethylaminocarbonyl, methylethylaminocarbonyl, etc.
[0065] "Dialkylamino" refers to the -NRR' group (where R and R' are alkyl groups as defined above), such as dimethylamino, methylethylamino, etc.
[0066] "Diaminoalkyl" means a straight-chain monovalent hydrocarbon group having one to six carbon atoms or a branched monovalent hydrocarbon group having three to six carbon atoms, which is replaced by two -NR'R'', wherein R' and R'' are each independently hydrogen or an alkyl group as defined above, such as diaminoethyl, 1,3-diaminopropyl, 2-amino-3-methylaminopropyl, etc.
[0067] "Diaminoalkylamino" refers to -NR a R b Group (where R) a It is hydrogen or alkyl and R b It is a diaminoalkyl group as defined above, such as diaminoethylamino, 1,3-diaminopropylamino, 2-amino-3-methylaminopropylamino, etc.
[0068] "Diaminoalkyloxy" or "diaminoalkoxy" refers to -OR a Group (where R) a It is a diaminoalkyl group as defined above, such as 2-diaminoethyloxy, 1,3-diaminopropyloxy, 2-amino-3-methylaminopropyloxy, etc.
[0069] "Fused cyclic amine group" refers to a fused divalent bicyclic ring, wherein the first ring is a saturated ring with 4 to 8 ring atoms, one of which is nitrogen, and the other ring atoms can be nitrogen, O, or S(O)n (where n is 0, 1, or 2), and the remaining ring atoms are carbon. Two adjacent ring atoms of the first ring are fused to two adjacent ring atoms of a phenyl, five-membered, or six-membered heteroaryl group as defined herein. Any two suitable ring atoms of the fused cyclic amine group can be attachment sites. Non-limiting examples of fused cyclic amine groups include indoline-2-one-1-yl, indolinel, isoindolinel, etc.
[0070] "Fused aryl" refers to a fused monovalent bicyclic ring, wherein two adjacent ring atoms of the phenyl group are fused to two adjacent ring atoms of a cycloalkyl or heterocyclic group as defined herein. Any two suitable ring atoms of the fused aryl group can be attachment points. Non-limiting examples of fused aryl groups include indenyl, 2,3-dihydrobenzofuranyl, 2-oxoindolinyl, indolinyl, isoindolinyl, etc.
[0071] "Fused arylalkyl" or "fused arylalkyl" means -(alkylene)-R (where R is a fused aryl group as defined above), such as indolylmethyl, indanylmethyl, indolylethyl, indolylpropyl, etc.
[0072] "Fused heteroaryl" refers to a fused monovalent bicyclic ring, wherein two adjacent ring atoms of a five- or six-membered heteroaryl group, as defined herein, are fused to two adjacent ring atoms of a cycloalkyl or heterocyclic group, as defined herein. Any two suitable ring atoms of the fused aryl group can be attachment sites. Non-limiting examples of fused heteroaryl groups include 2,3-dihydro-1H-pyrrolo[2,3-c]pyridine, 6,7-dihydro-5H-cyclopentadien[c]pyridine, etc.
[0073] "Fused heteroaryl" means -(alkylene)-R (where R is an aryl group as defined above) attached by methyl, ethyl, or propyl groups, such as 2,3-dihydro-1H-pyrrolo[2,3-c]pyridine, 6,7-dihydro-5H-cyclopentadieno[c]pyridine, etc.
[0074] "Halogenated group" refers to fluorine, chlorine, bromine, or iodine, with fluorine or chlorine being preferred.
[0075] "Haloalkyl" means an alkyl group as defined above that is substituted with one or more halogen atoms (such as one to five halogen atoms, such as fluorine or chlorine), including those substituted with different halogens, such as -CH2Cl, -CF3, -CHF2, -CH2CF3, -CF2CF3, -CF(CH3)2, etc. When an alkyl group is substituted only with fluorine, it may be referred to as a fluoroalkyl group in this application.
[0076] "Haloalkoxy" refers to an -OR group (where R is a haloalkyl group as defined above), such as -OCF3, -OCHF2, etc. When R is a haloalkyl group in which the alkyl group is substituted only by fluorine, it may be referred to as fluoroalkoxy in this application.
[0077] "Hydroxyalkyl" means a straight-chain monovalent hydrocarbon group having one to six carbon atoms, substituted with one or two hydroxyl groups, or a branched monovalent hydrocarbon group having three to six carbon atoms, provided that if two hydroxyl groups are present, they are not on the same carbon atom. Representative examples include, but are not limited to, hydroxymethyl, 2-hydroxyethyl, 2-hydroxypropyl, 3-hydroxypropyl, 1-(hydroxymethyl)-2-methylpropyl, 2-hydroxybutyl, 3-hydroxybutyl, 4-hydroxybutyl, 2,3-dihydroxypropyl, 1-(hydroxymethyl)-2-hydroxyethyl, 2,3-dihydroxybutyl, 3,4-dihydroxybutyl, and 2-(hydroxymethyl)-3-hydroxypropyl, preferably 2-hydroxyethyl, 2,3-dihydroxypropyl, and 1-(hydroxymethyl)-2-hydroxyethyl.
[0078] "Hydroxyalkylamino" refers to -NR a R b Group (where R) a It is hydrogen or alkyl and R b It is a hydroxyalkyl group as defined above, such as hydroxyethylamino, hydroxypropylamino, etc.
[0079] "Hydroxyalkyloxy" refers to -OR a Group (where R) a It is a hydroxyalkyl group as defined above, such as hydroxyethyloxy, hydroxypropyloxy, etc.
[0080] "Heterocyclic group" refers to a saturated or unsaturated monocyclic group having 4 to 8 ring atoms, one or two of which are selected from N, O, or S(O). n (where n is an integer from 0 to 2) heteroatoms, with the remaining ring atoms being carbon. Additionally, one or two ring carbon atoms in the heterocyclic group may optionally be replaced by a -CO- group. More specifically, the term heterocyclic group includes, but is not limited to, pyrrolidinyl, piperidinyl, perpiperidinyl, 2-oxopyrrolidinyl, 2-oxopyridinyl, morpholinyl, piperazine, tetrahydropyranyl, thiomorpholinyl, etc. When the heterocyclic group ring is unsaturated, it may contain one or two cyclic double bonds, provided that the ring is not aromatic. When the heterocyclic group contains at least one nitrogen atom, it is also referred to herein as a heterocyclic amino group and is a subset of heterocyclic groups.
[0081] "Heterocyclic alkyl" refers to a -(alkylene)-R group (where R is a heterocyclic ring as defined above (including specific heterocyclic rings)), such as tetrahydrofuranylmethyl, piperazineylmethyl, morpholinylethyl, etc.
[0082] "Heterocyclic amino" means -NRR' group, where R is hydrogen or alkyl and R' is a heterocyclic group as defined above (including specific heterocyclic rings).
[0083] "Heterocyclic alkylamino" refers to the -NRR' group (where R is hydrogen or alkyl and R' is a heterocyclic alkyl ring as defined above (including specific heterocyclic rings)), such as tetrahydrofuranylmethylamino, piperazinylethylamino, morpholinylethylamino, piperidinylmethylamino, etc.
[0084] "Heterocyclic oxygen group" refers to the -OR group, where R is a heterocyclic group as defined above (including specific heterocyclic rings).
[0085] "Heterocyclic alkyloxy" refers to the -OR group (where R is a heterocyclic alkyl ring as defined above (including specific heterocyclic rings)), such as tetrahydrofuranylmethyloxy, piperazineylethyloxy, morpholinylethyloxy, piperidinylmethyloxy, etc.
[0086] Unless otherwise stated, “heteroaryl” means a monovalent monocyclic or bicyclic aromatic group having 5 to 10 ring atoms, wherein one or more (in one embodiment, one, two, or three) of the ring atoms are heteroatoms selected from N, O, or S, and the remaining ring atoms are carbon. Representative examples include, but are not limited to, pyrrole, thiophene, thiazolyl, imidazolyl, furanyl, indolyl, isoyindolyl, oxazolyl, isoxazolyl, benzothiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, pyridinyl, pyrazinyl, pyridazinyl, triazolyl, tetrazolyl, etc. As defined herein, the terms “heteroaryl” and “aryl” are independent of each other. When a heteroaryl ring contains 5 or 6 ring atoms, it is also referred to herein as a 5- or 6-membered heteroaryl.
[0087] "Heteroarylene" refers to an alkylene-R group (where R is a heteroarylene as defined above), such as pyridylmethyl, pyridylethyl, thiazolylpropyl, etc.
[0088] "Heteroaryloxy group" refers to the -OR group, where R is a heteroaryl group as defined above (including a specific heteroaryl ring).
[0089] "Heteroaryloxyalkyl" refers to an alkylene-OR group (where R is a heteroaryl group as defined above), such as pyridyloxymethyl, pyridyloxyethyl, thiazolyloxypropyl, etc.
[0090] Unless otherwise stated, "heteroaryl" means a divalent monocyclic or bicyclic aromatic group having 5 to 10 ring atoms, wherein one or more (in one embodiment, one, two, or three) of the ring atoms are heteroatoms selected from N, O, or S, and the remaining ring atoms are carbon. Representative examples include, but are not limited to, pyrrolediyl, thiazolediyl, imidazolediyl, furandiyl, indolediyl, isoindolediyl, oxazolediyl, isoxazolediyl, benzothiazolediyl, benzoxazolediyl, quinolinediyl, isoquinolinediyl, pyridindiyl, pyrimidinediyl, triazolediyl, tetraazolediyl, etc.
[0091] "Optionally substituted aryl" means an aryl group as defined above that is substituted by one, two, or three substituents, each independently selected from alkyl, hydroxy, alkoxy, halogroup, cyano, haloalkyl, haloalkoxy, amino, alkylamino, dialkylamino, carboxyl, or alkoxycarbonyl groups as defined herein.
[0092] "Optionally substituted heteroaryl" means a heteroaryl group as defined above that is substituted by one, two or three substituents, each independently selected from alkyl, hydroxy, alkoxy, halogroup, cyano, haloalkyl, haloalkoxy, amino, alkylamino, dialkylamino, carboxyl or alkoxycarbonyl groups as defined herein.
[0093] "Optionally substituted heterocyclic group" means a heterocyclic group as defined above that is substituted by one, two or three substituents, each independently selected from alkyl, hydroxy, alkoxy, cyano, halogroup, haloalkyl, haloalkoxy, amino, alkylamino, dialkylamino, -COR (where R is alkyl), or alkoxycarbonyl groups as defined herein.
[0094] "Spirocyclic cyclic amino group" refers to a saturated bicyclic divalent ring having 6 to 10 ring atoms, one of which is nitrogen (N), and the other ring atoms can be heteroatoms selected from N, O, and S(O)n (where n is an integer selected from 0 to 2), the remaining ring atoms are carbon (C), and these rings are linked by only one atom, also called a spiro atom, most commonly a quaternary carbon ("spirocarbon"). Unless otherwise stated, the spirocyclic cyclic amino group may optionally be substituted by one or two substituents, each independently selected from alkyl, halogroup, alkoxy, hydroxyl, and cyano groups. Representative examples include, but are not limited to, those listed below. wait.
[0095] This disclosure also includes protected derivatives of compounds having formula (I). For example, when a compound having formula (I) contains a group such as a hydroxyl, carboxyl, thiol, or any group containing one or more nitrogen atoms, these groups can be protected by suitable protecting groups. A comprehensive list of suitable protecting groups can be found in TWGreene, Protective Groups in Organic Synthesis [Protective Groups in Organic Synthesis The disclosure of the compounds disclosed herein is found in John Wiley & Sons, Inc. (1999), and is incorporated herein by reference in its entirety. Protected derivatives of the compounds disclosed herein can be prepared by methods well known in the art.
[0096] This disclosure also includes polymorphic forms and deuterated forms of compounds having formula (I) or pharmaceutically acceptable salts thereof.
[0097] The term "pharmaceutically acceptable salt" refers to a salt that is pharmaceutically acceptable and possesses the desired pharmacological activity of the parent compound. Such salts include: acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc.; or acid addition salts formed with organic acids such as formic acid, acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid. Acids such as 4-toluenesulfonic acid, camphorsulfonic acid, glucohepanoic acid, 4,4'-methylenebis-(3-hydroxy-2-en-1-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tert-butylacetic acid, lauryl sulfate, gluconic acid, glutamic acid, hydroxynaphthenic acid, salicylic acid, stearic acid, mucoconic acid, etc.; or salts formed when acidic protons present in the parent compound are replaced by metal ions (e.g., alkali metal ions, alkaline earth metal ions, or aluminum ions); or salts formed by coordination with organic bases such as ethanolamine, diethanolamine, triethanolamine, tromethamine, etc. N -Methylglucosamine, etc. It should be understood that pharmaceutically acceptable salts are non-toxic. Further information regarding suitable pharmaceutically acceptable salts can be found in [link to relevant information]. Remington's Pharmaceutical Sciences [ Remington's Pharmaceutical Sciences [17th edition, Mack Publishing Company, Easton, PA, 1985, which is incorporated herein by reference in its entirety.]
[0098] Compounds having formula (I) may have an asymmetric center. Compounds having formula (I) containing asymmetrically substituted atoms can be separated in optical or racemic form. How to prepare the optical form is well known in the art, such as by resolution of the material. Unless a specific stereochemical or isomeric form is explicitly indicated, all chiral, diastereomeric, mixtures of chiral or diastereomeric forms, and racemic forms are within the scope of this disclosure. Those skilled in the art will also understand that when a compound is represented as an (R) stereoisomer, it may contain a corresponding (S) stereoisomer as an impurity, i.e., the (S) stereoisomer is less than about 5%, preferably 2%, by weight, and when it is represented as a mixture of R and S isomers, the amount of R or S isomer in the mixture is greater than about 5%, preferably 2%, w / w.
[0099] Some compounds having formula (I) can exist as tautomers and / or geometric isomers. All possible tautomers and cis and trans Isomers, both individually and in mixtures thereof, are within the scope of this disclosure. For example, hydroxylated compounds having formula (I) can exist as tautomers as follows: Furthermore, as used herein, the term alkyl includes all possible isomers of the alkyl group. Additionally, when cyclic groups such as aryl, heteroaryl, and heterocyclic groups are substituted, they include all positional isomers. Furthermore, all hydrates of the compounds disclosed herein are within the scope of this disclosure.
[0100] Some structures presented herein are drawn using one or more floating substituents. Unless otherwise specified or clearly apparent from the context, the one or more substituents may be present on any atom of the ring through which they are drawn, provided it is chemically feasible and the valence rules permit. For example, in the following structures: R 4 Floating substituents can replace the un-R-substituent portion of the six-membered aromatic ring in a bicyclic system. 5 Or R 6 Any hydrogen substituted, i.e., when any of a, b, d, and e is CH and not R 5 Or R 6 When replacing.
[0101] Compounds having formula (I) may also contain non-natural amounts of isotopes at one or more atoms constituting such compounds. Non-natural amounts of isotopes can be defined as ranging from amounts found in nature to amounts representing 100% of the atoms considered. This differs only when one or more isotope-enriched atoms are present. Exemplary isotopes that may be incorporated into compounds of the present invention (such as compounds having formula (I) and any embodiments thereof disclosed herein, including specific compounds) include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, and iodine, respectively as follows: 2 H, 3 H, 11 C 13 C 14 C 13 N、 15 N、 15 O、 17 O、 18 O、 32 P, 33 P, 35 S, 18 F, 36 Cl、 123 I, and 125 1. Isotope-labeled compounds (e.g., those labeled with .sup.3H and .sup.14C) are useful in the determination of the tissue distribution of compounds or substrates. Tritium-labeled (i.e., .sup.3H) and carbon-14 (i.e., .sup.14C) isotopes are used due to their ease of preparation and detectability. Furthermore, heavier isotopes such as deuterium (i.e., 2 Substitution of H) can confer certain therapeutic advantages due to improved metabolic stability (e.g., increased in vivo half-life or reduced dose requirement). In some embodiments, in the compounds disclosed herein, including those listed in Tables 1A and 1B below, one or more hydrogen atoms are... 2 H or 3 H substitution, or one or more carbon atoms being replaced 13 C- or 14 C-enriched carbon substitution. Positron-emitting isotopes (such as...) 15 O、 13 N、 11 C, and 15 F) It can be used in positron emission tomography (PET) studies to examine substrate acceptor occupancy. Isotope-labeled compounds can generally be prepared by replacing non-isotope-labeled reagents with isotope-labeled reagents, following procedures similar to those disclosed in the protocols or examples herein.
[0102] "Oxygenated" or "carbonyl" means (O) group.
[0103] "Optional" or "optionally" means that the event or situation described below may occur but is not required to occur, and means that the description includes both the scenario in which the event or situation occurs and the scenario in which it does not occur. For example, "optionally alkyl-substituted heterocyclic group" means that the alkyl group may be present but is not required to be present, and the description includes both the scenario in which the heterocyclic group is substituted with an alkyl group and the scenario in which the heterocyclic group is not substituted with an alkyl group.
[0104] "Pharmaceutically acceptable carrier or excipient" means a carrier or excipient that is generally safe and non-toxic, and is neither biologically nor otherwise undesirable for use in the preparation of pharmaceutical compositions, and includes carriers or excipients acceptable for both veterinary and human pharmaceutical use. As used in this specification and claims, "pharmaceuticalally acceptable carrier / excipient" includes both one and more such excipients.
[0105] As used herein, the term “about” is intended to define the numerical value it modifies, indicating that the value is variable within tolerance limits. When no specific tolerance limit is listed (such as the standard deviation of the average given in a chart or data table), the term “about” should be understood to mean a range that includes ±10%, preferably ±5%, of the listed values and ranges.
[0106] As used herein, the term “disease” is intended to be generally synonymous with and interchangeable with the terms “disorder,” “syndrome,” and “symptom” (as in medical conditions), since all of these reflect an abnormal condition of a human or animal body or one of its parts that impairs normal function, typically manifested as distinct signs and symptoms, and resulting in a shortened lifespan or reduced quality of life for the human or animal.
[0107] The term "patient" is generally synonymous with the term "subject" and includes all mammals, including humans. Examples of patients include humans; livestock such as cattle, goats, sheep, pigs, and rabbits; and companion animals such as dogs, cats, and horses. Preferably, a patient is a human.
[0108] The terms “inhibition” and “reduction” regarding EPPI, or any variations thereof, include any measurable reduction or complete inhibition to achieve a desired result. For example, a reduction may exist compared to normal conditions, such a reduction as about, at most about, or at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, or any range of EPPI activity derived therefrom.
[0109] "Treatment" of diseases includes: (1) Prevention of disease, that is, the prevention of the development of clinical symptoms of disease in mammals that may be exposed to or susceptible to disease but have not yet experienced or shown symptoms of disease; (2) Suppressing disease, that is, preventing (i.e. stabilizing) or reducing the development of disease or its clinical symptoms; or (3) Relieve disease, that is, the disease or its clinical symptoms subside.
[0110] "Therapeutic effective amount" means the amount of the disclosed compound and / or its pharmaceutically acceptable salts that, when administered to a patient to treat a disease, is sufficient to achieve such treatment of the disease. "Therapeutic effective amount" will vary depending on the compound, the disease and its severity, and the age, weight, etc., of the mammal to be treated.
[0111] Representative compounds having formula (I) are disclosed in Table 1A below: Other representative compounds having formula (I) are disclosed in Table 1B below: Example: Example A In Example A, a compound having formula (I) or a pharmaceutically acceptable salt thereof is as defined in the above description of the invention.
[0112] Example B In Example B, the compound having formula (I) or a pharmaceutically acceptable salt thereof as described in Example A, Z is a bond.
[0113] Example C In Example C, the compound having formula (I) or a pharmaceutically acceptable salt thereof as described in Example A, Z is NH, O, S, or SO2.
[0114] Example D In Example D, the compound having formula (I) or a pharmaceutically acceptable salt thereof, as described in any one of Examples A, B, and C, has a structure of formula (Ia), (Ib), (Ic), (Id), (If), (Ig), or (Ih): In compounds having formulas (Ia) to (Id), Z is a bond, and in compounds having formulas (Ie) to (Ih), Z is NH, O, S, SO, or SO2. For clarity, in Example D, compounds having formulas (Ia), (Ib), (Ic), and (Id) will be selected with reference to Example B, and compounds having formulas (If), (Ig), and (Ih) will be selected with reference to Example C.
[0115] (Di). In sub-example (Di), the compound having formula (I) or a pharmaceutically acceptable salt thereof as described in Examples A, B or D has structure (Ia).
[0116] (Dii). In sub-example (Dii), the compound having formula (I) or a pharmaceutically acceptable salt thereof as described in examples A, B or D has structure (Ib).
[0117] (Diii). In sub-example (Diii), the compound having formula (I) or a pharmaceutically acceptable salt thereof as described in Examples A, B or D has structure (Ic).
[0118] (Div). In the sub-example (Div), the compound having formula (I) or a pharmaceutically acceptable salt thereof as described in Examples A, B or D has a structure (Id).
[0119] (Dv). In sub-example (Dv), the compound having formula (I) or a pharmaceutically acceptable salt thereof as described in Examples A, C or D has structure (Ie).
[0120] (Dvi). In sub-examples (Dvi), compounds having formula (I) or pharmaceutically acceptable salts thereof, as described in Examples A, C or D, have a structure (If).
[0121] (Dvii). In sub-example (Dvii), a compound having formula (I) or a pharmaceutically acceptable salt thereof, as described in Examples A, C or D, has a structure (Ig).
[0122] (Dviii). In sub-example (Dviii), a compound having formula (I) or a pharmaceutically acceptable salt thereof as described in Examples A, C or D has structure (Ih).
[0123] Example E In Example E, the compound or a pharmaceutically acceptable salt thereof as described in any one of Examples A, C and D and sub-examples (Dv) to (Dviii) is wherein Z is NH.
[0124] Example F In Example F, the compound or a pharmaceutically acceptable salt thereof as described in any one of Examples A, C and D and sub-examples (Dv) to (Dviii) is wherein Z is O.
[0125] (Fi). In Example Fi, the compound or its pharmaceutically acceptable salt as described in any one of Examples A, C and D and sub-examples (Dv) to (Dviii) is wherein Z is a bond or O.
[0126] Example G In Example G, the compound or a pharmaceutically acceptable salt thereof, as described in any one of Examples A, C and D and sub-examples (Dv) to (Dviii), is wherein Z is SO2.
[0127] Example H In Example H, the compound or a pharmaceutically acceptable salt thereof as described in any one of Examples A to D and E to G and sub-examples (Di) to (Dviii) is wherein X is N.
[0128] Example I In Example I, the compound or its pharmaceutically acceptable salt as described in any one of Examples A to D and E to G and sub-examples (Di) to (Dviii) is wherein X is CH, or when attached to R 1 At that time, it was C.
[0129] (Ii). In Example Ii, the compound or a pharmaceutically acceptable salt thereof as described in any one of Examples A to E to G and Sub-Examples (Di) to (Dviii) is wherein X is N or CH.
[0130] Example J In Example J, the compound or a pharmaceutically acceptable salt thereof as described in any one of Examples A to D and E to Ii and sub-examples (Di) to (Dviii) is wherein R 1 Attached to the carbon between N and X.
[0131] Example K In Example K, the compound or its pharmaceutically acceptable salt as described in any one of Examples A to D and E to J and sub-examples (Di) to (Dviii) is wherein a, b, d, and e are each independently CH, or when attached to R 4 R 5 and R 6 For any of the options, it is C.
[0132] Example L In Example L, the compound or its pharmaceutically acceptable salt as described in any one of Examples A to D and E to J and sub-examples (Di) to (Dviii) is wherein a is N and b, d, and e are each independently CH, or when attached to R 4 R 5 and R 6 For any of the options, it is C.
[0133] Example M In Example M, the compound or its pharmaceutically acceptable salt as described in any one of Examples A to D and E to J and sub-examples (Di) to (Dviii) is wherein a and d are N and b and e are each independently CH, or when attached to R 4 R 5 and R 6 For any of the options, it is C.
[0134] Example N In Example N, the compound or its pharmaceutically acceptable salt as described in any one of Examples A to D and E to J and sub-examples (Di) to (Dviii) is wherein b is N and a, c, and e are each independently CH, or when attached to R 4 R 5 and R 6 For any of the options, it is C.
[0135] Example O In Example O, the compound or its pharmaceutically acceptable salt as described in any one of Examples A to D and E to J and sub-examples (Di) to (Dviii) is wherein b and e are N and a and d are each independently CH, or when attached to R 4 R 5 and R 6 For any of the options, it is C.
[0136] Example P In Example P, the compound or its pharmaceutically acceptable salt as described in any one of Examples A to D and E to J and sub-examples (Di) to (Dviii) is wherein d is N and a, b, and e are each independently CH, or when attached to R 4 R 5 and R 6 For any of the options, it is C.
[0137] Example Q In Example Q, the compound or its pharmaceutically acceptable salt as described in any one of Examples A to D and E to J and sub-examples (Di) to (Dviii) is wherein e is N and a, b, and d are each independently CH, or when attached to R 4 R 5 and R 6 For any of the options, it is C.
[0138] (Qi). In Example Qi, the compound or a pharmaceutically acceptable salt thereof, as described in any one of Examples A to D and E to J and sub-examples (Di) to (Dviii), is wherein... a is CH; b is CH, or when attached to R 4 R 5 Or R 6 For any one of the options, it is C; d is N, or when attached to R 4 R 5 Or R 6 For any one of them, it is C; and e is N, CH, or when attached to R 4 R 5 Or R 6 For any of the options, it is C.
[0139] Example R In Example R, the compound or a pharmaceutically acceptable salt thereof as described in any one of Examples A to C and E to Q is wherein n and m are 0.
[0140] Example S In Example S, the compound or a pharmaceutically acceptable salt thereof as described in any one of Examples A to C and E to Qi is wherein n is 1 and m is 0.
[0141] Example T In Example T, the compound or a pharmaceutically acceptable salt thereof as described in any one of Examples A to C and E to Qi is wherein n is 0 and m is 1.
[0142] Example U In Example U, the compound or a pharmaceutically acceptable salt thereof as described in any one of Examples A to C and E to Qi is wherein each n and m is 1.
[0143] Example V (V). In Example (V), the compound or a pharmaceutically acceptable salt thereof, as described in any one of Examples A to D, E to Qi and S to U and sub-examples D(i) to D(viii), is wherein alk 1 And / or alk, when present, each independently selected from methylene, ethylene, or propylene, preferably alk. 1 And / or alk, when present, are each independently selected from methylene or ethylene.
[0144] (Vi). In sub-example (Vi), the compound or a pharmaceutically acceptable salt thereof as described in any one of Examples A to D, E to Qi and S to V and sub-examples D(i) to D(viii) is wherein alk 1 And / or alk, when present, is methylene.
[0145] (Vii). In Example Vii, the compound or a pharmaceutically acceptable salt thereof, as described in any one of Examples A to D, E to Qi and S to U and sub-Examples D(i) to D(viii), is wherein alk 1 And / or alk, when present, is an alkylene group.
[0146] (Viii). In Example Viii, the compound or a pharmaceutically acceptable salt thereof as described in any one of Examples A to D, E to Qi, S to V and Vii and sub-Examples D(i) to D(viii) is wherein alk, when present, is methylene.
[0147] (Viv). In Example Viv, the compound or a pharmaceutically acceptable salt thereof, as described in any one of Examples A to D, E to Qi, S to V and Vii, and sub-examples D(i) to D(viii), is wherein alk 1 When present, it is either methylene or ethylene.
[0148] Example W In Example W, the compound or its pharmaceutically acceptable salt as described in any one of Examples A to D and E to V and Vii to Viv, and sub-examples D(i) to D(viii) and Vi, is wherein Ar is a phenylene or a 5- or 6-membered heteroaryl group, and each ring is enclosed by R. 2 and R 3 replace.
[0149] (Wi). In sub-example Wi, the compound or a pharmaceutically acceptable salt thereof, as described in any one of Examples A to D, E to V, Vii to Viv and W, and sub-examples D(i) to D(viii) and Vi, is wherein Ar is R 2 and R 3 Substituted phenylene. In one sub-example of sub-example Wi, the compound or a pharmaceutically acceptable salt thereof as described in any one of Examples A to W (including the sub-examples therein) is wherein -(alk) 1 ) m -S(=NR 8 (=NR) 9 )R 7 The carbon attached to the phenylene ring is located at the meta position of the carbons that attach the phenylene ring to the remaining portions of the compounds having formulas (I) and (Ia) to (Ih). In another sub-example Wi, the compound or a pharmaceutically acceptable salt thereof as described in any one of Examples A to W (including the sub-examples therein) is wherein -(alk) 1 ) m -S(=NR 8 (=NR) 9 )R 7 The carbon attached to the phenylene ring is located at the para position of the carbons that attach the phenylene ring to the remaining portions of the compounds having formulas (I) and (Ia) to (Ih), respectively.
[0150] (Wii). In sub-example Wii, the compound or a pharmaceutically acceptable salt thereof, as described in any one of Examples A to D, E to V, Vii to Viv and W, and sub-examples D(i) to D(viii) and Vi, is wherein Ar is a 5- or 6-membered heteroaryl group, such as a divalent pyridine, pyrimidine, pyridazine, thiophene, furan, thiazole, oxazole, isoxazole, pyrazole, triazole, oxadiazole, or imidazole, each ring being R 2 and R 3 Substitution. In a sub-example of embodiment Wii, Ar is a hexa-heteroaryl group, such as a divalent pyridine, pyrimidine, or pyridazine, wherein -(alk) 1 ) m -S(=NR 8 (=NR) 9 )R 7 The carbon attached to the pyridine, pyrimidine, or pyridazine ring is located at the meta position of the carbons of the remaining compounds having formulas (I) and (Ia) to (Ih), respectively.
[0151] (Wiii). For sub-examples Wiii, the compound or a pharmaceutically acceptable salt thereof, as described in any one of examples A to D, E to V and Vii to Viv, and sub-examples D(i) to D(viii) and Vi, is wherein Ar is a bicyclic heteroaryl group, such as divalent benzofuran, quinoline, quinazoline, benzimidazole, indazole, benzotriazole, or benzoxazole.
[0152] Example X In Example X, the compound or a pharmaceutically acceptable salt thereof, as described in Examples A to D, E to V and Vii to Viv, and sub-examples D(i) to D(viii) and Vi, is wherein Ar is a cyclic amino group, a spirocyclic cyclic amino group, or a bridged cyclic amino group, and each ring is divided by R 2 and R 3 replace.
[0153] (Xi). In sub-examples Xi, the compound or a pharmaceutically acceptable salt thereof, as described in any one of Examples A to D, E to V, V(ii) to Viv and X, and sub-examples D(i) to D(viii) and Vi, is wherein Ar is a cyclic amino group selected from divalent pyrrolidine, piperidine, or homopiperidine, and each ring is divided by R 2 and R 3 replace.
[0154] (Xii). In sub-examples Xii, the compound or a pharmaceutically acceptable salt thereof, as described in any one of Examples A to D, E to V, V(ii) to Viv and X, and sub-examples D(i) to D(viii) and Vi, is wherein Ar is a spirocyclic cyclic amino group or a bridged cyclic amino group, and each ring is R 2 and R 3 replace.
[0155] (Xiii). In sub-example Xiii, the compound or a pharmaceutically acceptable salt thereof, as described in any one of Examples A to D, E to V, Vii to Viv and X, and sub-examples D(i) to D(viii), Vi, Xi and Xii, is wherein the cyclic amino group, spirocyclic cyclic amino group and bridging cyclic amino group are selected from: Each ring is R 2 and R 3 Replace, and among them Is with -(alk) 1 ) m -S(=NR 8 (=NR) 9 )R 7 The attachment point, and It is the attachment point to the rest of the compound having formulas (I) to (Ih).
[0156] (Xiv). In Example Xiv, the compound or a pharmaceutically acceptable salt thereof, as described in any one of Examples A to D, E to V and Vii to Viv and sub-Examples D(i) to D(viii) and Vi, is wherein Ar is an arylene, a cyclic amino, or a spirocyclic cyclic amino group, and each ring is divided by R 2 and R 3 replace.
[0157] (Xv). In Example Xv, the compound or a pharmaceutically acceptable salt thereof, as described in any one of Examples A to D, E to V, Vii to Viv and Xiv and sub-Examples D(i) to D(viii) and Vi, is wherein Ar is phenylene, piperidinyl, or 2-azaspiro[3.3]heptene, and each ring is R 2 and R 3 Substitution. It should be understood that phenylene, piperidinyl and 2-azaspiro[3.3]heptene refer to divalent phenyl, piperidinyl and 2-azaspiro[3.3]heptane, respectively.
[0158] (Xvi). In Example Xvi, the compound or a pharmaceutically acceptable salt thereof, as described in any one of Examples A to D, E to V, Vii to Viv, Xiv and Xv, and sub-examples D(i) to D(viii) and Vi, is wherein Ar is Each ring is R 2 and R 3 Replace, and among them Is with -(alk) 1 ) m -S(=NR 8 (=NR) 9 )R 7 The attachment point, and It is the attachment point to the rest of the compound having formulas (I) to (Ih).
[0159] Example Y In Example Y, the compound or a pharmaceutically acceptable salt thereof, as described in Examples A to D, E to V, Vii to Viv, W, X and Xvi to Xvi, and sub-examples D(i) to D(viii), Wi to Wiii, Vi and Xi to Xiii, and any of the sub-examples contained herein, is wherein R 1 It does not exist; it is an alkyl, alkoxy, halogroup, haloalkyl, or haloalkoxy group.
[0160] (Yi). In sub-example Yi, the compound or a pharmaceutically acceptable salt thereof as described in any one of examples A to D, E to V, Vii to Viv, W, X, Xvi to Xvi and Y, and sub-examples D(i) to D(viii), Vi, Wi to Wiii and Xi to Xiii is wherein R 1 It is absent, alkyl or halogenated, preferably R. 1 It does not exist; it is methyl, ethyl, isopropyl, or fluorine.
[0161] (Yii). In sub-example Yiii, the compound or a pharmaceutically acceptable salt thereof as described in any one of examples A to D, E to V, Vii to Viv, W, X, Xvi to Xvi and Y, and sub-examples D(i) to D(viii), Vi, Wi to Wiii, Wi to Wiii, Xi to Xiii and Yi is wherein R 1 It does not exist; it is methyl, ethyl, or isopropyl.
[0162] (Yiii). In sub-example Yiii, the compound or a pharmaceutically acceptable salt thereof as described in any one of examples A to D, E to V, Vii to Viv, W, X, Xvi to Xvi and Y, and sub-examples D(i) to D(viii), Vi, Wi to Wiii, Xi to Xiii, Yi and Yiii is wherein R 1 It does not exist.
[0163] (Yiv). In sub-examples Yiv, the compound or a pharmaceutically acceptable salt thereof as described in any one of examples A to D, E to V, Vii to Viv, W, X, Xvi to Xvi and Y, and sub-examples D(i) to D(viii), Vi, Wi to Wiii and Xi to Xiii is wherein R 1 It is a halogenated group, a halogenated alkyl group, or a halogenated alkoxy group.
[0164] (Yv). In sub-example Yv, the compound or a pharmaceutically acceptable salt thereof as described in any one of examples A to D, E to V, Vii to Viv, W, X and Xvi to Xvi, and sub-examples D(i) to D(viii), Vi, Wi to Wiii and Xi to Xiii is wherein R 1 It is an amino, alkylamino, or dialkylamino, preferably an amino, methylamino, or dimethylamino.
[0165] (Yvi). In sub-example Yvi, the compound or a pharmaceutically acceptable salt thereof, as described in any one of examples A to D, E to V, Vii to Viv, W, X and Xvi to Xvi, and sub-examples D(i) to D(viii), Vi, Wi to Wiii and Xi to Xiii, is R. 1It is hydroxyalkyl, alkoxyalkyl, hydroxyalkoxy, alkoxyalkoxy, hydroxyalkylamino, alkoxyalkylamino, aminoalkyl, aminoalkoxy, aminoalkylamino, diaminoalkyl, diaminoalkoxy, diaminoalkylamino, or cyano, preferably hydroxymethyl, methoxymethyl, or ethoxymethyl.
[0166] Example Z In Example Z, the compound or a pharmaceutically acceptable salt thereof, as described in any one of Examples A to D, E to V, Vii to Viv, W, X, Xvi to Xvi and Y, and sub-examples D(i) to D(viii), Vi, Wi to Wiii, Xi to Xiii and Yi to Yvi, is wherein R 2 and R 3 Each of these groups is independent of the following: methyl, ethyl, methoxy, fluorine, trifluoromethyl, trifluoromethoxy, or cyano.
[0167] (Zi). In sub-examples Zi, the compound or a pharmaceutically acceptable salt thereof, as described in any one of examples A to D, E to V, Vii to Viv, W, X, Xvi to Xvi, Y and Z, and sub-examples D(i) to D(viii), Vi, Wi to Wiii, Xi to Xiii and Yi to Yvi, is wherein R 2 and R 3 It does not exist.
[0168] (Zii). In Example Ziii, the compound or a pharmaceutically acceptable salt thereof, as described in any one of Examples A to D, E to V, Vii to Viv, W, X, Xvi to Xvi, Y and Z, and sub-examples D(i) to D(viii), Vi, Wi to Wiii, Xi to Xiii and Yi to Yvi, is wherein R 2 and R 3 They do not exist independently, or they are fluorine.
[0169] Example A1 In Example A1, the compound or a pharmaceutically acceptable salt thereof as described in any one of Examples A to D, E to V, Vii to Viv, W, X, Xvi to Xvi, Y, Z and Zi, and sub-examples D(i) to D(viii), Vi, Wi to Wiii, Xi to Xiii, Yi to Yvi and Zi is wherein R 4 It does not exist; it is alkyl, alkoxy, alkylsulfonyl, halogroup, haloalkyl, haloalkoxy, cyano, carboxyl, alkoxycarbonyl, hydroxyl, aminocarbonyl, alkylaminocarbonyl, or dialkylaminocarbonyl.
[0170] (A1i). In sub-example A1i, the compound or a pharmaceutically acceptable salt thereof as described in any one of examples A to D, E to V, Vii to Viv, W, X, Xvi to Xvi, Y, Z, Zii and A1, and sub-examples D(i) to D(viii), Vi, Wi to Wiii, Xi to Xiii, Yi to Yvi and Zi is wherein R 4 It does not exist; it is methyl, methoxy, ethoxy, fluorine, chlorine, trifluoromethyl, hydroxy, cyano, or trifluoromethyloxy.
[0171] (A1ii). In sub-example A1ii, the compound or a pharmaceutically acceptable salt thereof as described in any one of examples A to D, E to V, Vii to Viv, W, X, Xvi to Xvi, Y, Z, Zii and A1, and sub-examples D(i) to D(viii), Vi, Wi to Wiii, Xi to Xiii, Yi to Yvi, Zi and A1i is wherein R 4 It does not exist; it is either methoxy or ethoxy.
[0172] (A1iii). In sub-example A1iii, the compound or a pharmaceutically acceptable salt thereof as described in any one of Examples A to D, E to V, Vii to Viv, W, X, Xvi to Xvi, Y, Z, Zii and A1, and sub-examples D(i) to D(viii), Vi, Wi to Wiii, Xi to Xiii, Yi to Yvi and Zi is wherein R 4 It is cyano, carboxyl, alkoxycarbonyl, alkylsulfonyl, hydroxy, aminocarbonyl, alkylaminocarbonyl, or dialkylaminocarbonyl.
[0173] (A1iv). In sub-example A1iv, the compound or a pharmaceutically acceptable salt thereof as described in any one of examples A to D, E to V, Vii to Viv, W, X, Xvi to Xvi, Y, Z, Zii and A1, and sub-examples D(i) to D(viii), Vi, Wi to Wiii, Xi to Xiii, Yi to Yvi, Zi, A1i and A1iii is wherein R 4 It is cyano, carboxyl, methoxycarbonyl, methanesulfonyl, aminocarbonyl, hydroxy, methylaminocarbonyl, dimethylaminocarbonyl, or.
[0174] (A1v). In sub-example A1v, the compound or a pharmaceutically acceptable salt thereof as described in any one of examples A to D, E to V, Vii to Viv, W, X, Xvi to Xvi, Y, Z, Zii and A1, and sub-examples D(i) to D(viii), Vi, Wi to Wiii, Xi to Xiii, Yi to Yvi, Zi, A1iii and A1iv is wherein R 4It is cyano, hydroxy, aminocarbonyl, methanesulfonyl, methylaminocarbonyl, or dimethylaminocarbonyl.
[0175] (A1vi). In sub-example A1vi, the compound or a pharmaceutically acceptable salt thereof as described in any one of examples A to D, E to V, Vii to Viv, W, X, Xvi to Xvi, Y, Z, Zii and A1, and sub-examples D(i) to D(viii), Vi, Wi to Wiii, Xi to Xiii, Yi to Yvi, Zi and A1iii to A1v is wherein R 4 It is aminocarbonyl, methylaminocarbonyl, or dimethylaminocarbonyl.
[0176] (A1vii). In sub-example A1vii, the compound or a pharmaceutically acceptable salt thereof as described in any one of examples A to D, E to V, Vii to Viv, W, X, Xvi to Xvi, Y, Z, Zii and A1, and sub-examples D(i) to D(viii), Vi, Wi to Wiii, Xi to Xiii, Yi to Yvi, Zi and A1i to A1vi is wherein R 4 Attach a six-membered ring containing a, b, d, and e of formulas (I) to (Ih) to any of the carbons shown in formulas (a) to (c): The wavy lines represent the attachment points to the rest of the molecule.
[0177] (A1viii). In Example A1viii, the compound or a pharmaceutically acceptable salt thereof as described in any one of Examples A to D, E to V, Vii to Viv, W, X, Xvi to Xvi, Y, Z, Zii and A1, and sub-examples D(i) to D(viii), Vi, Wi to Wiii, Xi to Xiii, Yi to Yvi, Zi is wherein R 4 It is an alkoxy or haloalkoxy group.
[0178] (A1ix). In Example A1ix, the compound or a pharmaceutically acceptable salt thereof as described in any one of Examples A to D, E to V, Vii to Viv, W, X, Xvi to Xvi, Y, Z, Zii, A1 and A1viii, and sub-examples D(i) to D(viii), Vi, Wi to Wiii, Xi to Xiii, Yi to Yvi and Zi is wherein R 4 It is methoxy or fluoromethoxy.
[0179] Example B1 In Example B1, the compound or a pharmaceutically acceptable salt thereof as described in any one of Examples A to D, E to V, Vii to Viv, W, X, Xvi to Xvi, Y, Z, Zii, A1, A1viii and A1ix, and sub-examples D(i) to D(viii), Vi, Wi to Wiii, Xi to Xiii, Yi to Yvi, Zi and A1i to A1vii is wherein R 5 and R 6 It does not exist.
[0180] (B1i). In sub-example B1i, the compound or a pharmaceutically acceptable salt thereof as described in any one of examples A to D, E to V, Vii to Viv, W, X, Xvi to Xvi, Y, Z, Zii, A1, A1viii and A1ix, and sub-examples D(i) to D(viii), Vi, Wi to Wiii, Xi to Xiii, Yi to Yvi, Zi and A1i to A1vi is wherein R 5 and R 6 Each of the following is independent of the following: alkyl, alkoxy, hydroxy, amino, halogenated, haloalkyl, or haloalkoxy.
[0181] (B1ii). In sub-example B1ii, the compound or a pharmaceutically acceptable salt thereof as described in any one of examples A to D, E to V, Vii to Viv, W, X, Xvi to Xvi, Y, Z, Zii, A1, A1viii and A1ix, and sub-examples D(i) to D(viii), Vi, Wi to Wiii, Xi to Xiii, Yi to Yvi, Zi, A1i to A1vi and B1i is wherein R 5 and R 6 Each of the following is independent of the following: methyl, methoxy, ethoxy, propoxy, hydroxy, fluorine, difluoromethyl, trifluoromethyl, difluoromethoxy, or trifluoromethoxy.
[0182] (B1iii). In sub-example B1iii, the compound or a pharmaceutically acceptable salt thereof as described in any one of Examples A to D, E to V, Vii to Viv, W, X, Xvi to Xvi, Y, Z, Zii, A1, A1viii and A1ix, and sub-examples D(i) to D(viii), Vi, Wi to Wiii, Xi to Xiii, Yi to Yvi, Zi, A1i to A1vi, B1i and B1ii is wherein R 5 and R 6 Each of these is independent of the following: methyl, methoxy, ethoxy, hydroxy, fluorine, difluoromethoxy, or trifluoromethoxy.
[0183] (B1iv). In sub-example B1iv, the compound or a pharmaceutically acceptable salt thereof as described in any one of examples A to D, E to V, Vii to Viv, W, X, Xvi to Xvi, Y, Z, Zii, A1, A1viii and A1ix, and sub-examples D(i) to D(viii), Vi, Wi to Wiii, Xi to Xiii, Yi to Yvi, Zi, A1i to A1vi and B1i to B1iii is wherein R 5 and R 6 Each of these substances, independently, does not exist; they are methoxy, ethoxy, propoxy, or fluorine.
[0184] (B1v). In sub-example B1v, the compound or a pharmaceutically acceptable salt thereof as described in any one of Examples A to D, E to V, Vii to Viv, W, X, Xvi to Xvi, Y, Z, Zii, A1, A1viii and A1ix, and sub-examples D(i) to D(viii), Vi, Wi to Wiii, Xi to Xiii, Yi to Yvi, Zi, A1i to A1vi and B1i to B1iv is wherein R 5 and R 6 The following is an example of a six-membered ring containing a, b, d, and e attached to equation I to (Ih). The wavy lines represent attachment points to the rest of the molecule. In one embodiment, R 4 It does not exist.
[0185] (B1vi). In Example B1vi, the compound or a pharmaceutically acceptable salt thereof as described in any one of Examples A to D, E to V, Vii to Viv, W, X, Xvi to Xvi, Y, Z, Zii and A1, and sub-examples D(i) to D(viii), Vi, Wi to Wiii, Xi to Xiii, Yi to Yvi, Zi, A1i, A1ii, B1i and B1v is wherein R 5 and R 6 Each of these is independent of the following: alkoxy, halogenated, or haloalkoxy groups.
[0186] (B1vii). In Example B1vii, the compound or a pharmaceutically acceptable salt thereof as described in any one of Examples A to D, E to V, Vii to Viv, W, X, Xvi to Xvi, Y, Z, Zii, A1 and B1vi, and sub-examples D(i) to D(viii), Xi to Xiii, Vi, Wi to Wiii, Yi to Yvi, Zi, A1i, A1ii, B1i and B1v is wherein R 5 and R 6Each of these is independent of the presence of methoxy, fluorine, or fluoromethoxy.
[0187] (B1viii). In Example B1viii, the compound or its pharmaceutically acceptable salt as described in Example B1vii is wherein R 4 It does not exist.
[0188] Example C1 In Example C1, the compound or a pharmaceutically acceptable salt thereof as described in any one of Examples A to D, E to V, Vii to Viv, W, X, Xvi to Xvi, Y, Z and Zi, and sub-examples D(i) to D(viii), Vi, Wi to Wiii, Xi to Xiii, Yi to Yvi and Zi, is wherein: R 4 It does not exist; R 5 It is not present; alkyl, alkoxy, hydroxy, halogroup, haloalkyl, or haloalkoxy; and R 6 It is hydroxyalkyl, alkoxyalkyl, hydroxyalkoxy, alkoxyalkoxy, hydroxyalkylamino, alkoxyalkylamino, aminoalkyl, aminoalkoxy, aminoalkylamino, heterocyclic, heterocyclic oxy, heterocyclic amino (wherein the heterocyclic group, alone or as part of the heterocyclic oxy and heterocyclic amino groups, may be optionally substituted by one, two or three substituents, each independently selected from alkyl, halogroup, hydroxy, alkoxy, hydroxyalkyl, alkoxyalkyl, and aminoalkyl), heterocyclic alkyl, heterocyclic alkyloxy, heterocyclic alkylamino (wherein the heterocyclic ring in the heterocyclic alkyl, heterocyclic alkyloxy, and heterocyclic alkylamino groups is substituted by 0 to 3 substituents, each independently selected from alkyl, halogroup, hydroxy, alkoxy, hydroxyalkyl, alkoxyalkyl, and aminoalkyl), cycloalkyloxy, phenyloxy, or heteroaryloxy (wherein the phenyl in the phenyloxy group and the heteroaryl in the heteroaryloxy group are substituted by 0 to 3 substituents, each independently selected from alkyl, hydroxy, alkoxy, halogroup, haloalkyl, haloalkoxy, and cyano).
[0189] (C1i). In sub-example C1i, the compound or its pharmaceutically acceptable salt as described in example C1 is wherein R 5 It is non-existent, methoxy, ethoxy, or hydroxyl, preferably R. 5 It is methoxy or ethoxy; and R 6It is 2-hydroxyethyloxy, 3-hydroxypropyloxy, 2-methoxyethyloxy, 2-ethoxyethyloxy, 3-methoxypropyloxy, 3-ethoxypropyloxy, 2-aminoethyloxy, 2-methylaminoethyloxy, 2-dimethylaminoethyloxy, 2-diethylaminoethyloxy, 3-aminopropyloxy, 3-methylaminopropyloxy, 3-dimethylaminopropyloxy, 3-diethylaminopropyloxy, pyrrolyloxy, piperidinyloxy, pyrrolylmethyloxy, piperidinylmethyloxy, pyrrolylethyloxy, piperidinylethyloxy, 2-hydroxyethylamino, 3-hydroxypropylamino, 2-methoxyethylamino, 2-ethoxyethyloxy 3-aminopropylamino, 3-methoxypropylamino, 3-ethoxypropylamino, 2-aminoethylamino, 2-methylaminoethylamino, 2-dimethylaminoethylamino, 2-diethylaminoethylamino, 3-aminopropylamino, 3-methylaminopropylamino, 3-dimethylaminopropylamino, 3-diethylaminopropylamino, pyrrolylamino, piperidinylamino, pyrrolylmethylamino, piperidinylmethylamino, pyrrolylethylamino, or piperidinylethylamino (wherein the pyrrolyl and piperidinyl groups in each of the above groups are substituted by 0 to 2 substituents, each independently selected from methyl, fluorine, hydroxy, or methoxy).
[0190] (C1ii). In Example C1ii, the compound or a pharmaceutically acceptable salt thereof as described in any one of Examples C1 and C1i is wherein R 5 and R 6 The following is an example of a six-membered ring containing a, b, d, and e attached to equations I to (Ih): The wavy lines represent the attachment points to the rest of the molecule.
[0191] Example D1 In Example D1, the compound or a pharmaceutically acceptable salt thereof as described in any one of Examples A to D, E to V, Vii to Viv, W, X, Xvi to Xvi, Y, Z and Zi, and sub-examples D(i) to D(viii), Vi, Wi to Wiii, Xi to Xiii, Yi to Yvi and Zi is wherein R 4 It does not exist, R 5 and R 6Each of the following is independently selected from hydroxyalkyl, alkoxyalkyl, hydroxyalkoxy, alkoxyalkoxy, hydroxyalkylamino, alkoxyalkylamino, aminoalkyl, aminoalkoxy, aminoalkylamino, heterocyclic, heterocyclic oxy, heterocyclic amino (wherein the heterocyclic group is substituted by 0 to 3 substituents, individually or as part of the heterocyclic oxy and heterocyclic amino groups, each independently selected from alkyl, halogroup, hydroxy, alkoxy, hydroxyalkyl, alkoxyalkyl, and aminoalkyl), heterocyclic alkyl, heterocyclic alkyloxy, heterocyclic alkylamino (wherein the heterocyclic ring in the heterocyclic alkyl, heterocyclic alkyloxy, and heterocyclic alkylamino groups is optionally substituted by one, two, or three substituents, each independently selected from alkyl, haloyl, hydroxy, alkoxy, hydroxyalkyl, alkoxyalkyl, and aminoalkyl), cycloalkyloxy, phenyloxy, or heteroaryloxy (wherein the phenyl group of the phenyloxy group and the heteroaryl group of the heteroaryloxy group are substituted by 0 to 3 substituents, each independently selected from alkyl, hydroxy, alkoxy, haloyl, haloalkyl, haloalkoxy, and cyano).
[0192] (D1i). In Example D1i, the compound or its pharmaceutically acceptable salt as described in Example D1 is wherein R 5 and R 6 Each of the following is independently 2-hydroxyethyloxy, 3-hydroxypropyloxy, 2-methoxyethyloxy, 2-ethoxyethyloxy, 3-methoxypropyloxy, 3-ethoxypropyloxy, 2-aminoethyloxy, 2-methylaminoethyloxy, 2-dimethylaminoethyloxy, 2-diethylaminoethyloxy, 3-aminopropyloxy, 3-methylaminopropyloxy, 3-dimethylaminopropyloxy, 3-diethylaminopropyloxy, pyrrolyloxy, piperidinyloxy, pyrrolylmethyloxy, piperidinylmethyloxy, pyrrolylethyloxy, piperidinylethyloxy, 2-hydroxyethylamino, 3-hydroxypropylamino, 2-methoxyethylamino, 2-ethyl oxyethylamino, 3-methoxypropylamino, 3-ethoxypropylamino, 2-aminoethylamino, 2-methylaminoethylamino, 2-dimethylaminoethylamino, 2-diethylaminoethylamino, 3-aminopropylamino, 3-methylaminopropylamino, 3-dimethylaminopropylamino, 3-diethylaminopropylamino, pyrrolylamino, piperidinylamino, pyrrolylmethylamino, piperidinylmethylamino, pyrrolylethylamino, or piperidinylethylamino (wherein the pyrrolyl and piperidinyl groups in each of the above groups are substituted by 0 to 2 substituents, each independently selected from methyl, fluorine, hydroxy, or methoxy).
[0193] (D1ii). In Example D1ii, the compound as described in any one of Examples D1 and D1i, or a pharmaceutically acceptable compound thereof, is wherein R 5 and R 6The following is a six-membered ring containing a, b, d, and e attached to equation I to (Ih): The wavy lines represent the attachment points to the rest of the molecule.
[0194] Example E1 In Example E1, the compound or a pharmaceutically acceptable salt thereof, as described in any one of Examples A to D, E to V, Vii to Viv, W, X, Xvi to Xvi, Y, Z, Zii, A1, A1viii, A1ix, B1, B1vi, B1vii, C1 and D1 to D1ii, and sub-examples D(i) to D(viii), Vi, Wi to Wiii, Xi to Xiii, Yi to Yvi, Zi, A1i to A1vii, B1i to B1v, C1i and C1ii, 7 It is an alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, aminocarbonylalkyl, carbonylaminoalkyl, carboxyaminoalkyl, cyanoalkyl, cycloalkyl, cycloalkylalkyl, aryl, fused aryl, heteroaryl, fused heteroaryl, heterocyclic, aralkyl, heteroarylalkyl, aryloxyalkyl, heteroaryloxyalkyl, fused aralkyl, fused heteroarylalkyl, or heterocyclic alkyl, wherein the cyclic portion of the cycloalkyl, aryl, fused aryl, heteroaryl, fused heteroaryl, heterocyclic, and cycloalkylalkyl, arylalkyl, heteroarylalkyl, aryloxyalkyl, heteroaryloxyalkyl, fused aralkyl, fused heteroarylalkyl, or heterocyclic alkyl is substituted with one, two, or three substituents, each independently selected from hydrogen, alkyl, haloyl, haloalkyl, haloalkoxy, hydroxy, alkoxy, cyano, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocyclic, and R 8 and R 9 Each of the following is independently selected from hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, aminocarbonylalkyl, carbonylaminoalkyl, carboxyaminoalkyl, cyanoalkyl, cycloalkyl, cycloalkylalkyl, aryl, fused aryl, heteroaryl, fused heteroaryl, heterocyclic, aralkyl, heteroarylalkyl, aryloxyalkyl, heteroaryloxyalkyl, fused arylalkyl, fused heteroarylalkyl, or heterocyclic alkyl, wherein the cyclic portion of the cycloalkyl, aryl, fused aryl, heteroaryl, fused heteroaryl, heterocyclic, and cycloalkylalkyl, arylalkyl, heteroarylalkyl, aryloxyalkyl, heteroaryloxyalkyl, fused arylalkyl, fused heteroarylalkyl, or heterocyclic alkyl is substituted with one, two, or three substituents, each independently selected from hydrogen, alkyl, haloalkyl, haloalkyl, haloalkoxy, hydroxyl, alkoxy, cyano, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocyclic.
[0195] (E1i). In sub-examples (E1i), the compound or a pharmaceutically acceptable salt thereof as described in any one of Examples A to D, E to V, Vii to Viv, W, X, Xvi to Xvi, Y, Z, Zii, A1, A1viii, A1ix, B1, B1vi, B1vii, C1 and D1 to D1ii and E1, and sub-examples D(i) to D(viii), Vi, Wi to Wiii, Xi to Xiii, Yi to Yvi, Zi, A1i to A1vii, B1i to B1v, C1i and C1ii is wherein R 7 It is an alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, aminocarbonylalkyl, carbonylaminoalkyl, carboxyaminoalkyl, cyanoalkyl, cycloalkyl, cycloalkylalkyl, aryl, fused aryl, heteroaryl, fused heteroaryl, heterocyclic, aralkyl, heteroarylalkyl, aryloxyalkyl, heteroaryloxyalkyl, fused aralkyl, fused heteroarylalkyl, or heterocyclic alkyl, wherein the cyclic portion of the cycloalkyl, aryl, fused aryl, heteroaryl, fused heteroaryl, heterocyclic, and cycloalkylalkyl, arylalkyl, heteroarylalkyl, aryloxyalkyl, heteroaryloxyalkyl, fused aralkyl, fused heteroarylalkyl, or heterocyclic alkyl is substituted with one, two, or three substituents, each independently selected from hydrogen, alkyl, haloyl, haloalkyl, haloalkoxy, hydroxy, alkoxy, cyano, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocyclic, and R 8 and R 9 It is hydrogen.
[0196] (E1ii). In sub-examples (E1ii), the compound or a pharmaceutically acceptable salt thereof as described in any one of Examples A to D, E to V, Vii to Viv, W, X, Xvi to Xvi, Y, Z, Zii, A1, A1viii, A1ix, B1, B1vi, B1vii, C1, D1 to D1ii and E1, and sub-examples D(i) to D(viii), Vi, Wi to Wii, Xi to Xiii, Yi to Yvi, Zi, A1i to A1vii, B1i to B1v, C1i and C1ii is wherein R 7 and R 8Each of the following groups is independently alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, aminocarbonylalkyl, carbonylaminoalkyl, carboxyaminoalkyl, cyanoalkyl, cycloalkyl, cycloalkylalkyl, aryl, fused aryl, heteroaryl, fused heteroaryl, heterocyclic, aralkyl, heteroarylalkyl, aryloxyalkyl, heteroaryloxyalkyl, fused aralkyl, fused heteroarylalkyl, or heterocyclic alkyl, wherein the cyclic portion of the cycloalkyl, aryl, fused aryl, heteroaryl, fused heteroaryl, heterocyclic, and cycloalkylalkyl, arylalkyl, heteroarylalkyl, aryloxyalkyl, heteroaryloxyalkyl, fused aralkyl, fused heteroarylalkyl, or heterocyclic alkyl is substituted with one, two, or three substituents, each independently selected from hydrogen, alkyl, haloalkyl, haloalkyl, haloalkoxy, hydroxy, alkoxy, cyano, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocyclic, and R 9 It is hydrogen.
[0197] (E1iii). In sub-examples (E1iii), the compound or a pharmaceutically acceptable salt thereof as described in any one of Examples A to D, E to V, Vii to Viv, W, X, Xvi to Xvi, Y, Z, Zii, A1, A1viii, A1ix, B1, B1vi, B1vii, C1, D1 to D1ii and E1, and sub-examples D(i) to D(viii), Vi, Wi to Wii, Xi to Xiii, Yi to Yvi, Zi, A1i to A1vii, B1i to B1v, C1i and C1ii is wherein R 7 R 8 and R 9 Each is independently an alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, aminocarbonylalkyl, carbonylaminoalkyl, carboxyaminoalkyl, cyanoalkyl, cycloalkyl, cycloalkylalkyl, aryl, fused aryl, heteroaryl, fused heteroaryl, heterocyclic, aralkyl, heteroarylalkyl, aryloxyalkyl, heteroaryloxyalkyl, fused arylalkyl, fused heteroarylalkyl, or heterocyclic alkyl, wherein the cyclic portion of the cycloalkyl, aryl, fused aryl, heteroaryl, fused heteroaryl, heterocyclic, and cycloalkylalkyl, arylalkyl, heteroarylalkyl, aryloxyalkyl, heteroaryloxyalkyl, fused arylalkyl, fused heteroarylalkyl, or heterocyclic alkyl is substituted with one, two, or three substituents, each independently selected from hydrogen, alkyl, haloalkyl, haloalkyl, haloalkoxy, hydroxyl, alkoxy, cyano, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocyclic.
[0198] (E1iv). In sub-examples (E1iv), the compound or a pharmaceutically acceptable salt thereof, as described in any one of Examples A to D, E to V, Vii to Viv, W, X, Xvi to Xvi, Y, Z, Zii, A1, A1viii, A1ix, B1, B1vi, B1vii, C1, D1 to D1ii and E1, and sub-examples D(i) to D(viii), Vi, Wi to Wiii, Xi to Xiii, Yi to Yvi, Zi, A1i to A1vii, B1i to B1v, C1i, C1ii and E1i to E1iii, wherein R 7 It is an alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, cycloalkyl, cycloalkylalkyl, or heterocyclic group, wherein the cycloalkyl and heterocyclic groups are substituted by one, two, or three substituents, each independently selected from hydrogen, alkyl, haloyl, haloalkyl, haloalkoxy, hydroxyl, alkoxy, cyano, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocyclic group.
[0199] (E1v). In sub-examples (E1v), the compound or a pharmaceutically acceptable salt thereof as described in any one of Examples A to D, E to V, Vii to Viv, W, X, Xvi to Xvi, Y, Z, Zii, A1, A1viii, A1ix, B1, B1vi, B1vii, C1, D1 to D1ii and E1, and sub-examples D(i) to D(viii), Vi, Wi to Wiii, Xi to Xiii, Yi to Yvi, Zi, A1i to A1vii, B1i to B1v, C1i, C1ii and E1i to E1iv is wherein R 7 It is an alkyl group.
[0200] (E1vi). In sub-examples (E1vi), the compound or a pharmaceutically acceptable salt thereof as described in any one of Examples A to D, E to V, Vii to Viv, W, X, Xvi to Xvi, Y, Z, Zii, A1, A1viii, A1ix, B1, B1vi, B1vii, C1, D1 to D1ii and E1, and sub-examples D(i) to D(viii), Vi, Wi to Wiii, Xi to Xiii, Yi to Yvi, Zi, A1i to A1vii, B1i to B1v, C1i, C1ii and E1i to E1iv is wherein R 7 It is hydroxyalkyl, aminoalkyl, or alkoxyalkyl.
[0201] (E1vii). In sub-examples (E1vii), the compound or a pharmaceutically acceptable salt thereof, as described in any one of Examples A to D, E to V, Vii to Viv, W, X, Xvi to Xvi, Y, Z, Zii, A1, A1viii, A1ix, B1, B1vi, B1vii, C1, D1 to D1ii and E1, and sub-examples D(i) to D(viii), Vi, Wi to Wiii, Xi to Xiii, Yi to Yvi, Zi, A1i to A1vii, B1i to B1v, C1i, C1ii and E1i to E1iv, is wherein R 7 It is a haloalkyl group.
[0202] (E1viii). In sub-examples (E1viii), the compound or a pharmaceutically acceptable salt thereof as described in any one of Examples A to D, E to V, Vii to Viv, W, X, Xvi to Xvi, Y, Z, Zii, A1, A1viii, A1ix, B1, B1vi, B1vii, C1, D1 to D1ii and E1, and sub-examples D(i) to D(viii), Vi, Wi to Wiii, Xi to Xiii, Yi to Yvi, Zi, A1i to A1vii, B1i to B1v, C1i, C1ii and E1i to E1iv is wherein R 7 It is cycloalkyl or cycloalkylalkyl.
[0203] (E1ix). In sub-examples (E1ix), the compound or a pharmaceutically acceptable salt thereof, as described in any one of Examples A to D, E to V, Vii to Viv, W, X, Xvi to Xvi, Y, Z, Zii, A1, A1viii, A1ix, B1, B1vi, B1vii, C1, D1 to D1ii and E1, and sub-examples D(i) to D(viii), Vi, Wi to Wiii, Xi to Xiii, Yi to Yvi, Zi, A1i to A1vii, B1i to B1v, C1i, C1ii and E1i to E1iv, is wherein R 7 It is a substituted heterocyclic group as described above.
[0204] (E1x). In sub-examples (E1x), the compound or a pharmaceutically acceptable salt thereof as described in any one of Examples A to D, E to V, Vii to Viv, W, X, Xvi to Xvi, Y, Z, Zii, A1, A1viii, A1ix, B1, B1vi, B1vii, C1, D1 to D1ii and E1, and sub-examples D(i) to D(viii), Vi, Wi to Wiii, Xi to Xiii, Yi to Yvi, Zi, A1i to A1vii, B1i to B1v, C1i, C1ii and E1ii to E1ix is wherein R8 and R 9 Each is independently hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocyclic, aralkyl, heteroaryl, aryloxyalkyl, heteroaryloxyalkyl, or heterocyclic alkyl, wherein the cyclic portion of the cycloalkyl, aryl, heteroaryl, heterocyclic, and cycloalkylalkyl, arylalkyl, heteroarylalkyl, aryloxyalkyl, heteroaryloxyalkyl, or heterocyclic alkyl is substituted with one, two, or three substituents, each independently selected from hydrogen, alkyl, haloyl, haloalkyl, haloalkoxy, hydroxyl, alkoxy, cyano, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocyclic. For clarity, refer to sub-example (E1i), R 8 and R 9 All are hydrogen, and referring to sub-example (E1iii), none are hydrogen; and referring to sub-example (E1ii), R 8 It's not hydrogen.
[0205] (E1xi). In sub-examples (E1xi), the compound or a pharmaceutically acceptable salt thereof as described in any one of Examples A to D, E to V, Vii to Viv, W, X, Xvi to Xvi, Y, Z, Zii, A1, A1viii, A1ix, B1, B1vi, B1vii, C1, D1 to D1ii, E to V, Vii to Viv, W, X, Xvi to Xvi, Y, Z, Zii, A1, A1viii, A1ix, B1, B1vi, B1vii, C1 and D1 to D1ii and E1, and sub-examples D(i) to D(viii), Vi, Wi to Wiii, Xi to Xiii, Yi to Yvi, Zi, A1i to A1vii, B1i to B1v, C1i, C1ii and E1i to E1x is wherein, unless otherwise stated, R 7 R 8 and R 9Each of these compounds independently is methyl, ethyl, cyclopropyl, cyclopropylmethyl, 1-cyclopropylethyl, 1-hydroxycyclopropyl-1-ylmethyl, 3,3-difluorobutylmethyl, cyclobutylmethyl, -CH2CH2NH2, -CH2CH2NH(COCH3), -CH2CH2NH(COphenyl), 2,2,2-trifluoroethyl, 2-hydroxyethyl, 2-hydroxy-2-methylpropyl, 2,3-dihydroxypropyl, 1-hydroxymethylethyl, 2-hydroxymethyl, 2-hydroxypropyl, carboxymethyl, morpholine- 4-yl, pyrrolyl-1-methyl, phenyl, phenylmethyl, 2-phenylethyl, 1-phenylethyl, 2-phenoxyethyl, 4-pyridin-4-ylphenylmethyl, 4-pyridin-4-ylphenyl, 2-oxazol-2-ylmethyl, 2-thiazol-2-ylmethyl, 1-methylimidazol-2-ylmethyl, pyridin-2-ylmethyl, pyridin-3-ylmethyl, pyridin-4-ylmethyl, 2-pyridin-2-yloxyethyl, 2-pyridin-3-yloxyethyl, or 2-pyridin-4-yloxyethyl.
[0206] (E1xii). In Example E1xii, the compound or a pharmaceutically acceptable salt thereof, as described in any one of Examples A to D, E to V, Vii to Viv, W, X, Xvi to Xvi, Y, Z, Zii, A1, A1viii, A1ix, B1, B1vi, B1vii, C1, D1 to D1ii and E1, and sub-examples D(i) to D(viii), Vi, Wi to Wiii, Xi to Xiii, Yi to Yvi, Zi, A1i to A1vii, B1i to B1v, C1i, C1ii and E1i to E1iv, wherein R 7 It is an alkyl or cycloalkyl group.
[0207] (E1xiii). In Example E1xiii, the compound or a pharmaceutically acceptable salt thereof as described in any one of Examples A to D, E to V, Vii to Viv, W, X, Xvi to Xvi, Y, Z, Zii, A1, A1viii, A1ix, B1, B1vi, B1vii, C1, D1 to D1ii, E1 and E1xii, and sub-examples D(i) to D(viii), Vi, Wi to Wiii, Xi to Xiii, Yi to Yvi, Zi, A1i to A1vii, B1i to B1v, C1i, C1ii and E1i to E1iv, wherein R 7 It is methyl or cyclopropyl.
[0208] (E1xiv). In Example E1xiv, the compound or a pharmaceutically acceptable salt thereof, as described in any one of Examples A to D, E to V, Vii to Viv, W, X, Xvi to Xvi, Y, Z, Zii, A1, A1viii, A1ix, B1, B1vi, B1vii, C1 and D1 to D1ii, E1 and E1xii and E1xiii, and sub-examples D(i) to D(viii), Vi, Wi to Wiii, Xi to Xiii, Yi to Yvi, Zi, A1i to A1vii, B1i to B1v, C1i and C1ii, wherein R 8 and R 9 It is hydrogen or alkyl.
[0209] (E1xv). In Examples E1xv, the compound or a pharmaceutically acceptable salt thereof, as described in any one of Examples A to D, E to V, Vii to Viv, W, X, Xvi to Xvi, Y, Z, Zii, A1, A1viii, A1ix, B1, B1vi, B1vii, C1 and D1 to D1ii, and sub-examples D(i) to D(viii), Vi, Wi to Wiii, Xi to Xiii, Yi to Yvi, Zi, A1i to A1vii, B1i to B1v, C1i and C1ii, wherein R 8 and R 9 It is hydrogen, methyl, ethyl, or isopropyl.
[0210] Example F1 In Example F1, the compound or a pharmaceutically acceptable salt thereof as described in any one of Examples A to E1xv and the sub-examples contained herein, wherein X is N or CH; a is CH; b is CH, or when attached to R 4 R 5 Or R 6 For any one of the options, it is C; d is N, or when attached to R 4 R 5 Or R 6 For any one of the options, it is C; e is N, CH, or when attached to R 4 R 5 Or R 6 For any one of the options, it is C; Z represents a bond or an O; m and n are each 0 or 1 independently; alk is an alkylene group; alk 1 It is an alkylene group; Ar is an arylene, a cyclic amino group, or a spirocyclic cyclic amino group, and each ring is divided by R. 2 and R 3 replace; R 1 It does not exist; R 2 and R 3 They do not exist independently, or are fluorine; R 4 R 5 and R 6 One of them is an alkoxy or a haloalkoxy; and R 4 R 5 and R 6 The remaining two are independently absent: alkoxy, halogroup, or haloalkoxy. R 7 It is an alkyl or cycloalkyl group; and R 8 and R 9 Each is either hydrogen or alkyl.
[0211] (F1i). In Example F1i, the compound or a pharmaceutically acceptable salt thereof as described in any one of Examples A to E1xv and the sub-examples contained herein, wherein X is N or CH; a is CH; b is CH, or when attached to R 4 R 5 Or R 6 For any one of the options, it is C; d is N, or when attached to R 4 R 5 Or R 6 For any one of the options, it is C; e is N, CH, or when attached to R 4 R 5 Or R 6 For any one of the options, it is C; Z represents a bond or an O; m and n are each 0 or 1 independently; alk is methylene; alk 1 It is methylene or ethylene; Ar is Each ring is R 2 and R 3 Replace, and among them Is with -(alk) 1 ) m -S(=NR 8 (=NR)9 )R 7 The attachment point, and It is the attachment point to the rest of the compound having formula (I); R 1 It does not exist; R 2 and R 3 They do not exist independently, or are fluorine; R 4 R 5 and R 6 One of them is methoxy or fluoromethoxy; and R 4 R 5 and R 6 The remaining two are independently non-existent: methoxy, fluorine, or fluoromethoxy. R 7 It is methyl or cyclopropyl; and R 8 and R 9 Each can be hydrogen, methyl, ethyl, or isopropyl.
[0212] (F1ii). In Example F1ii, the compound or a pharmaceutically acceptable salt thereof is selected from Tables 1A and 1B. In some embodiments, the compound or a pharmaceutically acceptable salt thereof is selected from Table 1A. In some embodiments, the compound or a pharmaceutically acceptable salt thereof is selected from Table 1B.
[0213] General synthesis scheme The compounds disclosed herein can be prepared by the method described in the reaction scheme shown below.
[0214] The starting materials and reagents used to prepare these compounds may be obtained from commercial suppliers such as Aldrich Chemical Co. (Milwaukee, Wisconsin), Bachem (Torrance, California), or Sigma (St. Louis, Missouri) or prepared by methods known to those skilled in the art following procedures listed in the following references: Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1–17 (John Willie & Son, 1991); Rodd's Chemistry of Carbon Compounds, Volumes 1–5 and Supplements (Elsevier Science Publishers, 1989); Organic Reactions, Volumes 1–40 (John Willie & Son, 1991). References include: March's Advanced Organic Chemistry (John Willie & Son, 4th edition); and Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989). These schemes are merely illustrative of some methods for synthesizing the compounds disclosed herein, and various modifications can be made to these schemes, as will be apparent to those skilled in the art upon reading this disclosure. If desired, the starting materials and intermediates of the reaction, as well as the final products, can be separated and purified using conventional techniques, including but not limited to filtration, distillation, crystallization, and chromatography. Such materials can be characterized using conventional methods, including physical constants and spectroscopic data.
[0215] Unless otherwise specified, the reactions described herein occur at atmospheric pressure in the temperature range of about -78°C to about 150°C, such as about 0°C to about 125°C, and further as at about room temperature (or ambient temperature), such as about 20°C.
[0216] Compounds having formula (I) as defined in the invention can be prepared as illustrated and described in Scheme 1 below.
[0217] Option 1 Compounds having Formula 1 (where hal is a halogenated group such as chlorine, and X is CH, N, or R) 1 R 4 R 5 and R 6 (as defined in the invention) and compounds having Formula 2 (where Z, n, m, Ar, R) 2 R 3 and R 7 The reaction (as defined in the invention summary) provides a sulfide of a compound having Formula 3. This reaction is carried out at room temperature or under heating using an organic base (such as DIEA, TEA, etc.) or an inorganic base in an aprotic organic solvent (such as NMP, 1,3-dioxolane, TOU (2,5,7,10-tetraoxaundecanane), DMSO, DMPU, HMA, 1,4-dioxane, tetrahydrofuran (THF), dimethylformamide (DMF), etc.). Compounds having Formula 1 (such as 4-chloro-1,7-naphthidine or 4-chloro-8-methoxypyrido[3,4-d]pyrimidine) are commercially available. Compounds having Formula 1 can also be obtained by treating a hydroxyl compound (such as 8-methoxy-1,7-naphthidine-4-ol) with an organic aprotic base in an aprotic solvent under heating or at room temperature using a chlorinating agent (such as P(O)Cl3). As described in the following working example, a compound having formula 3 is converted into a compound having formula (I) by treatment with ammonia and tert-butyl hypochlorite.
[0218] test The ENPP1 inhibitory activity of the compounds disclosed herein can be tested using the in vitro assays described in the following biological examples 1 and 2.
[0219] Dosing and Pharmaceutical Composition Generally, the compounds disclosed herein will be administered in a therapeutically effective amount via any acceptable mode of administration for agents of similar efficacy. The therapeutically effective amount of the compounds disclosed herein can range from about 0.01 to about 500 mg per kg of patient body weight per day, and can be administered in single or multiple doses. Suitable dose levels can be from about 0.1 to about 250 mg / kg per day; or from about 0.5 to about 100 mg / kg per day. Suitable dose levels can be from about 0.01 to about 250 mg / kg per day, from about 0.05 to about 100 mg / kg per day, or from about 0.1 to about 50 mg / kg per day. Within this range, the dose can be from about 0.05 to about 0.5 mg / kg per day, from about 0.5 to about 5 mg / kg per day, or from about 5 to about 50 mg / kg per day. For oral administration, these compositions can be provided in tablet form containing about 1.0 to about 1000 mg of the active ingredient, particularly about 1, 5, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 400, 500, 600, 750, 800, 900, and 1000 mg of the active ingredient. The actual amount of the compounds disclosed herein (i.e., the active ingredients) will depend on a variety of factors, such as the severity of the disease to be treated, the patient's age and relative health condition, the potency of the compound used, the route and form of administration, and other factors.
[0220] Generally, the compounds disclosed herein will be administered as pharmaceutical compositions via any of the following routes: oral, systemic (e.g., transdermal, intranasal, or via suppository), or parenteral (e.g., intramuscular, intravenous, or subcutaneous). Preferred administration is oral administration using a convenient daily dosage regimen, which can be adjusted according to the severity of the disease. The compositions may be in the form of tablets, pills, capsules, semi-solid dosage forms, powders, sustained-release formulations, solutions, suspensions, elixirs, aerosols, or any other suitable composition.
[0221] The choice of formulation depends on a variety of factors, such as the mode of drug administration (e.g., for oral administration, formulations in tablet, pill, or capsule form (including enteric-coated or sustained-release tablets, pills, or capsules) are preferred) and the bioavailability of the drug substance. Recently, drug formulations have been developed, particularly for drugs exhibiting poor bioavailability, based on the principle that bioavailability can be increased by increasing surface area (i.e., reducing particle size). For example, U.S. Patent No. 4,107,288 describes a drug formulation having particles in the size range of 10 to 1,000 nm, wherein the active material is loaded on a cross-linked matrix of macromolecules. U.S. Patent No. 5,145,684 describes the production of a drug formulation in which the drug substance is pulverized into nanoparticles (average particle size of 400 nm) in the presence of a surface modifier and then dispersed in a liquid medium to give a drug formulation exhibiting very high bioavailability.
[0222] These compositions typically consist of a combination of the compounds disclosed herein with at least one pharmaceutically acceptable excipient. The acceptable excipient is non-toxic, facilitates administration, and does not adversely affect the therapeutic benefit of the compounds disclosed herein. Such excipients can be any solid, liquid, semi-solid, or, in the case of aerosol compositions, gaseous excipients commonly available to those skilled in the art.
[0223] Solid pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glyceryl monostearate, sodium chloride, and skim milk powder. Liquid and semi-solid excipients can be selected from glycerol, propylene glycol, water, ethanol, and various oils, including those of petroleum, animal, plant, or synthetic origin, such as peanut oil, soybean oil, mineral oil, and sesame oil. Preferred liquid carriers, particularly for injectable solutions, include water, saline, aqueous dextrose, and ethylene glycol.
[0224] Compressed gases can be used to disperse the compounds disclosed herein into aerosol form. Suitable inert gases for this purpose include nitrogen, carbon dioxide, etc.
[0225] Other suitable pharmaceutical excipients and their formulations are described in Remington's Pharmaceutical Sciences, edited by EW Martin (Mack Publishing Company, 20th edition, 2000).
[0226] The levels of compounds in a formulation can vary within the full range employed by those skilled in the art. Typically, based on the total formulation, the formulation will contain approximately 0.01–99.99 wt.% of the compounds disclosed herein, on a weight percentage (wt.%) basis, with the balance being one or more suitable pharmaceutical excipients. For example, the compounds may be present at a level of approximately 1–80 wt.%.
[0227] The compounds disclosed herein can be combined with one or more other drugs to treat diseases or conditions for which the compounds disclosed herein or other drugs may be effective. Such one or more other drugs may be administered concurrently or sequentially with the compounds disclosed herein via their usual route and in their usual amounts. When the compounds disclosed herein are used concurrently with one or more other drugs, pharmaceutical compositions containing unit dosage forms of such other drugs and the compounds disclosed herein are preferred. However, combination therapies may also include the administration of the compounds disclosed herein and one or more other drugs at different overlapping schedules. It is also contemplated that when used in combination with one or more other active ingredients, the compounds disclosed herein and other active ingredients can be administered at lower doses than when used individually. Therefore, the pharmaceutical compositions disclosed herein also include those containing one or more other drugs in addition to the compounds disclosed herein.
[0228] The above combinations include not only combinations of the disclosed compounds with one other drug, but also combinations with two or more other active drugs. Similarly, the disclosed compounds may be used in combination with other drugs used to prevent, treat, control, improve, or reduce the risk of diseases or conditions in which the disclosed compounds are useful. Such other drugs may be administered concurrently or sequentially with the disclosed compounds via their usual route and in their usual amount. When the disclosed compounds are used concurrently with one or more other drugs, pharmaceutical compositions containing such other drugs in addition to the disclosed compounds may be used. Therefore, the pharmaceutical compositions disclosed also include those containing one or more other active ingredients in addition to the disclosed compounds. The weight ratio of the disclosed compounds to the second active ingredient may vary and will depend on the effective dose of each ingredient. Typically, the respective effective doses will be used.
[0229] In cases where a subject in need has cancer or is at risk of developing cancer, the disclosed compounds may be used to treat that subject in any combination with one or more other anticancer agents. In some embodiments, one or more anticancer agents are pro-apoptotic agents. Examples of anticancer agents include, but are not limited to, any of the following: gossyphol, genasense, polyphenol E, chlorhexidine, all-trans retinoic acid (ATRA), lichenin, tumor necrosis factor-associated apoptosis-inducing ligand (TRAIL), 5-aza-2'-deoxycytidine, all-trans retinoic acid, doxorubicin, vincristine, etoposide, gemcitabine, imatinib. TM Gemcitabine, 17-N-allylamino-17-demethoxygerdromycin (17-AAG), flapindole, LY294002, bortezomib, trastuzumab, BAY 11-7082, PKC412, or PD184352, Taxol TM (Also known as "paclitaxel," a well-known anticancer drug that works by enhancing and stabilizing microtubule formation), and Taxol TM Analogs such as Taxotere TM Compounds sharing a basic taxane skeleton as a common structural feature have also shown the ability to arrest cells in the G2-M phase due to stabilized microtubules, and can be combined with the compounds described herein for cancer treatment.
[0230] Further examples of anticancer agents used in combination with the compounds disclosed herein include inhibitors of mitogen-activated protein kinase signaling, such as U0126, PD98059, PD184352, PD0325901, ARRY-142886, SB239063, SP600125, and BAY. 43-9006, Wollman penicillin, or LY294002; Syk inhibitors; antibodies (e.g., rituxan); MET inhibitors, such as foretinib, cabozantinib, or crizotinib; VEGFR inhibitors, such as sunitinib, sorafenib, regorafenib, lenvatinib, vandetanib, cabozantinib, axitinib; EGFR inhibitors, such as afatinib, brinib, cabozantinib, erlotinib, gefitinib, neratinib, lapatinib; PI3K inhibitors, such as XL147, XL765, BKM120 (buparlisib), GDC-0941, BYL719, IPI145, BAY80-6946, BEX235 (dacrolimus). (dactolisib), CAL101 (idelalisib), GSK2636771, TG100-115; mTOR inhibitors, such as rapamycin (sirolimus), tamsulosin, ileolis, XL388, XL765, AZD2013, PF04691502, PKI-587, BEZ235, GDC0349; MEK inhibitors, such as AZD6244, trametinib, PD184352, pimasertinib, GDC-0973, AZD8330; and proteasome inhibitors, such as carfilzomib, MLN9708, delanzomib, or bortezomib.
[0231] Other anticancer agents that can be used in combination with the compounds disclosed herein include adriamycin, dactinomycin, bleomycin, vinblastine, cisplatin, axivecin; ararubicin; acodazole hydrochloride; acronin; adorine; interleukin; hexamethylmelamine; ampicillin; ametrine acetate; aminoglutethimide; acridine; anastrozole; atrazomycin; asparaginase; and triamcinolone. Azacitidine; Azatiprine; Azomycin; Balmasta; Benzotiprine; Bicalutamide; Bismuth subsalicylate; Dinefadroxil dimethicone; Bleomycin sulfate; Buquina sodium; Brompirimidine; Busulfan; Actinomycin; Capprotestone; Carbetamide; Carbetin; Carboplatin; Carmustine; Carrubicin hydrochloride; Carzelazin; Sildenafil; Chlormethazine; Claridine; Crizonatol mesylate mesylate); cyclophosphamide; cytarabine; dacarbazine; daunorubicin hydrochloride; decitabine; dextromethorphan; dezaguanine; dezaguanine mesylate; diazinon; doxorubicin; doxorubicin hydrochloride; droloxifen; droloxifen citrate; drotahistine propionate; dazomycin; edaraxacum; efornithine hydrochloride; ethacridine; enloplatin; enprofen; epirubicin hydrochloride; irbuprofen; isopycin hydrochloride; estradiol; estradiol sodium phosphate; estradiol; Etoposide; Etoposide phosphate; Chlorpheniramine; Fadroxil hydrochloride; Fazalabin; Feniveryl Aamine; Fluorouracil; Fludarabine phosphate; Fluuracil; Flucitabine; Phosphorione; Fostracin sodium; Gemcitabine; Gemcitabine hydrochloride; Hydroxyurea; Idarubicin hydrochloride; Ifosfamide; Imofocin; Interleukin II (including recombinant interleukin II or Ril2), Interferon α-2a; Interferon α-2b; Interferon α-n1; Interferon α-n3; Interferon β-1a; Interferon γ-1b; Isopropylplatin; Irinotecan hydrochloride; Lanreotide acetate; Letrozole; Leuprorelin acetate; Riazol hydrochloride; Lometraxo sodium; Lomustine; Loxoanthraquinone hydrochloride; Masoronol; Metformin; Nitrogen mustard hydrochloride; Medroxyprogesterone acetate; Meropenem; Minoril; Mercaptopurine; Methotrexate; Methotrexate sodium; Chlorpheniramine; Metformin; Mildolipid; Mitoxin; Mitoxin; Mitoxin; Mitospeptide; Mitoxin; Mitoxin hydrochloride Anthraquinone; Mycophenolic acid; Nocodazole; Nopramine; Omaplatin; Oxysoxime; Pegaspargase; Peribacin; Pendimethicone; Pelosinomycin sulfate; Pephosphonamide; Piperabromide; Piperabromide; Pirroanthraquinone hydrochloride; Procainamide; Promethene; Porphyrom sodium; Methylmitromycin; Prenimustine; Procarbazine hydrochloride; Puromycin; Puromycin hydrochloride; Pyrazofurane; Lipoadenosine; Rogulam; Safungo; Safungo; Semustine; Citric acid; Sparfosate sodium; Sparmycin; Germanium spiroamine hydrochloride; Spiromustine; Spiroplatin; Streptomycin; Streptozotocin;Sulfochlorpheniramine; Talithromycin; Ticogalane sodium; Tegafur; Tiloanthraquinone hydrochloride; Temopofen; Teniposide; Tiroxicoron; Testrolide; Thiomipril; Thioguanine; Thiotepa; Thiazofuranoline; Tirazamine; Toremifene citrate; Tritoprolone acetate; Tricerebroside phosphate; Trimethotraxa; Trimethotraxa glucuronide; Triptorelin; Tobaccochloride hydrochloride; Uracil nitrogen mustard; Uretoprolone; Vaportide; Vertepofen; Vincristine sulfate; Vincristine sulfate; Vincristine sulfate; Vincristine sulfate; Vinpicroline sulfate; Vincristine sulfate; Vincristine sulfate; Vincristine sulfate; Vincristine sulfate; Vincristine sulfate; Vincristine sulfate; Vincristine sulfate; Vincristine sulfate; Vorticillium; Zonipram; Netostatin; Zorubicin hydrochloride.
[0232] Other anticancer agents that can be combined with compounds disclosed herein, such as 8-(3-(4-acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one, dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; ararubicin; acylfulvene; adenocyclopentanol; adorexin; adeleukin; ALL-TK antagonists; hexamethylmelamine; Aminomustine; Amidox; Amifostine; Aminolevulinic acid; Amrubicin; Acridine; Anagrel; Anastrozole; Andrographolide; Angiogenesis inhibitor; Antagonist D; Antagonist G; Antalex; Anti-dorsal morphogenetic protein-1; Anti-androgen, prostate cancer; Anti-estrogen; Antitumor; Antisense oligonucleotide; Glycine afedipine; Apoptosis gene regulator; Apoptosis regulator; Depurinated nucleic acid; ara-CDP-DL- PTBA; Arginine deaminase; Asulacrine; Atamitan; Amostain; Anestain 1; Anestain 2; Anestain 3; Azasetron; Azartoxin; Diazotyrosine; Baccatin III derivative; Balanol; Palmastat; BCR / ABL antagonist; Benzodihydroporphyrin; Benzoylstaurosporine; β-lactam derivative; β-alexin (thine); subaclavin B; betulinic acid; Bfgf inhibitor; bicalutamide; bisperidin; diazidopropyltriamine; nefenadine; bistratene A; bizole; breflate; brompirimidine; budotitanol; sulfonyl thionine; calcipotriol; carboxystatin C; camptothecin derivative; canarypox IL-2; capecitabine; formamide-amino-triazole; carboxymethylamino-triazole; CaRest M3; CARN 700; Cartilage-derived inhibitors; Capelin; Casein kinase inhibitors (ICOS); Prunella vulgaris; Cetrolene B; Citrirol; Chlorin; Chloroquinoxaline sulfonamide; Cicalprost; Cisporphyrin; Cladribine; Clomiphene analogs; Clotrimazole; Collosimycin A; Collosimycin B; Cobustatin A4; Cobustatin analogs; Conagenin; Crambescidin 816; Clinato; Nostocytoplasmic peptide 8; Nostocytoplasmic peptide A derivative; Curacin A; Cyclopentaquinone; Cycloplatam; Cypemycin; Cytarabine octadecyl phosphate; Cytolysin; Hexestrol phosphate; Dacizumab; Decitabine; Dehydroepiandronate B; Diloxacin; Dexamethasone; Dextromethorphan; Dextromethorphan;Dextromethorphan; Dexamethasone; Membrane sucrose B; Didox; Diethylnorsemine; Dihydro-5-azacytidine; 9-Dioxamycin; Bifenromustine; Diococcal; Dolasetron; Deoxyfluorouridine; Droxithofin; Drocannabinol; Pyromycin SA; Ebuselenoline; Ekomustine; Edifosine; Ezocuronium; Effornithine; Ethiributine; Epirubicin; Iridostamine; Estrogen-stimulating hormone ... Agents; estrogen antagonists; estanidazole; etoposide phosphate; exemestane; fadroxil; fazalabin; fenivel-Amin; filgrastim; finasteride; frapinol; flucalostine; fluasterone; fludarabine; fludoramycin hydrochloride; fosminex; formestan; fostracin; formustin; gadolinium texaphyrin; gallium nitrate Gallotabine; Ganirelix; Gelatinase inhibitor; Gemcitabine; Glutathione inhibitor; Hepsulfam; Modulin; Hexamethyldiacetamide; Hypericin; Ibandronic acid; Idarubicin; Edoxifen; Igamonone; Imofocin; Ilomasta; Imidazolidine; Imiquimod; Immunostimulatory peptides; Insulin-like growth factor-1 receptor inhibitors; Interferon agonists; Interferon; Interleukin; Iodobenzylguanidine; Iodoxorubicin; Ipomocarboxol; Iroplact; Isoprazole; Isohomohalicondrin B; Itasetron; Jasplakinolide; Kahalalide F; Lamellarin-N triacetate); lanreotide; leinamycin; levofloxacin; lentinan sulfate; leptolstatin; letrozole; leukemia inhibitory factor; leukocyte alpha interferon; leuprolide + estrogen + Progesterone; Leuprorelin; Levamisole; Ribavirin; Linear polyamine analogs; Lipophilic disaccharide peptides; Lipophilic platinum compounds; Lissoclinamide 7; Lobaplatin; Earthworm phospholipids; Lometroxoside; Clonidamine; Loxoanthraquinone; Lovastatin; Loxoribine; Letotecan; Tersafoline; Lisotheophylline; Cleavage peptides; Metformin; Mannostatin A; Malimastastatin; Masrophenone; Mammary serine; Matrix dissolving factor inhibitors; Matrix metalloproteinase inhibitors; Minoliqui; Meparon; Metformin; Methionin; Metoclopramide; Metoclopramide; MIF inhibitors; Mifepristone; Mitefosine; Mililastine; Mismatched double-stranded RNA; Mitoguanidine; Dibromoceramide; Mitomycin analogs;Mitonaphthylamine; Metoprolol fibroblast growth factor-saponin; Mitoxantrone; Mofarotin; Moraxetin; Monoclonal antibody; Human chorionic gonadotropin; Monophospholipid A; Diethylstilbestrol; Moparinol; Multidrug resistance gene inhibitors; Therapies based on multiple tumor suppressor factor 1; Nitrogen mustard anticancer agents; Indian Ocean sponge (mycaperoxide) B; Mycobacterium cell wall extract; Myriaporone; N-acetyl-binarin; N-substituted benzamide; Nafarelin; Naretepen; Naloxone+ Pentazocine; Napavin; Naphterpin; Natostin; Nedaplatin; Nemorubicin; Neridronate; Neutral endopeptidase; Nilumet; Nisamycin; Nitric oxide regulator; Nitrogen oxide antioxidant; Nitrullyn; O6-benzylguanine; Octreotide; Ocicenone; Oligonucleotide; Ondansetron; Ondansetron; Oracin; Oral cytokine inducer; Omaplatin; Oxatabolone; Oxaliplatin; Oxaunomycin; Palauamine; Palmitoylrhizoxin; Pamidronate; Ginsenoside Triol; Panomiphen; Paracoccin; Pazepril; Pegaspargase; Pedesine; Sodium lignosulfonate; Pentostat Ding; Pantozole; Perfluorobromide; Pesophosphatamide; Perillyl alcohol; Benzodiazecin; Phenylacetyl acetate; Phosphatase inhibitors; Sapelelin; Pilocarpine hydrochloride; Pirarubicin; Pyritoxine; Placetin A; Placetin B; Plasminogen activator inhibitors; Platinum complexes; Platinum compounds; Platinum-triamine complexes; Porphyrin sodium; Methylmitomycin; Prednisone; Propylbis-Acridinone; Prostaglandin J2; Proteasome inhibitors; Protein A-based immunomodulators; Protein kinase C inhibitors, Microalgae; Protein tyrosine phosphatase inhibitors; Purine nucleoside phosphorylase inhibitors; Hydroxyalkaloid; Pyrazoline acridine; Pyridoxal-modified hemoglobin polyoxyethylene conjugates; RAF antagonists; Raltitrexed; Ramosetron; RAS farnesyltransferase inhibitors; RAS inhibitors; RAS-GAP inhibitors; Demethylated retepritin; Rhenium etidronate Re 186; Stromatrium; Ribozyme; R.sub.11 Retinoamide; Roguliamine; Roxithromycin; Romotide; Roquimetac; Rubiginone B1; Ruboxyl; Safungo; Saintopin; SarCNU; Muscle Phytophthol A; Saxaglastine; Sdi 1 mimic; Semustine; Senescence-derived 1; Positive oligonucleotide; Signal transduction inhibitor; Signal transduction regulator; Single-chain antigen-binding protein; Cizonan; Sobuzosen; Borcarb sodium; Sodium phenylacetate; SolvorolSomatostatin-binding protein; Sonamamine; Phosphoaspartic acid; Spiramycin D; Spiromustin; Spleen pentapeptide; Spongin inhibitor 1; Squalamine; Stem cell inhibitor; Stem cell division inhibitor; Stipiamide; Matrix-degrading inhibitor; Sulphinosine; Potent vasoactive intestinal peptide antagonist; Suradista; Sulphamine; Sorghum extract; Synthetic glycosaminoglycans; Tamustine; Tamoxifen methyl iodide; Tauromustine; Tazarotene; Tecogallan sodium; Tegafur; Tellurapyrylium; Telomerase inhibitor; Temopofol; Temozolomide; Teniposide; Tetrachlorodecoxide; Tetrazomine; Thaliblastine; Ticolarin; Thrombopoietin; Thrombopoietin mimic; Thymofasin; Thymopoietin receptor agonist; Thymotrene; Thyroid-stimulating hormone; Ethymolporphyrin tin Ethyl etiopurpurin); terazamine; dichenol dichloride; topsentin; toremifene; pluripotent stem cell factor; translation inhibitor; retinoic acid; triacetyluridine; trimethoprim; trimethoprim; triptorelin; tropisetron; tolostaniel; tyrosine kinase inhibitor; tyrosine phosphorylation inhibitor; UBC inhibitor; ubenimex; urogenital sinus-derived growth inhibitor; urokinase receptor antagonist; vaporpeptide; variolin B; vector system, erythrocyte gene therapy; verarate; veratrine; verdins; verteporfin; vinorelbine; vinxaltine; vitaxin; vorazole; zanoteron; zeniplatin; zilascorb; and fenestrated statin ester.
[0233] Another type of anticancer agent that can be used in combination with the compounds disclosed herein includes alkylating agents, antimetabolites, natural products, or hormones, such as nitrogen mustard (e.g., nitrogen mustard hydrochloride, cyclophosphamide, chlorambucil, etc.), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomustine, etc.), or triazines (dacarbazine, etc.). Examples of antimetabolites include, but are not limited to, folic acid analogs (e.g., methotrexate), or pyrimidine analogs (e.g., cytarabine), and purine analogs (e.g., mercaptopurine, thioguanine, pentostatin).
[0234] Examples of natural products that may be useful in combination with the compounds disclosed herein include, but are not limited to, vinca alkaloids (e.g., vincristine), epipodophyllotoxin (e.g., etoposide), antibiotics (e.g., daunorubicin, doxorubicin, bleomycin), enzymes (e.g., L-asparaginase), or biological response modifiers (e.g., interferon α).
[0235] Examples of alkylating agents that can be used in combination with the compounds disclosed herein include, but are not limited to, nitrogen mustard (e.g., nitrogen mustard hydrochloride, cyclophosphamide, chlorambucil, melphalan, etc.), ethyleneimine and methylmelamine (e.g., hexamethylmelamine, thiotepa), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomustine, semustine, streptozotocin, etc.), or triazines (dacarbazine, etc.). Examples of antimetabolites include, but are not limited to, folic acid analogs (e.g., methotrexate), or pyrimidine analogs (e.g., fluorouracil, fluorouracil, cytarabine), and purine analogs (e.g., mercaptopurine, thioguanine, pentostatin).
[0236] Examples of hormones and antagonists useful in combination with the compounds disclosed herein include, but are not limited to, corticosteroids (e.g., prednisone), progesters (e.g., hydroxyprogesterone caproate, megestrol acetate, medroxyprogesterone acetate), estrogens (e.g., diethylstilbestrol, ethinylestradiol), antiestrogens (e.g., tamoxifen), androgens (e.g., testosterone propionate, flumethasone), antiandrogens (e.g., flutamide), and gonadotropin-releasing hormone analogs (e.g., leuprolide). Other agents for the treatment or prevention of cancer that may be used in the methods and compositions described herein include platinum coordination complexes (e.g., cisplatin, carboplatin), anthraquinones (e.g., mitoxantrone), substituted ureas (e.g., hydroxyurea), methylhydrazine derivatives (e.g., procarbazine), and adrenocortical inhibitors (e.g., mitotane, aminoglutethimide).
[0237] Examples of anticancer agents that arrest cells in the G2-M phase through stabilized microtubules and can be used in combination with irreversible Btk inhibitor compounds include, but are not limited to, the following marketed and developing drugs: irbuprozil (also known as R-55104), dolastatin 10 (also known as DLS-10 and NSC-376128), and mivobulin hydroxyethyl sulfonate. isethionate (also known as CI-980), vincristine, NSC-639829, Discodermolide (also known as NVP-XX-A-296), ABT-751 (Abbott, also known as E-7010), Altorhyrtin (such as Altorhyrtin A and Altorhyrtin C), spongistatin (such as spongistatin 1, spongistatin 2, spongistatin 3, spongistatin 4, spongistatin 5, spongistatin 6, spongistatin 7, spongistatin 8, and spongistatin 9), cimadolic acid hydrochloride (also known as LU-103793 and NSC-D-669356), epothilone (such as epothilone A, epothilone B, epothilone C (also known as desoxyepothilone A or dEpoA), epothilone D (also known as KOS-862, dEpoB, and desoxyepothilone) B), Epothilone E, Epothilone F, N-oxide of Epothilone B, N-oxide of Epothilone A, 16-aza-epothilone B, 21-aminoepothilone B (also known as BMS-310705), 21-hydroxyepothilone D (also known as Desoxyepothilone) F and dEpoF), 26-fluoroepotassium), aurestatin PE (also known as NSC-654663), Soblidotin (also known as TZT-1027), LS-4559-P (Pharmacia, also known as LS-4577), LS-4578 (Pharmacia, also known as LS-477-P), LS-4477 (Pharmacia), LS-4559 (Pharmacia), RPR-112378 (Aventis), vincristine sulfate, DZ-3358 (Daiichi), FR-182877 (Fujisawa, also known as WS-9885B), GS-164 (Takeda), GS-198 (Takeda), KAR-2 (Hungarian Academy of Sciences) (of Sciences), BSF-223651 (BASF).Also known as ILX-651 and LU-223651), SAH-49960 (Lilly / Novartis), SDZ-268970 (Lilly / Novartis), AM-97 (Armad / Kyowa Hakko), AM-132 (Armad), AM-138 (Armad / Kyowa Hakko), IDN-5005 (Indena), Nostocin 52 (also known as LY-355703), AC-7739 (Ajinomoto, also known as AVE-8063A and CS-39.HCl), AC-7700 (Ajinomoto, also known as AVE-8062, AVE-8062A, CS-39-L-Ser.HCl, and RPR-258062A), Vitilevamide, Tubulysin A, Canadensol, Cyanobacterium cyanide (also known as NSC-106969), T-138067 (Tularik, also known as T-67, TL-138067 and TI-138067), COBRA-1 (Parker Hughes Institute, also known as DDE-261 and WHI-261), H10 (Kansas State University), H16 (Kansas State University), Oncocidin A1 (also known as BTO-956 and DIME), DDE-313 (Parker Hughes Institute), Fijianolide B. Laulimalide, SPA-2 (Parker Hughes Institute), SPA-1 (Parker Hughes Institute, also known as SPIKET-P), 3-IAABU (Cytoskeleton / Mount Sinai School of Medicine) Medicine), also known as MF-569), Narcosine (also known as NSC-5366), Nascapine, D-24851 (AstaMedica), A-105972 (Abbott Laboratories), Hammetrine, 3-BAABU (Cytoskeleton / Mount Sinai School of Medicine),Also known as MF-191), TMPN (Arizona State University), Vanadobenone acetylacetone, T-138026 (Duraric Company), Monsatrol, Inanocine (also known as NSC-698666), 3-1AABE (Cytoskeleton / Mount Sinai School of Medicine), A-204197 (Abbott Laboratories), T-607 (Duraric Company, also known as T-900607), RPR-115781 (Annette Company), Eleutherobin (such as desmethyleleutherobin, desaetyleleutherobin, isoeleutherobin A, and Z-Isoeleutherobin), Caribaeolin, Halichondrin B B), D-64131 (Astar Pharmaceuticals), D-68144 (Astar Pharmaceuticals), Diazonamide A (a chlorinated cyclic peptide), A-293620 (Abbott Laboratories), NPI-2350 (Nereus), Root mead lactone A, TUB-245 (Annette), A-259754 (Abbott Laboratories), Diozostatin, (-)-Phenylahistin (also known as NSCL-96F037), D-68838 (Astar Pharmaceuticals), D-68836 (Astar Pharmaceuticals), Myosin B, D-43411 (Zentaris, also known as...) These are known as D-81862), A-289099 (Abbott Laboratories), A-318315 (Abbott Laboratories), HTI-286 (also known as SPA-110, trifluoroacetate) (Wyeth), D-82317 (Zentaris), D-82318 (Zentaris), SC-12983 (NCI), Resverastatin sodium phosphate, BPR-OY-007 (National Health Research Institutes), and SSR-250411 (Sanofi).
[0238] Further examples of anticancer agents used in combination with the compounds disclosed herein include immune checkpoint inhibitors. Exemplary immune checkpoint inhibitors include inhibitors (small molecules or biologics) targeting immune checkpoint molecules such as CD27, CD28, CD40, CD122, CD96, CD73, CD39, CD47, OX40, GITR, CSF1R, JAK, PI3Kδ, PI3Kγ, TAM kinase, arginase, CD137 (also known as 4-1BB), ICOS, A2AR, A2BR, HIF-2α, B7-H3, B7-H4, BTLA, CTLA-4, LAG3, TIM3, VISTA, CD96, TIGIT, PD-1, PD-L1, and PD-L2. In some embodiments, the immune checkpoint molecules are selected from the following stimulating checkpoint molecules: CD27, CD28, CD40, ICOS, OX40, GITR, CD137, and STING. In some embodiments, the immune checkpoint molecule is an inhibitory checkpoint molecule selected from the following: B7-H3, B7-H4, BTLA, CTLA-4, IDO, TDO, arginase, KIR, LAG3, PD-1, TIM3, CD96, TIGIT, and VISTA. In some embodiments, the compounds provided herein may be used in combination with one or more reagents selected from the following: KIR inhibitors, TIGIT inhibitors, LAIR1 inhibitors, CD160 inhibitors, 2B4 inhibitors, and TGFRβ inhibitors.
[0239] In some embodiments, the inhibitor of the immune checkpoint molecule is a PD-1 inhibitor, such as an anti-PD-1 monoclonal antibody. In some embodiments, the anti-PD-1 monoclonal antibody is nivolumab, pembrolizumab (also known as MK-3475), pidilizumab, SHR-1210, PDR001, or AMP-224. In some embodiments, the anti-PD-1 monoclonal antibody is nivolumab, or pembrolizumab, or PDR001. In some embodiments, the anti-PD1 antibody is pembrolizumab.
[0240] In some embodiments, the inhibitor of the immune checkpoint molecule is a PD-L1 inhibitor, such as an anti-PD-L1 monoclonal antibody. In some embodiments, the anti-PD-L1 monoclonal antibody is BMS-935559, MEDI4736, MPDL3280A (also known as RG7446), or MSB0010718C. In some embodiments, the anti-PD-L1 monoclonal antibody is MPDL3280A (atelizumab) or MEDI4736 (dulvarubb).
[0241] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of CTLA-4, such as an anti-CTLA-4 antibody. In some embodiments, the anti-CTLA-4 antibody is ipilimumab or trimemumab. In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of LAG3, such as an anti-LAG3 antibody. In some embodiments, the anti-LAG3 antibody is BMS-986016 or LAG525. In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of GITR, such as an anti-GITR antibody. In some embodiments, the anti-GITR antibody is TRX518 or MK-4166, INCAGN01876 or MK-1248. In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of OX40, such as an anti-OX40 antibody or OX40L fusion protein. In some embodiments, the anti-OX40 antibody is MEDI0562 or INCAGN01949, GSK2831781, GSK-3174998, MOXR-0916, PF-04518600, or LAG525. In some embodiments, the OX40L fusion protein is MEDI6383.
[0242] Example The preparation methods of the following compounds having formula (I) are provided to enable those skilled in the art to more clearly understand and implement this disclosure. They should not be considered as limiting the scope of this disclosure, but merely as illustrative and representative of this disclosure.
[0243] All solvents used were commercially available and ready for use without further purification. Reactions were typically carried out using anhydrous solvents under a nitrogen inert atmosphere.
[0244] Protons were recorded at 400 MHz or 300 MHz on a Bruker 400 NMR spectrometer equipped with a Bruker 400 BBO probe or a Bruker BBFO ULTRASHIELD™ 300 AVANCE III. 1 H-spectroscopy. All deuterated solvents typically contain 0.03% to 0.05% v / v tetramethylsilane, which is used as a reference signal ( 1 H and 13 C. Both are set to d0.00).
[0245] LCMS analysis was performed on a SHIMADZU LCMS consisting of a UFLC 20-AD and an LCMS 2020 MS detector. The diode array detector was scanned from 190–400 nm. The mass spectrometer was equipped with an electrospray ionization (ESI) source operating in either positive or negative mode. The mass spectrometer was scanned between m / z 90–900 with scan times ranging from 0.5 to 3.0 s.
[0246] HPLC analysis was performed on a SHIMADZU UFLC equipped with two LC20 AD pumps and an SPD-M20A photodiode array detector. An XBridge C18 column, 3.5 µm, 4.6 × 100 mm, was used. A linear gradient was applied, starting with 90% A (A: 0.05% TFA in water) and ending within 10 min with 95% B (B: 0.05% TFA in MeCN), for a total run time of 15 min. The column temperature was 40 °C, and the flow rate was 1.5 mL / min. The photodiode array detector was scanned from 200–400 nm.
[0247] Thin-layer chromatography (TLC) was performed on Alugram® (silica gel 60 F254) from Manchery-Nagel, typically using UV to visualize the spots. In some cases, alternative visualization methods were employed. In these cases, iodine (prepared by adding approximately 1 g of I₂ to 10 g of silica gel and mixing thoroughly), ninhydrin (commercially available from Aldrich), or Magic Stain (prepared by thoroughly mixing 25 g of (NH₄)₆Mo₇O₇ in 450 mL of water and 50 mL of concentrated H₂SO₄) was used. 24 TLC plates were developed to visualize the compounds using 4H₂O and 5 g of (NH₄)₂Ce(IV)(NO₃)₆. Rapid chromatography was performed using 40–63 µm (230–400 mesh) silica gel from Silicycle, following techniques similar to those disclosed in Still, WC; Kahn, M. and Mitra, M., *Journal of Organic Chemistry*, 1978, 43, 2923. Typical solvents used for rapid chromatography or thin-layer chromatography are mixtures of chloroform / methanol, dichloromethane / methanol, ethyl acetate / methanol, and hexane / ethyl acetate.
[0248] Synthesis Example Example 1 Synthesis of (3-(((8-methoxy-1,7-naphthid-4-yl)oxy)methyl)phenyl)(methyl)-λ6-thionediamine Step 1: 5-(((2-methoxypyridin-3-yl)amino)methylene)-2,2-dimethyl-1,3-dioxane-4,6-dione A solution of 2-methoxypyridine-3-amine (3.00 g, 24.2 mmol, 1 equivalent), 2,2-dimethyl-1,3-dioxane-4,6-dione (4.50 g, 31.46 mmol, 1.3 equivalent), and trimethoxymethane (3.60 g, 33.8 mmol, 1.4 equivalent) in acetonitrile (30 mL) was stirred at 80 °C under a nitrogen atmosphere for 2 h. After cooling to room temperature, the resulting solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using EA / PE (25:75) elution. Fractions containing the desired product were combined and concentrated under reduced pressure to give the title compound (6.50 g, 97%) as a yellow solid.
[0249] Step 2: 8-Methoxy-1,7-Naphthyl-4-ol A mixture of 5-(((2-methoxypyridin-3-yl)amino)methylene)-2,2-dimethyl-1,3-dioxane-4,6-dione (1.50 g, 5.4 mmol) in diphenyl ether (38 mL) was stirred at 225 °C for 1.5 h. After cooling to room temperature, PE was added to the reaction mixture, and the precipitated solid was collected by filtration and washed with PE. The crude product was purified by reversed-phase rapid chromatography with elution of ACN / H2O (23:77) to give the title compound (600 mg, 63%) as a white solid.
[0250] Step 3: 4-Chloro-8-methoxy-1,7-naphthidine At room temperature, DIEA (2.35 g, 18.16 mmol, 2 equivalents) and POCl3 (1.67 g, 10.89 mmol, 1.2 equivalents) were added to a stirred solution of 8-methoxy-1,7-naphthidine-4-ol (1.60 g, 9.08 mmol, 1 equivalent) in toluene (32 mL). After stirring overnight at 70 °C, the resulting mixture was concentrated under reduced pressure. The crude product was then purified by reversed-phase rapid chromatography with elution of ACN / H2O (35:65) to give the title compound (1.11 g, 62%) as a yellow solid.
[0251] Step 4: 8-Methoxy-4-((3-(methylthioalkyl)phenyl)methoxy)-1,7-naphthidine At 0 °C, NaH (74 mg, 3.08 mmol, 3 equivalents) was added to a stirred solution of 3-(methylthioalkyl)phenyl)methanol (237 mg, 1.54 mmol, 1.5 equivalents) in DMF (4 mL). After stirring for 10 min, 4-chloro-8-methoxy-1,7-naphthidine (200 mg, 1.02 mmol, 1 equivalent) was added. The resulting mixture was stirred at 80 °C for 2 h. After cooling to room temperature, the reaction mixture was quenched with water and extracted with EtOAc. The combined organic phases were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography with EA / PE (15:85) elution to give the title compound (130 mg, 40%) as a yellow solid.
[0252] Step 5: (3-(((8-methoxy-1,7-naphthidin-4-yl)oxy)methyl)phenyl)(methyl)-λ6-thionediamine At -15°C under a nitrogen atmosphere, NH3-H2O (897 mg, 20 equivalents, 25% v / v) was added to a solution of 8-methoxy-4-((3-(methylthioalkyl)phenyl)methoxy)-1,7-naphthidine (100 mg, 0.32 mmol, 1 equivalent) in ACN (3 mL). The resulting mixture was stirred at the same temperature for 1 h and tert-butyl hypochlorite (174 mg, 1.60 mmol, 5 equivalents) was added. After stirring at -15°C for 1 h, NH3-H2O (448 mg, 10 equivalents, 25% v / v) was added. The reaction mixture was stirred from -15°C to room temperature overnight. The resulting mixture was concentrated under reduced pressure and purified by reversed-phase rapid chromatography with ACN / H2O (15:85) to give a crude product, which was further purified by reversed-phase preparative HPLC under the following conditions (column: XBridge Prep OBD C18 column, 30...). 150 mm, 5 µm; mobile phase A: water (10 nmol / L NH4HCO3), mobile phase B: ACN; flow rate: 60 mL / min; gradient: 2% B to 24% B over 10 min; wavelength: 254 nm / 220 nm; RT1 (min): 9.07), to obtain the title compound (7.4 mg, 6%) as a white solid. MS (ESI, positive ion) m / z: 343.1 (M+1). 1 H NMR (400 MHz, DMSO- d 6, ppm ) δ 8.79 (d, J = 5.2 Hz, 1H), 8.25 (t, J = 1.8 Hz,1H), 8.11 - 8.02 (m, 2H), 7.81 - 7.74 (m, 1H), 7.64 (t, J = 7.7 Hz, 1H), 7.56 (d, J = 5.9 Hz, 1H), 7.39 (d, J = 5.3 Hz, 1H), 5.51 (s, 2H), 4.05 (s, 3H), 3.04 (s, 3H), 2.98 (s, 2H).
[0253] Example 2 Synthesis of cyclopropyl(3-(((8-methoxy-1,7-naphthid-4-yl)oxy)methyl)phenyl)-λ6-thionediamine Step 1: 3-(cyclopropylthioalkyl)benzoic acid A mixture of 3-thioalkylbenzoic acid (5.00 g, 30.80 mmol, 1 equivalent) in DMSO (50 mL) was supplemented with bromocyclopropane (5.88 g, 46.21 mmol, 1.5 equivalent) and potassium tert-butoxide (9.10 g, 77.02 mmol, 2.5 equivalent). The resulting mixture was stirred at 80 °C for 24 h. After cooling to room temperature, the reaction mixture was diluted with water, the pH was adjusted to 5 with 1 N HCl (aqueous solution), and extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with elution of CH2Cl2 / MeOH (10:1) to give the title compound (3.99 g, 61%) as a colorless oil.
[0254] Step 2: 3-(cyclopropylthio)phenyl]methanol The title compound was synthesized in a manner similar to that described in step 1 of Example 5, except that 3-(cyclopropylthioalkyl)benzoic acid (24.00 g, 117.37 mmol) was used. [3-(cyclopropylthioalkyl)phenyl]methanol (20.00 g, 86%) was obtained as a yellow oil.
[0255] Step 3: 4-((3-(cyclopropylthio)benzyl)oxy)-8-methoxy-1,7-naphthidine The title compound was synthesized in a manner similar to that described in step 4 of Example 1, except that (3-(cyclopropylthio)phenyl)methanol (511 mg, 2.84 mmol) was used. The title compound was obtained as a yellow solid (169 mg, 35%).
[0256] Step 4: Cyclopropyl(3-(((8-methoxy-1,7-naphthidin-4-yl)oxy)methyl)phenyl)-λ6-thionediamine The title compound was synthesized in a manner similar to that described in Example 1, step 5, except that 4-((3-(cyclopropylthio)phenyl)methoxy)-8-methoxy-1,7-naphthidine (210 mg, 0.62 mmol) was used. The crude product was purified by preparative HPLC under the following conditions: (UV 254 nm / 220 nm, Xbridge Prep OBD C18 column, 30... 150 mm, 5 μm water (10 mmol / L NH4HCO3) ACN 60 mL / min over 10 min (3% B to 33% B 8.68). Fractions containing the desired product were combined and lyophilized to give the title compound (3.2 mg, 1%) as a yellow solid. MS (ESI, positive ion) m / z: 369.1 (M+1). 1 H NMR (400 MHz, DMSO- d 6, ppm ) δ 8.78 (d, J = 5.2 Hz, 1H), 8.18 (d, J = 1.8 Hz, 1H), 8.08 (d, J = 5.8 Hz, 1H), 8.01 (dt, J = 7.9, 1.6 Hz, 1H), 7.76 (d, J = 7.6 Hz, 1H), 7.63 (t, J = 7.7 Hz, 1H), 7.56 - 7.50 (m, 1H), 7.37 (d, J = 5.3 Hz, 1H), 5.51 (s, 2H), 4.05 (s, 3H), 2.84 (s, 2H), 2.76 - 2.68 (m, 1H), 0.99 - 0.92 (m, 2H), 0.85 - 0.74 (m, 2H).
[0257] Example 3 Synthesis of (4-(((8-methoxy-1,7-naphthid-4-yl)oxy)methyl)phenyl)(methyl)-λ6-thionediamine Step 1: 8-Methoxy-4-((4-(methylthioalkyl)phenyl)methoxy)-1,7-naphthidine The title compound was synthesized in a manner similar to that described in step 4 of Example 1, except that (4-(methylthioalkyl)phenyl)methanol (435 mg, 2.82 mmol) was used. The title compound (480 mg, 49%) was obtained as a grayish-white solid.
[0258] Step 2: (4-(((8-methoxy-1,7-naphthid-4-yl)oxy)methyl)phenyl)(methyl)-λ6-thionediamine The title compound was synthesized in a manner similar to that described in step 5 of Example 1, except that 8-methoxy-4-((4-(methylthioalkyl)phenyl)methoxy)-1,7-naphthidine (430 mg, 1.37 mmol). The crude product was purified by preparative HPLC under the following conditions: (column: XBridge Prep RP OBD C18 column, 30...) 150 mm, 5 µm; Mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; Flow rate: 60 mL / min; Gradient: 2% B to 28% B over 10 min; Wavelength: 254 nm / 220 nm; RT1 (min): 9.3). Fractions containing the desired product were combined and lyophilized to give the title compound (6.6 mg, 11%) as a white solid. MS (ESI, positive ion) m / z: 343.1 (M+1). 1 HNMR (400 MHz, DMSO- d 6, ppm ) δ 8.78 (d, J = 5.2 Hz, 1H), 8.14 - 8.05 (m, 3H), 7.77 - 7.70 (m, 2H), 7.58 (d, J = 5.9 Hz, 1H), 7.36 (d, J = 5.3 Hz, 1H), 5.51 (s, 2H), 4.05 (s, 3H), 3.03 (s, 3H), 2.96 (s, 2H).
[0259] Example 4 Synthesis of ((1-(8-methoxy-1,7-naphthidin-4-yl)piperidin-4-yl)methyl)(methyl)-λ6-thionediamine Step 1: (1-(8-methoxy-1,7-naphthid-4-yl)piperidin-4-yl)methanol DIEA (996 mg, 7.70 mmol, 3.0 equivalent) and piperidin-4-ylmethanol (739 mg, 6.42 mmol, 2.5 equivalent) were added to a solution of 4-chloro-8-methoxy-1,7-naphthidine (500 mg, 2.56 mmol, 1.0 equivalent) in NMP (6 mL). The resulting mixture was stirred at 100 °C for 2 h. After cooling to room temperature, the solution was concentrated under reduced pressure and purified by reversed-phase rapid chromatography with elution of ACN / H2O (37 / 63) to give (1-(8-methoxy-1,7-naphthidine-4-yl)piperidin-4-yl)methanol (577 mg, 80%) as a brown solid.
[0260] Step 2: Methyl mesylate (1-(8-methoxy-1,7-naphthyl-4-yl)piperidin-4-yl) At 0 °C, TEA (412 mg, 4.07 mmol, 2 equivalents), DMAP (24 mg, 0.20 mmol, 0.1 equivalents), and methanesulfonic anhydride (532 mg, 3.05 mmol, 1.5 equivalents) were added to a solution of (1-(8-methoxy-1,7-naphthid-4-yl)piperidin-4-yl)methanol (557 mg, 2.03 mmol, 1 equivalent) in DCM (6 mL). The resulting mixture was stirred at room temperature for 2 h. The solution was quenched with H2O and extracted with DCM. The organic layer was washed with brine, dried over Na2SO4, and filtered. The filtrate was concentrated under reduced pressure to give the title compound (750 mg, 99%) as a brown oil.
[0261] Step 3: 8-Methoxy-4-(4-((methylthio)methyl)piperidin-1-yl)-1,7-naphthidine Sodium methanethiol (7.13 g, 20.35 mmol, 1 equivalent) was added to a solution of 8-methoxy-4-(4-((methylthioalkyl)methyl)piperidin-1-yl)-1,7-naphthidine (715 mg, 2.35 mmol, 1 equivalent) in EtOH (8 mL). The resulting mixture was stirred at 35 °C for 2 h. The solution was then concentrated under reduced pressure and purified by silica gel column chromatography with elution using MeOH / DCM (6 / 94) to give the title compound (543 mg, 82%) as a yellow oil.
[0262] Step 4: ((1-(8-methoxy-1,7-naphthidin-4-yl)piperidin-4-yl)methyl)(methyl)-λ6-thionediamine The title compound was synthesized in a manner similar to that described in step 5 of Example 1, except that 8-methoxy-4-(4-((methylthio)methyl)piperidin-1-yl)-1,7-naphthidine (200 mg, 0.65 mmol). The crude product was purified by preparative HPLC under the following conditions: (column: XBridge Prep RP OBD C18 column, 30...) 150 mm, 5 µm; Mobile phase A: water (10 mmol / L NH4HCO3), Mobile phase B: ACN; Flow rate: 60 mL / min; Gradient: 2% B to 22% B over 10 min; Wavelength: 254 nm / 220 nm; RT1 (min): 9.2). Fractions containing the desired product were combined and lyophilized to give the title compound (21 mg, 9.4%) as a white solid. MS (ESI, positive ion) m / z: 334.2 (M+1). 1 H NMR (400 MHz, DMSO- d 6 , ppm ) δ 8.67 (d, J = 5.0 Hz, 1H), 8.02 (d, J = 5.9 Hz, 1H), 7.32 (d, J = 6.0 Hz, 1H), 7.15 (d, J = 5.1 Hz, 1H), 4.03 (s, 3H), 3.51 (d, J =12.4 Hz, 2H), 3.07 (d, J = 6.0 Hz, 2H), 2.93 - 2.81 (m, 5H), 2.38 (s, 2H), 2.30- 2.17 (m, 1H), 2.11 (d, J = 12.8 Hz, 2H), 1.71 - 1.57 (m, 2H).
[0263] Example 5 Synthesis of (3-(((7-methoxyquinoline-4-yl)oxy)methyl)phenyl)(methyl)-λ6-thionediamine Step 1: 3-(methylthioalkyl)phenyl]methanol Under a nitrogen atmosphere at 0 °C, LiAlH4 (14.2 mL, 2 M in THF) was slowly added to a solution of 3-(methylthioalkyl)benzoic acid (4.00 g, 23.78 mmol, 1 equivalent) in 40 mL of THF. After stirring at room temperature for 2 h, the mixture was quenched by adding a saturated ammonium chloride solution and concentrated under reduced pressure. The residue was purified by silica gel column chromatography with EtOAc / PE (43:57) as elution to give the title compound (3.08 g, 84%) as a colorless oil.
[0264] Step 2: 7-Methoxy-4-((3-(methylthioalkyl)phenyl)methoxy)quinoline At 0 °C, NaH (233 mg, 9.72 mmol, 3 equivalents) was added to a stirred solution of (3-(methylthioalkyl)phenyl)methanol (500 mg, 3.24 mmol, 1 equivalent) in DMF (10 mL). After stirring for 10 min, 4-chloro-7-methoxyquinoline (941 mg, 4.86 mmol, 1.5 equivalents) was added. The mixture was stirred at 80 °C for 2 h. The resulting mixture was quenched with H₂O, then extracted with EtOAc and washed with brine. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the title compound (750 mg, 74%) as a yellow oil. MS (ESI, positive ion) m / z: 312.0 (M+1).
[0265] Step 3: (3-(((7-methoxyquinoline-4-yl)oxy)methyl)phenyl)(methyl)-λ6-thionediamine The title compound was synthesized in a manner similar to that described in step 5 of Example 1, except that 7-methoxy-4-((3-(methylthioalkyl)phenyl)methoxy)quinoline (650 mg, 2.08 mmol) was used. The crude product was purified by preparative HPLC under the following conditions: (column: XBridge Prep RP OBD C18 column, 30...). 150 mm, 5 µm; Mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; Flow rate: 60 mL / min; Gradient: 6% B to 36% B over 10 min; Wavelength: 254 nm / 220 nm; RT1 (min): 9.4). Fractions containing the desired product were combined and lyophilized to give the title compound as a white solid (35.9 mg, 5%). MS (ESI, positive ion) m / z: 342.1 (M+1).1 H NMR (400 MHz, DMSO-) d 6, ppm ) δ 8.68 (d, J = 5.2 Hz, 1H), 8.25 (t, J = 1.8 Hz, 1H), 8.13- 8.02 (m, 2H), 7.78 (dt, J = 7.6, 1.4 Hz, 1H), 7.64 (t, J = 7.7 Hz, 1H), 7.35 (d, J = 2.5 Hz, 1H), 7.21 (dd, J = 9.1, 2.6 Hz, 1H), 7.03 (d, J = 5.3 Hz, 1H), 5.48 (s, 2H), 3.91 (s, 3H), 3.04 (s, 3H), 2.97 (s, 2H).
[0266] Example 6 Synthesis of (3-(((6,7-dimethoxyquinoline-4-yl)oxy)methyl)phenyl)(methyl)-λ6-thionediamine Step 1: 6,7-Dimethoxy-4-((3-(methylthioalkyl)phenyl)methoxy)quinoline The title compound was synthesized in a manner similar to that described in step 4 of Example 1, except that 4-chloro-6,7-dimethoxyquinoline (800 mg, 3.57 mmol) was used. The title compound was obtained as a brown solid (1.00 g, 81%).
[0267] Step 2: (3-(((6,7-dimethoxyquinoline-4-yl)oxy)methyl)phenyl)(methyl)-λ6-thionediamine The title compound was synthesized in a manner similar to that described in step 5 of Example 1, except that 6,7-dimethoxy-4-((3-(methylthioalkyl)phenyl)methoxy)quinoline (900 mg, 2.63 mmol) was used. The crude product was purified by preparative HPLC under the following conditions: (column: XBridge Prep RP OBD C18 column, 30...). 150 mm, 5 µm; Mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; Flow rate: 60 mL / min; Gradient: 6% B to 36% B over 10 min; Wavelength: 254 nm / 220 nm; RT1 (min): 9.4). Fractions containing the desired product were combined and lyophilized to give the title compound (16.8 mg, 1.7%) as a grayish-white solid. MS (ESI, positive ion) m / z: 372.1 (M+1). 1 H NMR (400 MHz, DMSO- d 6, ppm )δ 8.54 (d, J = 5.2 Hz, 1H), 8.31 (s, 1H), 8.03(d, J = 8.0 Hz, 1H), 7.75 (d, J = 7.6 Hz, 1H), 7.63 (d, J = 7.6 Hz, 1H), 7.44 (s,1H), 7.34 (s, 1H), 7.00 (d, J = 5.2 Hz, 1H), 5.49 (s, 2H), 3.91 (d, J = 7.2 Hz, 6H), 3.03 (s, 3H), 2.95 (s, 2H).
[0268] Example 7 Synthesis of (3-(((6,7-dimethoxyquinazolin-4-yl)oxy)methyl)phenyl)(methyl)-λ6-thionediamine Step 1: 6,7-Dimethoxy-4-((3-(methylthioalkyl)phenyl)methoxy)quinazolin Cs₂CO₃ (1.45 g, 4.45 mmol, 1 equivalent) and (3-(methylthioalkyl)phenyl)methanol (514 mg, 3.33 mmol, 1.5 equivalent) were added to a stirred mixture of 4-chloro-6,7-dimethoxyquinazoline (500 mg, 2.22 mmol, 1 equivalent) in DMF (10 mL). The resulting mixture was stirred at 80 °C for 2 h. After cooling to room temperature, the mixture was diluted with EtOAc, washed with water and brine, and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with EtOAc / PE (45:55) elution to give the title compound (719 mg, 92%) as a white solid.
[0269] Step 2: (3-(((6,7-dimethoxyquinazoline-4-yl)oxy)methyl)phenyl)(methyl)-λ6-thionediamine The title compound was synthesized in a manner similar to that described in step 5 of Example 1, except that 6,7-dimethoxy-4-((3-(methylthioalkyl)phenyl)methoxy)quinazoline (500 mg, 1.46 mmol) and chloramine-T (1.66 g, 7.30 mmol) were used. The crude product was purified by preparative HPLC under the following conditions: (column: Welch Ultimate XB-Phenyl, 30). 250 mm, 10 μm; Mobile phase A: water (10 mmol / L NH4HCO3), Mobile phase B: ACN; Flow rate: 60 mL / min; Gradient: 11% B to 41% B over 10 min; Wavelength: 254 nm / 220 nm; RT1 (min): 9.9). Fractions containing the desired product were combined and lyophilized to give the title compound (2 mg, 1%) as a grayish-white solid. MS (ESI, positive ion) m / z: 373.1 (M+1). 1 H NMR (400 MHz, DMSO-d 6 , ppm ) δ 8.66 (s, 1H),8.26 (s, 1H), 8.03 (d, J = 8.0, 1H), 7.76 (d, J = 7.6 Hz, 1H), 7.61 (t, J= 8 Hz, 1H), 7.40 (s, 1H), 7.34 (s, 1H), 5.74 (s, 2H), 3.96 (s, 3H), 3.92 (s, 3H), 3.03 (s, 3H).
[0270] Example 8 Synthesis of cyclopropyl(3-(((6,7-dimethoxyquinoline-4-yl)oxy)methyl)phenyl)-λ6-thionediamine Step 1: 4-((3-(cyclopropylthio)phenyl)methoxy)-6,7-dimethoxyquinoline The title compound was synthesized in a manner similar to that described in Example 2, step 3, except that 4-chloro-6,7-dimethoxyquinoline (500 mg, 2.23 mmol) and (3-(cyclopropylthio)phenyl)methanol (806 mg, 4.47 mmol) were used. The title compound (560 mg, 68%) was obtained as a yellow solid.
[0271] Step 2: Cyclopropyl(3-(((6,7-dimethoxyquinoline-4-yl)oxy)methyl)phenyl)-λ6-thionediamine The title compound was synthesized in a manner similar to that described in step 5 of Example 1, except that 4-((3-(cyclopropylthio)phenyl)methoxy)-6,7-dimethoxyquinoline (460 mg, 1.25 mmol) was used. The crude product was purified by preparative HPLC under the following conditions: (column: Xbridge Prep OBD C18 column, 30...) 150 mm, 5 µm; Mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; Flow rate: 60 mL / min; Gradient: 6% B to 36% B over 10 min; Wavelength: 254 nm / 220 nm; RT1 (min): 8.68). Fractions containing the desired product were combined and lyophilized to give the title compound as a white solid (22.5 mg, 4%). MS (ESI, positive ion) m / z: 398.1 (M+1). 1 HNMR (400 MHz, DMSO- d 6, ppm ) δ 8.54 (d, J = 5.3 Hz, 1H), 8.25 (t, J= 1.9 Hz, 1H), 7.99 (d, J = 8.0 Hz 1H), 7.74 (d, J = 7.8, 1.3 Hz, 1H), 7.62 (t, J = 7.7 Hz, 1H),7.44 (s, 1H), 7.34 (s, 1H), 7.00 (d, J = 5.3 Hz, 1H), 5.50 (s, 2H), 3.92 (d, J =7.2 Hz, 6H), 2.80 (s, 2H), 2.73 - 2.65 (s, 1H), 0.97 - 0.88 (s, 2H), 0.83 -0.71 (s, 2H).
[0272] Example 9 Synthesis of cyclopropyl(3-(((6,7-dimethoxyquinazolin-4-yl)oxy)methyl)phenyl)-λ6-thionediamine Step 1: 4-((3-(cyclopropylthio)benzyl)oxy)-6,7-dimethoxyquinazoline The title compound was synthesized in a manner similar to that described in step 4 of Example 1, except that 4-chloro-6,7-dimethoxyquinazoline (1.00 g, 4.45 mmol) and (3-(cyclopropylthioalkyl)phenyl)methanol (960 mg, 5.3 mmol) were used. The title compound (1.20 g, 68%) was obtained as a brown solid.
[0273] Step 2: Cyclopropyl(3-(((6,7-dimethoxyquinazoline-4-yl)oxy)methyl)phenyl)-λ6-thionediamine Under a nitrogen atmosphere at room temperature, NH3-H2O (7.61 g, 54.28 mmol, 20.0 equivalent, 25% v / v) was added to a solution of 4-((3-(cyclopropylthio)benzyl)oxy)-6,7-dimethoxyquinazoline (1.00 g, 2.71 mmol, 1.0 equivalent) in 20 mL of ACN, and the mixture was stirred at room temperature for 1 h. Tert-butyl hypochlorite (1.47 g, 13.54 mmol, 5.0 equivalent) was added at 0 °C, and the mixture was stirred at room temperature for 1 h. NH3 was then added. H2O (7.61 g, 54.28 mmol, 20.0 equivalents, 25%) was added, and the mixture was stirred overnight at room temperature. The reaction was then concentrated under reduced pressure. The residue was purified by reversed-phase rapid chromatography with ACN / H2O (36 / 64) as elution to give a crude product, which was further purified by preparative HPLC under the following conditions (column: YMC-Actus Triart C18ExRs, 30). 150 mm, 5 µm; mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; flow rate: 60 mL / min; gradient: 9% B to 39% B over 10 min; wavelength: 254 nm / 220 nm; RT1 (min): 9.5), to obtain the title compound (11.4 mg, 1%) as a white solid. MS (ESI, positive ion) m / z: 399.1 (M+1). 1 H NMR (400 MHz, DMSO- d 6, ppm ) δ 8.66 (s, 1H), 8.19 (t, J =1.8 Hz, 1H), 7.97 (dt, J = 7.8, 1.4 Hz, 1H), 7.73 (dt, J = 7.9, 1.3 Hz, 1H), 7.59(t, J = 7.7 Hz, 1H), 7.39 (s, 1H), 7.34 (s, 1H), 5.73 (s, 2H), 3.96 (s, 3H), 3.92 (s, 3H), 2.79 (s, 2H), 2.74 - 2.63 (m, 1H), 0.97 - 0.88 (m, 2H), 0.83 -0.71 (m, 2H).
[0274] Example 10 Synthesis of (3-(((6-fluoro-7-methoxyquinoline-4-yl)oxy)methyl)phenyl)(methyl)-λ6-thionediamine Step 1: 6-Fluoro-7-methoxy-4-((3-(methylthio)phenyl)methoxy)quinoline The title compound was synthesized in a manner similar to that described in step 2 of Example 5, except that 4-chloro-6-fluoro-7-methoxyquinoline (1.00 g, 4.725 mmol) was used. The title compound (440 mg, 28%) was obtained as a pale yellow solid.
[0275] Step 2: (3-(((6-fluoro-7-methoxyquinoline-4-yl)oxy)methyl)phenyl)(methyl)-λ6-thionediamine The title compound was synthesized in a manner similar to that described in step 5 of Example 1, except that 6-fluoro-7-methoxy-4-((3-(methylthioalkyl)phenyl)methoxy)quinoline (340 mg, 1.032 mmol) was used. The crude product was purified by preparative HPLC under the following conditions: (column: XBridge Prep RP OBD C18 column, 30...). 150 mm, 5 µm; mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; flow rate: 60 mL / min; gradient: 10% B to 40% B over 10 min; wavelength: 254 nm / 220 nm; RT1 (min): 9.4), to obtain the title compound (13.1 mg, 3.5%) as a grayish-white solid. MS (ESI, positive ion) m / z: 360.0 (M+1). 1 H NMR (400 MHz, DMSO- d 6, ppm ) δ8.68 (d, J = 5.3 Hz, 1H), 8.24 (t, J = 1.8 Hz, 1H), 8.05 (d, J = 7.9 Hz, 1H), 7.86- 7.76 (m, 2H), 7.64 (t, J = 7.7 Hz, 1H), 7.55 (d, J = 8.3 Hz, 1H), 7.09 (d, J =5.3 Hz, 1H), 5.49 (s, 2H), 4.00 (s, 3H), 3.04 (s, 3H), 2.96 (s, 2H) Example 11 Synthesis of (4-((6,7-dimethoxyquinoline-4-yl)oxy)phenyl)(methyl)-λ6-thionediamine Step 1: 6,7-Dimethoxy-4-(4-(methylthioalkyl)phenoxy)quinoline Cs₂CO₃ (1.09 g, 3.35 mmol, 1 equivalent) and 4-(methylthio)phenol (1.25 g, 8.94 mmol, 4 equivalent) were added to a stirred mixture of 4-chloro-6,7-dimethoxyquinoline (500 mg, 2.23 mmol, 1 equivalent) in DMSO (10 mL). The resulting mixture was stirred overnight at 120 °C. After cooling to room temperature, the mixture was diluted with water (100 mL) and extracted with EtOAc. The combined organic layers were washed with water and brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with EtOAc / PE (40:60) elution to give the title compound (630 mg, 83%) as a grayish-white solid.
[0276] Step 2: (4-((6,7-dimethoxyquinoline-4-yl)oxy)phenyl)(methyl)-λ6-thionediamine The title compound was synthesized in a manner similar to that described in step 5 of Example 1, except that 6,7-dimethoxy-4-(4-(methylthioalkyl)phenoxy)quinoline (1.30 g, 3.97 mmol) was used. The crude product was purified by preparative HPLC under the following conditions: (column: XBridge Prep RP OBD C18 column, 30...) 150 mm, 5 µm; Mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; Flow rate: 60 mL / min; Gradient: 2% B to 32% B over 10 min; Wavelength: 254 nm / 220 nm; RT1 (min): 9.5). Fractions containing the desired product were combined and lyophilized to give the title compound (30 mg, 2%) as a grayish-white solid. MS (ESI, positive ion) m / z: 358.1 (M+1). 1 H NMR (400 MHz, DMSO-d) 6 , ppm ) δ 8.55 (d, J = 5.2 Hz, 1H), 8.16 - 8.14 (m, 2H), 7.44(d, J = 4.4 Hz, 2H), 7.42 - 7.40 (m, 2H), 6.66 (d,J = 5.2 Hz, 1H), 3.96 (s, 3H), 3.91 (s, 3H), 3.06 (s, 3H), 2.97 (s, 2H).
[0277] Example 12 Synthesis of ((2-(6,7-dimethoxyquinoline-4-yl)-2-azaspiro[3.3]hept-6-yl)methyl)(methyl)-λ6-thionediamine) Step 1: 6-[(methanesulfonyloxy)methyl]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester At 0 °C, TEA (890 mg, 8.79 mmol, 1 equivalent) and MsCl (604 mg, 5.27 mmol, 1.2 equivalent) were added to a stirred solution of 6-(hydroxymethyl)-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (1.00 g, 4.39 mmol, 1 equivalent) in DCM (12 mL). After stirring at room temperature for 2 h, the resulting mixture was diluted with DCM (100 mL) and washed with water and brine. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the title compound (1.34 g, 99%) as a yellow solid.
[0278] Step 2: 6-[(methylthioalkyl)methyl]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester At room temperature, sodium methanethiol (6.68 mL, 20% in H2O) was added to a stirred solution of tert-butyl 6-[(methanesulfonyloxy)methyl]-2-azaspiro[3.3]heptane-2-carboxylate (1.34 g, 4.38 mmol, 1 equivalent) in EtOH (10 mL). After stirring for 2 h, the reaction mixture was concentrated under reduced pressure and purified by silica gel column chromatography with EA / PE (18:82) to give the title compound (894 mg, 79%) as a yellow solid.
[0279] Step 3: 6-[(methylthioalkyl)methyl]-2-azaspiro[3.3]heptane At room temperature, tert-butyl 6-[(methylthioalkyl)methyl]-2-azaspiro[3.3]heptane-2-carboxylate (300 mg, 1.16 mmol, 1 equivalent) and 2,6-dimethylpyridine (0.12 g, 1.16 mmol, 1 equivalent) and TMSOTf (0.78 g, 3.498 mmol, 3 equivalent) were added to a solution of 6-[(methylthioalkyl)methyl]-2-azaspiro[3.3]heptane-2-carboxylate in DCM (10 mL). After stirring for 2 h, the reaction mixture was concentrated under reduced pressure to give the title compound (380 mg, crude) as a pale yellow oil, which was used directly in the next step without further purification.
[0280] Step 4: 6,7-Dimethoxy-4-(6-((methylthioalkyl)methyl)-2-azaspiro(3,3)hept-2-yl)quinoline At room temperature, 4-chloro-6,7-dimethoxyquinoline (350 mg, 1.57 mmol, 1.0 equivalent) was added to a solution of 6-((methylthioalkyl)methyl)-2-azaspiro[3.3]heptane (2.10 g, crude) in NMP (8 mL) and DIEA (3 mL). The resulting mixture was stirred at 130 °C for 2 h. After cooling to room temperature, the crude product was purified by reversed-phase rapid chromatography with elution of ACN / H2O (85:15) to give the title compound (440 mg, 81%) as a brown solid.
[0281] Step 2: ((2-(6,7-dimethoxyquinoline-4-yl)-2-azaspiro(3,3)hept-6-yl)methyl)(methyl)-λ6-thionediamine The title compound was synthesized in a manner similar to that described in step 5 of Example 1, except that 6,7-dimethoxy-4-(6-((methylthio)methyl)-2-azaspiro(3,3)hept-2-yl)quinoline (440 mg, 1.27 mmol). The crude product was purified by preparative HPLC under the following conditions: (XBridge Prep OBD C18 column, 30...) 150 mm, 5 µm; Mobile phase A: water (10 nmol / L NH4HCO3), mobile phase B: ACN; Flow rate: 60 mL / min; Gradient: 2% B to 25% B over 10 min; Wavelength: 254 nm / 220 nm; RT1 (min): 8.5). Fractions containing the desired product were combined and lyophilized to give the title compound (36.9 mg, 7%) as a white solid. MS (ESI, positive ion) m / z: 375.2 (M+1). 1H NMR (400 MHz, DMSO- d 6 , ppm ) δ 8.24 (d, J = 5.2 Hz, 1H), 7.20 (s,1H), 7.17 (s, 1H), 6.17 (d, J = 5.3 Hz, 1H), 4.39 (s, 2H), 4.20 (s, 2H), 3.88(d, J = 4.7 Hz, 6H), 3.13 (d, J = 7.0 Hz, 2H), 2.80 (s, 3H), 2.77 - 2.66 (m, 1H), 2.49 - 2.45 (m, 2H), 2.23 (s, 2H), 2.20 - 2.10 (m, 2H).
[0282] Example 13 Synthesis of (4-(((6,7-dimethoxyquinoline-4-yl)oxy)methyl)phenyl)(methyl)-λ6-thionediamine Step 1: 6,7-Dimethoxy-4-((4-(methylthioalkyl)phenyl)methoxy)quinoline The title compound was synthesized in a manner similar to that described in step 2 of Example 5, except that 4-chloro-6,7-dimethoxyquinoline (600 mg, 2.68 mmol) and (4-(methylthioalkyl)phenyl)methanol (1.03 g, 6.70 mmol) were used. The title compound (629 mg, 89%) was obtained as an orange solid.
[0283] Step 2: (4-(((6,7-dimethoxyquinoline-4-yl)oxy)methyl)phenyl)(methyl)-λ6-thionediamine The title compound was synthesized in a manner similar to that described in step 5 of Example 1, except that 6,7-dimethoxy-4-((4-(methylthioalkyl)phenyl)methoxy)quinoline (400 mg, 1.17 mmol) was used. The crude product was purified by preparative HPLC under the following conditions: (Column: XBridge Prep Shield RP18 OBD C18 column, 30...) 150 mm, 5 µm; Mobile phase A: water (10 nmol / L NH4HCO3), mobile phase B: ACN; Flow rate: 60 mL / min; Gradient: 2% B to 32% B over 10 min; Wavelength: 254 nm / 220 nm; RT1 (min): 9.92). Fractions containing the desired product were combined and lyophilized to give the title compound as a white solid (6.6 mg, 1%). MS (ESI, positive ion) m / z: 372.1 (M+1). 1 H NMR (400 MHz, DMSO- d 6, ppm ) δ 8.53 (d, J = 5.3 Hz, 1H), 8.14 - 8.06 (m,2H), 7.77 - 7.70 (m, 2H), 7.43 (s, 1H), 7.34 (s, 1H), 6.97 (d, J = 5.4 Hz, 1H), 5.50 (s, 2H), 3.92 (d, J = 4.6 Hz, 6H), 3.03 (s, 3H), 2.93 (s, 2H).
[0284] Example 14 Synthesis of cyclopropyl(4-((6,7-dimethoxyquinoline-4-yl)oxy)phenyl)-λ6-thionediamine 2,2,2-trifluoroacetate Step 1: 4-(4-(cyclopropylthio)phenoxy)-6,7-dimethoxyquinoline At room temperature, Cs₂CO₃ (1.20 g, 3.683 mmol, 2.06 equivalents) was added in portions to a stirred mixture of 4-chloro-6,7-dimethoxyquinoline (400 mg, 1.788 mmol, 1 equivalent) and 4-(cyclopropylthioalkyl)phenol (450 mg, 2.707 mmol, 1.51 equivalents) in DMSO (8 mL). The resulting mixture was stirred overnight at 120 °C. After cooling to room temperature, the reaction mixture was diluted with water and then extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by reversed-phase rapid chromatography with elution of ACN / H₂O (52:48) to give 4-(4-(cyclopropylthioalkyl)phenoxy)-6,7-dimethoxyquinoline (450 mg, 70%) as a pale yellow solid.
[0285] Step 2: Cyclopropyl(4-((6,7-dimethoxyquinoline-4-yl)oxy)phenyl)-λ4-thionimineonium 2,4,6-trimethylbenzenesulfonate A mixture of 4-(4-(cyclopropylthioalkyl)phenoxy)-6,7-dimethoxyquinoline (200 mg, 0.566 mmol, 1 equivalent) and 2,4,6-trimethylbenzenesulfonylhydroxylamine (365 mg, 1.696 mmol, 3.00 equivalent) in DCM (4 mL) was stirred at room temperature for 1 h. The resulting mixture was concentrated under reduced pressure to give cyclopropyl(4-((6,7-dimethoxyquinoline-4-yl)oxy)phenyl)-λ4-thionimineonium 2,4,6-trimethylbenzenesulfonate (340 mg, crude) as a brown solid. The resulting mixture was used directly in the next step without further purification.
[0286] Step 3: Cyclopropyl(4-((6,7-dimethoxyquinoline-4-yl)oxy)phenyl)-λ6-thionediamine 2,2,2-trifluoroacetate The title compound was synthesized in a manner similar to that described in step 3 of Example 40, except that cyclopropyl(4-((6,7-dimethoxyquinoline-4-yl)oxy)phenyl)-λ4-thionimineonium 2,4,6-trimethylbenzenesulfonate (340 mg, crude) was used instead of (4-(((7-methoxyquinoline-4-yl)oxy)methyl)phenyl)(methyl)-λ4-thionimineonium 2,4,6-trimethylbenzenesulfonate. The crude product was purified by reversed-phase rapid chromatography with elution of ACN / H2O (31:69) and then further purified by preparative HPLC under the following conditions (column: Xselect CSH Prep C18 column, 30...). 250 mm, 10 μm; mobile phase A: water (0.05% TFA), mobile phase B: ACN; flow rate: 60 mL / min; gradient: 2% B to 27% B over 10 min; wavelength: 254 nm / 220 nm; RT1 (min): 8.5), to obtain cyclopropyl(4-((6,7-dimethoxyquinoline-4-yl)oxy)phenyl)-λ6-thionediamine 2,2,2-trifluoroacetate (4.4 mg, 1%) as a white solid. MS (ESI, positive ion) m / z: 384.2 (M+1-114). 1 H NMR (400 MHz, DMSO- d 6) δ 8.76 (d, J = 5.8Hz, 1H), 8.27 (d,J = 8.5 Hz, 2H), 7.74 (d, J = 8.6 Hz, 2H), 7.65 (s, 1H), 7.52(s, 1H), 7.00 (d, J = 6.1 Hz, 1H), 3.99 (d, J = 20.5 Hz, 6H), 3.51 - 3.44 (m,1H), 1.36 - 1.24 (m, 4H). 19 F NMR (377 MHz, DMSO) δ -73.95 (s, 3 F).
[0287] Example 15 Synthesis of ((2-(8-methoxy-1,7-naphthidin-4-yl)-2-azaspiro[3.3]hept-6-yl)methyl)(methyl)-λ6-thionediamine Step 1: 8-Methoxy-4-(6-((methylthioalkyl)methyl)-2-azaspiro[3.3]hept-2-yl)-1,7-naphthidine DIEA (664 mg, 5.13 mmol, 5.00 equivalent) and 4-chloro-8-methoxy-1,7-naphthidine (200 mg, 1.02 mmol, 1.00 equivalent) were added to a solution of 6-((methylthioalkyl)methyl)-2-azaspiro[3.3]heptane (750 mg, crude) in NMP (10 mL). The reaction mixture was stirred at 130 °C for 3 h. After cooling to room temperature, the reaction mixture was purified by reversed-phase rapid chromatography with elution of ACN / H2O (35:65) to give 8-methoxy-4-(6-((methylthioalkyl)methyl)-2-azaspiro[3.3]hept-2-yl)-1,7-naphthidine (250 mg, 77%) as a brown solid.
[0288] Step 2: ((2-(8-methoxy-1,7-naphthidin-4-yl)-2-azaspiro[3.3]hept-6-yl)methyl)(methyl)-λ6-thionediamine The title compound was synthesized in a manner similar to that described in step 3 of Example 41, except that 8-methoxy-4-(6-((methylthioalkyl)methyl)-2-azaspiro[3.3]hept-2-yl)-1,7-naphthidine (250 mg, 0.79 mmol). The crude product was purified by reversed-phase rapid chromatography with elution of ACN / H2O (45:55) and then further purified by preparative HPLC under the following conditions (column: Xbridge Prep OBD C18 column, 30...). 150 mm, 5 µm; mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; flow rate: 60 mL / min; gradient: 2% B to 16% B over 10 min; wavelength: 254 nm / 220 nm; RT1 (min): 8.68), to obtain ((2-(8-methoxy-1,7-naphthidin-4-yl)-2-azaspiro[3.3]hept-6-yl)methyl)(methyl)-λ6-thionediamine (8.2 mg, 2%) as a grayish-white solid. MS (ESI, positive ion) m / z: 346.1 (M+1). 1 H NMR (400 MHz, DMSO- d 6, ppm ) δ 8.41 (d, J = 5.2 Hz, 1H), 7.87 (d, J = 6.0 Hz, 1H), 7.36 (d, J = 6.4 Hz, 1H), 6.42 (d, J = 5.2 Hz, 1H), 4.40 (s, 2H), 4.24 (s, 2H), 3.98 (s, 3H), 3.13 (d, J = 7.2 Hz, 2H), 2.81 (s,3H), 2.78 - 2.66 (m, 1H), 2.51 - 2.43 (m, 2H), 2.28 (s, 2H), 2.20 - 2.10 (m,2H).
[0289] Example 16 Synthesis of ((2-(6,7-dimethoxyquinazoline-4-yl)-2-azaspiro[3.3]hept-6-yl)methyl)(methyl)-λ6-thionediamine Step 1: 6,7-Dimethoxy-4-(6-((methylthioalkyl)methyl)-2-azaspiro[3.3]hept-2-yl)quinazolin At room temperature, DIEA (310 mg, 2.40 mmol, 2 equivalents) and 6-((methylthioalkyl)methyl)-2-azaspiro[3.3]heptane (226 mg, 1.44 mmol, 1.2 equivalents) were added to a stirred solution of 4-chloro-6,7-dimethoxyquinazoline (270 mg, 1.20 mmol, 1 equivalent) in NMP (5 mL). The resulting mixture was stirred at 130 °C for 2 h. After cooling to room temperature, the crude product was purified by reversed-phase rapid chromatography with elution using ACN / H2O (60:40) to give 6,7-dimethoxy-4-(6-((methylthioalkyl)methyl)-2-azaspiro[3.3]hept-2-yl)quinazoline (230 mg, 55%) as a yellow solid.
[0290] Step 2: ((2-(6,7-dimethoxyquinazoline-4-yl)-2-azaspiro[3.3]hept-6-yl)methyl)(methyl)-λ6-thionediamine The title compound was synthesized in a manner similar to that described in step 3 of Example 41, except that 6,7-dimethoxy-4-(6-((methylthioalkyl)methyl)-2-azaspiro[3.3]hept-2-yl)quinazoline (170 mg, 0.49 mmol). The crude product was purified by reversed-phase rapid chromatography with elution of ACN / H2O (25:75) and then further purified by preparative HPLC under the following conditions (column: XBridge Prep Shield RP18 OBD C18 column, 30 °C). 150 mm, 5 μm; Mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; Flow rate: 60 mL / min; Gradient: 2% B to 25% B over 10 min; Wavelength: 254 nm / 220 nm; RT1 (min): 9.13). Fractions containing the desired product were combined and lyophilized to give ((2-(6,7-dimethoxyquinazoline-4-yl)-2-azaspiro[3.3]hept-6-yl)methyl)(methyl)-λ6-thionediamine (17.6 mg, 9%) as a white solid. MS (ESI, positive ion) m / z: 376.1 (M+1). 1 HNMR (400 MHz, DMSO- d 6, ppm ) δ 8.33 (s, 1H), 7.15 (d, J= 24.0 Hz, 2H), 4.56 (s,2H), 4.38 (s, 2H), 3.89 (s, 6H), 3.13 (d, J = 7.0 Hz, 2H), 2.82 - 2.66 (m, 4H), 2.52 (s, 1H), 2.50 - 2.43 (m, 1H), 2.24 (s, 2H), 2.20 - 2.10 (m, 2H).
[0291] Example 17 Synthesis of cyclopropyl(3-(((6-fluoro-7-methoxyquinazoline-4-yl)oxy)methyl)phenyl)-λ6-thionediamine Step 1: 4-((3-(cyclopropylthio)phenyl)methoxy)-6-fluoro-7-methoxyquinazoline At room temperature, Cs₂CO₃ (2.30 g, 7.05 mmol, 3 equivalents) and (3-(cyclopropylthioalkyl)phenyl)methanol (635 mg, 3.52 mmol, 1.5 equivalents) were added to a stirred solution of 4-chloro-6-fluoro-7-methoxyquinazoline (500 mg, 2.35 mmol, 1 equivalent) in DMF (10 mL). After stirring at 80 °C for 2 h, the resulting mixture was cooled to room temperature. The reaction mixture was then diluted with H₂O and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was concentrated under reduced pressure and purified by silica gel column chromatography with EtOAc / PE (34:66) to give 4-((3-(cyclopropylthioalkyl)phenyl)methoxy)-6-fluoro-7-methoxyquinazoline (507 mg, 60%) as a yellow solid.
[0292] Step 2: (cyclopropyl(3-(((6-fluoro-7-methoxyquinazoline-4-yl)oxy)methyl)phenyl)-λ4-thionyl)azannium 2,4,6-trimethylbenzenesulfonate At room temperature, 2,4,6-trimethylbenzenesulfonylhydroxylamine (724 mg, 3.36 mmol, 3 equivalents) was added to a stirred solution of 4-((3-(cyclopropylthioalkyl)phenyl)methoxy)-6-fluoro-7-methoxyquinazoline (400 mg, 1.12 mmol, 1 equivalent) in DCM (8 mL). After stirring for 1 h, the resulting mixture was concentrated under reduced pressure to give (cyclopropyl(3-(((6-fluoro-7-methoxyquinazoline-4-yl)oxy)methyl)phenyl)-λ4-thionyl)azainium 2,4,6-trimethylbenzenesulfonate (450 mg, crude) as a white solid. MS (ESI, positive ion) m / z: 372.0 (M+1-200).
[0293] Step 3: Cyclopropyl(3-(((6-fluoro-7-methoxyquinazoline-4-yl)oxy)methyl)phenyl)-λ6-thionediamine The title compound was synthesized in a manner similar to that described in step 3 of Example 40, except that (cyclopropyl(3-(((6-fluoro-7-methoxyquinazolin-4-yl)oxy)methyl)phenyl)-λ4-thionyl)azainium 2,4,6-trimethylbenzenesulfonate (400 mg, crude) was used instead of (4-(((7-methoxyquinazolin-4-yl)oxy)methyl)phenyl)(methyl)-λ4-thionylimineonium 2,4,6-trimethylbenzenesulfonate). The crude product was purified by reversed-phase rapid chromatography with elution of ACN / H2O (34:66) and then further purified by preparative HPLC under the following conditions (column: XBridgePrep Shield RP18 OBD C18 column, 30...). 150 mm, 5 µm; Mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; Flow rate: 60 mL / min; Gradient: 12% B to 42% B over 10 min; Wavelength: 254 nm / 220 nm; RT1 (min): 9.62). Fractions containing the desired product were combined and lyophilized to give cyclopropyl(3-(((6-fluoro-7-methoxyquinazoline-4-yl)oxy)methyl)phenyl)-λ6-thionediamine (26.2 mg, 9%) as a white solid. MS (ESI, positive ion) m / z: 387.1 (M+1). 1 H NMR (400 MHz, DMSO- d 6, ppm ) δ 8.77 (s, 1H), 8.16 (t, J= 1.8Hz, 1H), 8.01 - 7.94 (m, 1H), 7.87 (d, J = 11.0 Hz, 1H), 7.78 - 7.74 (m, 1H), 7.65 - 7.49 (m, 2H), 5.72 (s, 2H), 4.04 (s, 3H), 2.80 (s, 2H), 2.76 - 2.68(m, 1H), 0.97 - 0.86 (m, 2H), 0.82 - 0.75 (m, 2H). 19 F NMR (376 MHz, DMSO- d 6 ) δ-130.56 (s, 1 F).
[0294] Example 18 Synthesis of (3-(((7-methoxy-1,8-naphthid-4-yl)oxy)methyl)phenyl)(methyl)-λ6-thionediamine Step 1: 2-Methoxy-5-((3-(methylthioalkyl)phenyl)methoxy)-1,8-naphthidine Cs₂CO₃ (2.00 g, 6.16 mmol, 2.0 equivalent) and (3-(methylthioalkyl)phenyl)methanol (713 mg, 4.62 mmol, 1.5 equivalent) were added to a solution of 5-chloro-2-methoxy-1,8-naphthidine (600 mg, 3.08 mmol, 1.0 equivalent) and KF (17 mg, 0.30 mmol, 0.1 equivalent) in DMF (10 mL). The reaction mixture was stirred at 100 °C for 3 h. After cooling to room temperature, the resulting mixture was diluted with EtOAc and washed with H₂O. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography with EtOAc / PE (78:22) to give 2-methoxy-5-((3-(methylthioalkyl)phenyl)methoxy)-1,8-naphthidine (900 mg, 74%) as a light yellow oil.
[0295] Step 2: (3-(((7-methoxy-1,8-naphthidin-4-yl)oxy)methyl)phenyl)(methyl)-λ6-thionediamine The title compound was synthesized in a manner similar to that described in step 3 of Example 41, except that 2-methoxy-5-((3-(methylthioalkyl)phenyl)methoxy)-1,8-naphthidine (600 mg, 1.92 mmol). The crude product was purified by reversed-phase rapid chromatography with elution of ACN / H2O (35:65) and then further purified by preparative HPLC under the following conditions (column: Xselect CSH Prep C18 column, 30...). 250 mm, 10 μm; mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; flow rate: 60 mL / min; gradient: 8% B to 38% B over 10 min; wavelength: 254 nm / 220 nm; RT1 (min): 8.5), to obtain (3-(((7-methoxy-1,8-naphthidin-4-yl)oxy)methyl)phenyl)(methyl)-λ6-thionediamine (38.1 mg, 5%) as a grayish-white solid. MS (ESI, positive ion) m / z: 343.0 (M+1). 1 H NMR (400 MHz, DMSO- d 6, ppm )δ 8.77 (d, J = 5.6 Hz, 1H), 8.46 (d, J = 8.8 Hz, 1H), 8.23 (d, J = 2.0 Hz, 1H), 8.09 - 8.02 (m, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.64 (d, J = 7.6 Hz, 1H), 7.15 (d, J = 5.6 Hz, 1H), 7.07 (d, J = 8.8 Hz, 1H), 5.50 (s, 2H), 4.01 (s, 3H), 3.03 - 2.97 (m, 5H).
[0296] Example 19 Synthesis of cyclopropyl(3-(((7-methoxy-1,8-naphthid-4-yl)oxy)methyl)phenyl)-λ6-thionediamine Step 1: 5-(((6-methoxypyridin-2-yl)amino)methylene)-2,2-dimethyl-1,3-dioxane-4,6-dione A mixture of 2,2-dimethyl-1,3-dioxane-4,6-dione (5.20 g, 36.08 mmol, 2.2 equivalents) in trimethoxymethane (22 mL) was refluxed for 2 h. The solution was cooled to room temperature, 6-methoxypyridin-2-amine (2.00 g, 16.11 mmol, 1 equivalent) was added, and the resulting solution was stirred overnight at 105 °C. The mixture was cooled to room temperature, and the resulting precipitate was filtered, washed with EtOH, and dried under vacuum to give 5-(((6-methoxypyridin-2-yl)amino)methylene)-2,2-dimethyl-1,3-dioxane-4,6-dione (4.01 g, 88%) as an orange solid.
[0297] Step 2: 7-Methoxy-1,8-Naphthyl-4-ol A mixture of 5-(((6-methoxypyridin-2-yl)amino)methylene)-2,2-dimethyl-1,3-dioxane-4,6-dione (4.00 g, 14.37 mmol, 1.0 equivalent) in phenoxybenzene (40 mL) was stirred at 225 °C for 1.5 h. After cooling to room temperature, the mixture was diluted with Et2O. The resulting precipitate was filtered, washed with Et2O, and dried to give 7-methoxy-1,8-naphthidine-4-ol (968 mg, 30%) as a gray solid.
[0298] Step 3: 5-Chloro-2-methoxy-1,8-naphthidine At room temperature, DIEA (7.34 g, 56.76 mmol, 2 equivalents) and POCl3 (5.22 g, 34.05 mmol, 1.2 equivalents) were added to a stirred solution of 7-methoxy-1,8-naphthidine-4-ol (5.00 g, 28.38 mmol, 1 equivalent) in toluene (100 mL). After stirring at 70 °C for 2 h, the reaction mixture was concentrated under reduced pressure and purified by silica gel column chromatography with EtOAc / PE (46:54) to give 5-chloro-2-methoxy-1,8-naphthidine (2.30 g, 37%) as a yellow solid.
[0299] Step 4: 5-((3-(cyclopropylthio)phenyl)methoxy)-2-methoxy-1,8-naphthidine A solution of (3-(cyclopropylthio)phenyl)methanol (1.10 g, 6.10 mmol, 1.48 equivalents) in DMF (15 mL) was treated with NaH (500 mg, 12.50 mmol, 3.0 equivalents, 60%) at 0 °C under a nitrogen atmosphere for 10 min, followed by dropwise addition of 5-chloro-2-methoxy-1,8-naphthidine (800 mg, 4.11 mmol, 1 equivalent) at 0 °C. The resulting mixture was stirred at room temperature under a nitrogen atmosphere for 2 h. The reaction was quenched at 0 °C by the addition of water and extracted with EtOAc. The combined organic layers were washed with brine and dried over anhydrous Na₂SO₄. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reversed-phase rapid chromatography with elution of ACN / H2O (28:72) to give 5-((3-(cyclopropylthioalkyl)phenyl)methoxy)-2-methoxy-1,8-naphthidine (580 mg, 41%) as a yellow solid.
[0300] Step 5: Cyclopropyl(3-(((7-methoxy-1,8-naphthidin-4-yl)oxy)methyl)phenyl)-λ6-thionediamine The title compound was synthesized in a manner similar to that described in step 3 of Example 41, except that 5-((3-(cyclopropylthio)phenyl)methoxy)-2-methoxy-1,8-naphthidine (440 mg, 1.30 mmol) was used. The crude product was purified by reversed-phase rapid chromatography with elution of ACN / H2O (28:72) and then further purified by preparative HPLC under the following conditions (column: Xbridge Prep OBD C18 column, 30...). 150 mm, 5 µm; Mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; Flow rate: 60 mL / min; Gradient: 9% B to 39% B over 10 min; Wavelength: 254 nm / 220 nm; RT1 (min): 8.68). Fractions containing the desired product were combined and lyophilized to give cyclopropyl(3-(((7-methoxy-1,8-naphthidin-4-yl)oxy)methyl)phenyl)-λ6-thionediamine (4.5 mg, 0.9%) as a white solid. MS (ESI, positive ion) m / z: 369.1 (M+1). 1 H NMR (400 MHz, DMSO- d 6, ppm ) δ 8.77 (d, J =5.4 Hz, 1H), 8.45 (d, J= 8.9 Hz, 1H), 8.15 (d, J = 2.2 Hz, 1H), 7.96 (d, J = 7.9Hz, 1H), 7.72 (d, J = 7.6 Hz, 1H), 7.58 (t, J = 7.7 Hz, 1H), 7.14 (d, J = 8.9 Hz, 1H), 7.04 (d, J = 5.5 Hz, 1H), 5.62 (s, 2H), 4.05 (s, 3H), 2.77 (s, 2H), 2.73 -2.64 (m, 1H), 0.96 - 0.85 (m, 2H), 0.82 - 0.72 (m, 2H).
[0301] Example 20 Synthesis of (3-fluoro-5-(((6-fluoro-7-methoxyquinazolin-4-yl)oxy)methyl)-phenyl)(methyl)-λ6-thionediamine Step 1: 6-Fluoro-4-((3-Fluoro-5-(methylthio)phenyl)methoxy)-7-methoxyquinazoline To a solution of 4-chloro-6-fluoro-7-methoxyquinazoline (600 mg, 2.82 mmol, 1.0 equivalent) and KF (16 mg, 0.28 mmol, 0.1 equivalent) in DMF (10 mL), (3-fluoro-5-(methylthioalkyl)phenyl)methanol (729 mg, 4.23 mmol, 1.5 equivalent) and Cs₂CO₃ (1.84 g, 5.64 mmol, 2.0 equivalent) were added. The reaction mixture was stirred at 100 °C for 3 h. After cooling to room temperature, the resulting mixture was diluted with H₂O and extracted with DCM. The organic layer was washed with brine (200 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography with EtOAc / PE (38:62) to give 6-fluoro-4-((3-fluoro-5-(methylthioalkyl)phenyl)methoxy)-7-methoxyquinazoline (900 mg, 74%) as a grayish-white solid.
[0302] Step 2: (3-Fluoro-5-(((6-Fluoro-7-methoxyquinazoline-4-yl)oxy)methyl)phenyl)(methyl)-λ4-thionimineonium 2,4,6-trimethylbenzenesulfonate At 0 °C, 2,4,6-trimethylbenzenesulfonylhydroxylamine (926 mg, 4.30 mmol, 3.0 equivalent) was added to a solution of 6-fluoro-4-((3-fluoro-5-(methylthioalkyl)phenyl)methoxy)-7-methoxyquinazoline (500 mg, 1.43 mmol, 1.0 equivalent) in DCM (5 mL). The reaction mixture was stirred at room temperature for 1 h. The resulting mixture was concentrated under reduced pressure to give (3-fluoro-5-(((6-fluoro-7-methoxyquinazoline-4-yl)oxy)methyl)phenyl)(methyl)-λ4-thionimineonium 2,4,6-trimethylbenzenesulfonate (800 mg, crude) as a grayish-white solid. The crude product was used directly in the next step without further purification.
[0303] Step 3: (3-Fluoro-5-(((6-Fluoro-7-methoxyquinazoline-4-yl)oxy)methyl)phenyl)(methyl)-λ6-thionediamine The title compound was synthesized in a manner similar to that described in step 3 of Example 40, except that (3-fluoro-5-(((6-fluoro-7-methoxyquinazolin-4-yl)oxy)methyl)phenyl)(methyl)-λ4-thionimineonium 2,4,6-trimethylbenzenesulfonate (500 mg, crude) was used instead of (4-(((7-methoxyquinazolin-4-yl)oxy)methyl)phenyl)(methyl)-λ4-thionimineonium 2,4,6-trimethylbenzenesulfonate). The crude product was purified by reversed-phase rapid chromatography with elution of ACN / H2O (35:65) and then further purified by preparative HPLC under the following conditions (column: XbridgePrep OBD C18 column, 30...). 150 mm, 5 µm; mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; flow rate: 60 mL / min; gradient: 11% B to 41% B over 10 min; wavelength: 254 nm / 220 nm; RT1 (min): 8.68), to obtain (3-fluoro-5-(((6-fluoro-7-methoxyquinazoline-4-yl)oxy)methyl)phenyl)(methyl)-λ6-thionediamine (30.3 mg, 7%) as a grayish-white solid. MS (ESI, positive ion) m / z: 379.1 (M+1). 1 H NMR (400 MHz, DMSO- d 6, ppm δ 8.79 (s, 1H), 8.06 (d, J= 1.6 Hz, 1H), 7.97 (d, J = 11.2 Hz, 1H), 7.81 (d, J = 8.4, 1H), 7.69 (d, J = 9.2, 1H), 7.56 (d, J = 8.0 Hz, 1H), 5.72 (s, 2H), 4.05 (s, 3H), 3.15 (s, 2H), 3.07 (s, 3H). 19 F NMR (376 MHz, DMSO- d 6 ) δ -111.40 (s, 1F), δ -130.53 (s, 1F).
[0304] Example 21 (3-(((6-fluoro-7-methoxyquinazolin-4-yl)oxy)methyl)phenyl)(methyl)-λ6-thionidimine Step 1: 6-Fluoro-7-methoxy-3H-quinazolin-4-one Formamidinium acetate (5.51 g, 52.92 mmol, 2 equivalents) was added to a stirred solution of 2-amino-5-fluoro-4-methoxybenzoic acid (4.90 g, 26.46 mmol, 1 equivalent) in 2-methoxyethanol (100 mL) at room temperature. After stirring at 120 °C for 2 h, the resulting mixture was cooled to room temperature and dissolved in water (200 mL). The precipitated solid was collected by filtration, washed with water (150 mL), and dried under reduced pressure to give 6-fluoro-7-methoxy-3H-quinazolin-4-one (4.67 g, 91%) as a yellow solid.
[0305] Step 2: 4-Chloro-6-fluoro-7-methoxyquinazoline At room temperature, DIEA (5.99 g, 46.35 mmol, 2 equivalents) and phosphoryl trichlorophosphate (17.77 g, 115.88 mmol, 5 equivalents) were added to a stirred solution of 6-fluoro-7-methoxy-3H-quinazolin-4-one (4.50 g, 23.17 mmol, 1 equivalent) in toluene (90 mL). After stirring at 90 °C for 2 h, the resulting mixture was concentrated under reduced pressure, diluted with H2O, and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give 4-chloro-6-fluoro-7-methoxyquinazolin (4.80 g, 97%) as a yellow solid.
[0306] Step 3: 6-Fluoro-7-methoxy-4-((3-(methylthio)phenyl)methoxy)quinazolin At room temperature, Cs₂CO₃ (2.30 g, 7.05 mmol, 3 equivalents) and (3-(methylthioalkyl)phenyl)methanol (544 mg, 3.52 mmol, 1.5 equivalents) were added to a stirred solution of 4-chloro-6-fluoro-7-methoxyquinazoline (500 mg, 2.35 mmol, 1 equivalent) in DMF (10 mL). After stirring at 80 °C for 2 h, the resulting mixture was concentrated under reduced pressure, diluted with H₂O, and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was concentrated under reduced pressure and purified by silica gel column chromatography with EtOAc / PE (33:67) to give 6-fluoro-7-methoxy-4-((3-(methylthioalkyl)phenyl)methoxy)quinazoline (610 mg, 70%) as a yellow solid.
[0307] Step 4: ((3-(((6-fluoro-7-methoxyquinazoline-4-yl)oxy)methyl)phenyl)(methyl)-λ4-thionyl)azannium 2,4,6-trimethylbenzenesulfonate At room temperature, 2,4,6-trimethylbenzenesulfonylhydroxylamine (781 mg, 3.63 mmol, 3 equivalents) was added to a stirred solution of 6-fluoro-7-methoxy-4-((3-(methylthioalkyl)phenyl)methoxy)-quinazoline (400 mg, 1.21 mmol, 1 equivalent) in DCM (8 mL). After stirring for 1 h, the resulting mixture was concentrated under reduced pressure to give ((3-(((6-fluoro-7-methoxyquinazoline-4-yl)oxy)methyl)phenyl)(methyl)-λ4-thionyl)azainium 2,4,6-trimethylbenzenesulfonate (560 mg, crude) as a white solid.
[0308] Step 5: (3-(((6-fluoro-7-methoxyquinazoline-4-yl)oxy)methyl)phenyl)(methyl)-λ6-thionediamine The title compound was synthesized in a manner similar to that described in step 3 of Example 40, except that (3-(((6-fluoro-7-methoxyquinazolin-4-yl)oxy)methyl)phenyl)(methyl)-λ4-thionyl)azonium 2,4,6-trimethylbenzenesulfonate (400 mg, crude) was used instead of (4-(((7-methoxyquinazolin-4-yl)oxy)methyl)phenyl)(methyl)-λ4-thionylimineonium 2,4,6-trimethylbenzenesulfonate. The crude product was purified by reversed-phase rapid chromatography with elution of ACN / H2O (22:78) and then further purified by preparative HPLC under the following conditions (column: Xselect CSHPrep C18 OBD column, 30...). 150 mm, 5 µm; Mobile phase A: water (0.1% FA), Mobile phase B: ACN; Flow rate: 60 mL / min; Gradient: 3% B to 25% B over 8 min; Wavelength: 254 nm / 220 nm; RT1 (min): 7.17. Fractions containing the desired product were combined and lyophilized to give (3-(((6-fluoro-7-methoxyquinazoline-4-yl)oxy)methyl)phenyl)(methyl)-λ6-thionediamine (32.5 mg, 11%) as a white solid. MS (ESI, positive ion) m / z: 361.1 (M+1). 1 HNMR (400 MHz, DMSO- d 6, ppm ) δ 8.78 (s, 1H), 8.22 (t, J = 1.9 Hz, 1H), 8.03 (d, J =7.8 Hz, 1H), 7.89 (d, J = 11.0 Hz, 1H), 7.78 (d, J = 7.7 Hz, 1H), 7.61 (t, J = 7.7Hz, 1H), 7.55 (d, J = 8.0 Hz, 1H), 5.72 (s, 2H), 4.04 (s, 3H), 3.03 (s, 3H). 19 FNMR (376 MHz, DMSO- d 6 ) δ -130.57 (s, 1 F).
[0309] Example 22 Synthesis of cyclopropyl(4-(((7-methoxy-1,8-naphthid-4-yl)oxy)methyl)phenyl)-λ6-thionediamine Step 1: 4-(cyclopropylthioalkyl)benzoic acid At room temperature, potassium tert-butoxide (3.64 g, 32.43 mmol, 2.5 equivalents) and bromocyclopropane (1.6 mL) were added to a stirred solution of 4-mercaptobenzoic acid (2.00 g, 12.97 mmol, 1 equivalent) in DMSO (20 mL). The resulting mixture was stirred overnight at 120 °C. After cooling to room temperature, the mixture was dissolved in water (200 mL) and acidified to pH = 5 with 1 M HCl (aqueous solution). The precipitated solid was collected by filtration, washed with water (150 mL), and dried under vacuum to give 4-(cyclopropylthioalkyl)benzoic acid (1.69 g, 67%) as a white solid.
[0310] Step 2: (4-(cyclopropylthio)phenyl)methanol At 0 °C, LiAlH4 (2.8 mL, 5.60 mmol, 2.18 equivalents) was added to a stirred solution of 4-(cyclopropylthioalkyl)benzoic acid (500 mg, 2.57 mmol, 1 equivalent) in THF (10 mL). After stirring at room temperature for 2 h, the reaction mixture was diluted with water (100 mL) and extracted with EtOAc (100 mL × 2). The combined organic layers were washed with brine (200 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure and purified by silica gel column chromatography with elution using MeOH / DCM (9: 91) to give (4-(cyclopropylthioalkyl)phenyl)methanol (292 mg, 62%) as a colorless oil.
[0311] Step 3: 5-((4-(cyclopropylthio)phenyl)methoxy)-2-methoxy-1,8-naphthidine At room temperature, Cs₂CO₃ (2.00 g, 6.16 mmol, 3 equivalents), (4-(cyclopropylthioalkyl)phenyl)methanol, and KF (11 mg, 0.20 mmol, 0.1 equivalents) were added to a stirred solution of 5-chloro-2-methoxy-1,8-naphthidine (400 mg, 2.05 mmol, 1 equivalent) in DMF (8 mL). The resulting mixture was stirred at 100 °C for 2 h. After cooling to room temperature, the reaction mixture was diluted with water and extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure and purified by silica gel column chromatography with EA / PE (61:39) elution to give 5-((4-(cyclopropylthioalkyl)phenyl)methoxy)-2-methoxy-1,8-naphthidine (390 mg, 55%) as a yellow solid.
[0312] Step 4: Cyclopropyl(4-(((7-methoxy-1,8-naphthidin-4-yl)oxy)methyl)phenyl)-λ6-thionediamine The title compound was synthesized in a manner similar to that described in step 3 of Example 41, except that 5-((4-(cyclopropylthio)phenyl)methoxy)-2-methoxy-1,8-naphthidine (400 mg, 1.18 mmol) was used. The crude product was purified by reversed-phase rapid chromatography with elution of ACN / H2O (30:70) and then further purified by preparative HPLC under the following conditions (column: Xbridge Prep OBD C18 column, 30...). 150 mm, 5 µm; Mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; Flow rate: 60 mL / min; Gradient: 5% B to 35% B over 10 min; Wavelength: 254 nm / 220 nm; RT1 (min): 8.68). Fractions containing the desired product were combined and lyophilized to give cyclopropyl(4-(((7-methoxy-1,8-naphthidin-4-yl)oxy)methyl)phenyl)-λ6-thionediamine (19.6 mg, 4%) as a white solid. MS (ESI, positive ion) m / z: 369.1 (M+1). 1 H NMR (400 MHz, DMSO- d 6, ppm ) δ 8.77 (d, J =5.4 Hz, 1H), 8.50 (d, J = 8.9 Hz, 1H), 8.08 - 8.01 (m, 2H), 7.72 (d,J = 8.2 Hz, 2H), 7.13 (d, J = 5.5 Hz, 1H), 7.07 (d, J = 8.9 Hz, 1H), 5.49 (s, 2H), 4.01 (s,3H), 2.79 (s, 2H), 2.76 - 2.68 (m, 1H), 0.97 - 0.92 (m, 2H), 0.86 - 0.75 (m,2H).
[0313] Example 23 Synthesis of (2-(1-(6-fluoro-7-methoxyquinazoline-4-yl)piperidin-4-yl)ethyl)(methyl)-λ6-thionediamine Step 1: 6-Fluoro-7-methoxy-4-(4-(2-(methylthio)ethyl)piperidin-1-yl)quinazolin At room temperature, DIEA (910 mg, 7.041 mmol, 5 equivalents) and 4-(2-(methylthioalkyl)ethyl)piperidine hydrochloride (420 mg, 2.14 mmol, 1.5 equivalents) were added to a solution of 4-chloro-6-fluoro-7-methoxyquinazoline (300 mg, 1.41 mmol, 1 equivalent) in NMP (6 mL). The resulting mixture was stirred at 100 °C for 3 h. After cooling to room temperature, the reaction mixture was purified by reversed-phase rapid chromatography with elution using ACN / H2O (68:32) to give 6-fluoro-7-methoxy-4-(4-(2-(methylthioalkyl)ethyl)piperidine-1-yl)quinazoline (400 mg, 84%) as a brown solid.
[0314] Step 2: (2-(1-(6-fluoro-7-methoxyquinazoline-4-yl)piperidin-4-yl)ethyl)(methyl)-λ6-thionediamine The title compound was synthesized in a manner similar to that described in step 3 of Example 41, except that 6-fluoro-7-methoxy-4-(4-(2-(methylthio)ethyl)piperidin-1-yl)quinazoline (350 mg, 1.04 mmol). The crude product was purified by reversed-phase rapid chromatography with elution of ACN / H2O (28:72) and then further purified by preparative HPLC under the following conditions (column: XBridge Prep OBD C18 column, 30...). 150 mm, 5 µm; mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; flow rate: 60 mL / min; gradient: 5% B to 30% B over 8 min; wavelength: 254 nm / 220 nm; RT1 (min): 7.63), to obtain (2-(1-(6-fluoro-7-methoxyquinazoline-4-yl)piperidin-4-yl)ethyl)(methyl)-λ6-thionediamine (27.5 mg, 7%) as a white solid. MS (ESI, positive ion) m / z: 366.1 (M+1). 1 H NMR (400 MHz, DMSO- d 6, ppm ) δ 8.56 (s, 1H), 7.66 (d, J = 12.2 Hz, 1H), 7.39 (d, J = 8.5 Hz, 1H), 4.19 (d, J = 13.0 Hz, 2H), 4.00 (s, 3H), 3.16 -2.98 (m, 4H), 2.86 (s, 3H), 2.27 (s, 2H), 1.87 - 1.78 (m, 2H), 1.77 - 1.67(m, 3H), 1.44 - 1.33 (m, 2H). 19 F NMR (377 MHz, DMSO- d 6 ) δ -132.81 (s, 1 F).
[0315] Example 24 Synthesis of (2-(1-(6-fluoro-7-methoxyquinoline-4-yl)piperidin-4-yl)ethyl)(methyl)-λ6-thionediamine Step 1: 6-Fluoro-7-methoxy-4-(4-(2-(methylthio)ethyl)piperidin-1-yl)quinoline DIEA (1526 mg, 11.81 mmol, 5.0 equivalent) and 4-(2-(methylthioalkyl)ethyl)piperidine hydrochloride (693 mg, 3.54 mmol, 1.5 equivalent) were added to a solution of 4-chloro-6-fluoro-7-methoxyquinoline (500 mg, 2.36 mmol, 1.0 equivalent) in NMP. The reaction mixture was stirred at 130 °C for 3 h. The mixture was then cooled to room temperature. The crude product was purified by reversed-phase rapid chromatography with elution of ACN / H2O (65:35) to give 6-fluoro-7-methoxy-4-(4-(2-(methylthioalkyl)ethyl)piperidine-1-yl)quinoline (450 mg, 56%) as a grayish-white solid.
[0316] Step 2: (2-(1-(6-fluoro-7-methoxyquinoline-4-yl)piperidin-4-yl)ethyl)(methyl)-λ6-thionediamine The title compound was synthesized in a manner similar to that described in step 3 of Example 41, except that 6-fluoro-7-methoxy-4-(4-(2-(methylthioalkyl)ethyl)piperidin-1-yl)quinoline (350 mg, 1.04 mmol). The crude product was purified by reversed-phase rapid chromatography with elution of ACN / H2O (20:80) and then further purified by preparative HPLC under the following conditions (column: XBridge Prep Shield RP18 OBD C18 column, 30 °C). 150 mm, 5 µm; mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; flow rate: 60 mL / min; gradient: 5% B to 35% B over 10 min; wavelength: 254 nm / 220 nm; RT1 (min): 9.42), to obtain (2-(1-(6-fluoro-7-methoxyquinoline-4-yl)piperidin-4-yl)ethyl)(methyl)-λ6-thionediamine (51.9 mg, 13%) as a grayish-white solid. MS (ESI, positive ion) m / z: 365.1 (M+1). 1 H NMR (400 MHz, DMSO- d 6, ppm )δ 8.60 (d, J = 5.2 Hz, 1H), 7.60(d, J = 8.4 Hz, 1H), 7.51 (d, J = 8.4 Hz, 1H), 6.92 (d, J= 5.2 Hz, 1H), 3.99 (s,3H), 3.46 (d, J = 9.2 Hz, 2H), 3.10 - 3.01 (m, 2H), 2.87 (s, 3H), 2.83 - 2.73(m, 2H), 2.36 - 2.30 (m, 2H), 1.90 - 1.82 (m, 2H), 1.82 - 1.72 (m, 2H), 1.67- 1.45 (m, 3H). 19 F NMR (376 MHz, DMSO- d 6 ) δ -133.51 (s, 1 F).
[0317] Example 25 Synthesis of (2-(1-(8-methoxypyridano[3,4-d]pyrimidin-4-yl)piperidin-4-yl)ethyl)(methyl)-λ6-thionediamine Step 1: 1-(8-methoxypyrido[3,4-d]pyrimidin-4-yl)-4-(2-(methylthioalkyl)ethyl)piperidine DIEA (991 mg, 7.67 mmol, 5 equivalents) and 4-(2-(methylthioalkyl)ethyl)piperidine hydrochloride (450 mg, 2.30 mmol, 1.5 equivalents) were added to a solution of 4-chloro-8-methoxypyrido[3,4-d]pyrimidinidine (300 mg, 1.5 mmol, 1 equivalent) in NMP (6 mL). The resulting mixture was stirred at 100 °C for 2 h. After cooling to room temperature, the crude product was purified by reversed-phase rapid chromatography with elution of ACN / H2O (60:40) to give 1-(8-methoxypyrido[3,4-d]pyrimidin-4-yl)-4-(2-(methylthioalkyl)ethyl)piperidine (330 mg, 67%) as a yellow solid.
[0318] Step 2: (2-(1-(8-methoxypyridano[3,4-d]pyrimidin-4-yl)piperidin-4-yl)ethyl)(methyl)-λ6-thionediamine The title compound was synthesized in a manner similar to that described in step 3 of Example 41, except that 1-(8-methoxypyridano[3,4-d]pyrimidin-4-yl)-4-(2-(methylthioalkyl)ethyl)piperidine (280 mg, 0.87 mmol). The crude product was purified by reversed-phase rapid chromatography with elution of ACN / H2O (23:77) and then further purified by preparative HPLC (column: Xbridge Prep OBD C18 column, 30). 150 mm, 5 µm; Mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; Flow rate: 60 mL / min; Gradient: 2% B to 29% B over 10 min; Wavelength: 254 nm / 220 nm; RT1 (min): 8.68). Fractions containing the desired product were combined and lyophilized to give (2-(1-(8-methoxypyridino[3,4-d]pyrimidin-4-yl)piperidin-4-yl)ethyl)(methyl)-λ6-thionediamine (27.4 mg, 8%) as a yellow solid. MS (ESI, positive ion) m / z: 349.1 (M+1). 1 H NMR (400 MHz, DMSO- d 6, ppm δ8.64 (s, 1H), 8.04 (d, J = 5.9 Hz, 1H), 7.30 (d, J = 5.9 Hz, 1H), 4.33 (d, J = 13.0Hz, 2H), 4.01 (s, 3H), 3.19 - 3.08 (m, 2H), 3.05 - 2.99 (m, 2H), 2.85 (s,3H), 2.28 (s, 2H), 1.83 (d, J = 13.0 Hz, 2H), 1.75 - 1.66 (m, 3H), 1.41 - 1.27 (m, 2H).
[0319] Example 26 Synthesis of (2-(1-(8-methoxy-1,7-naphthidin-4-yl)piperidin-4-yl)ethyl)(methyl)-λ6-thionediamine Step 1: 4-(2-((methanesulfonyl)oxy)ethyl)piperidine-1-carboxylic acid tert-butyl ester At 0 °C, TEA (11.91 g, 117.73 mmol, 3 equivalents), DMAP (0.48 g, 3.925 mmol, 0.1 equivalents), and methanesulfonic anhydride (20.51 g, 117.74 mmol, 3 equivalents) were added to a solution of tert-butyl piperidine-1-carboxylate (9.00 g, 3.00 g, 150 mL) in DCM. After stirring at room temperature for 2 h, the reaction mixture was diluted with water and extracted with DCM. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give tert-butyl piperidine-1-carboxylate (10.00 g, crude), a pale yellow oil, which was used directly in the next step without further purification.
[0320] Step 2: tert-butyl 4-(2-(methylthioalkyl)ethyl)piperidine-1-carboxylate Sodium methanethiol (113.98 g, 325.30 mmol, 1 equivalent) was added to a solution of tert-butyl piperidine-1-carboxylate (10.00 g, 32.53 mmol, 1 equivalent) in EtOH (150 mL). After stirring at room temperature for 2 h, the resulting mixture was concentrated under reduced pressure. The residue was diluted with water and extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure and purified by silica gel column chromatography with EA / PE (20:80) elution to give tert-butyl piperidine-1-carboxylate (7.00 g, 69% (two steps)) as a colorless oil.
[0321] Step 3: 4-(2-(methylthio)ethyl)piperidine hydrochloride A solution of tert-butyl 4-(2-(methylthio)ethyl)piperidine-1-carboxylate (851 mg, 3.28 mmol) in HCl (10 mL, gas, 4 M in 4-dioxane) was stirred at room temperature for 1 h. The resulting mixture was concentrated under reduced pressure to give 4-(2-(methylthio)ethyl)piperidine hydrochloride (716 mg, crude) as a white solid.
[0322] Step 4: 8-Methoxy-4-(4-(2-(methylthio)ethyl)piperidin-1-yl)-1,7-naphthidine DIEA (1.34 g, 10.36 mmol, 2.5 equivalence) was added to a stirred mixture of 4-(2-(methylthio)ethyl)piperidine hydrochloride (400 mg, crude) and 4-chloro-8-methoxy-1,7-naphthidine (600 mg, 3.08 mmol) in NMP (8 mL) at room temperature. The resulting mixture was stirred at 130 °C for 3 h. After cooling to room temperature, the crude product was purified by reversed-phase rapid chromatography using ACN / water (56:44) under the following conditions to give 8-methoxy-4-(4-(2-(methylthio)ethyl)piperidine-1-yl)-1,7-naphthidine (480 mg, 64%) as a brown solid.
[0323] Step 5: (2-(1-(8-methoxy-1,7-naphthidin-4-yl)piperidin-4-yl)ethyl)(methyl)-λ6-thionediamine The title compound was synthesized in a manner similar to that described in step 3 of Example 41, except that 8-methoxy-4-(4-(2-(methylthio)ethyl)piperidin-1-yl)-1,7-naphthidine (430 mg, 1.35 mmol). The crude product was purified by preparative HPLC under the following conditions (column: XBridge Prep Shield RP18 OBDC18 column, 30...). 150 mm, 5 µm; mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; flow rate: 60 mL / min; gradient: 2% B to 25% B over 10 min; wavelength: 254 nm / 220 nm; RT1 (min): 9.02), to obtain (2-(1-(8-methoxy-1,7-naphthidin-4-yl)piperidin-4-yl)ethyl)(methyl)-λ6-thionediamine (59.8 mg, 12%) as a yellow solid. MS (ESI, positive ion) m / z: 348.1 (M+1). 1 H NMR (400 MHz, DMSO- d 6) δ 8.67 (d, J = 5.0Hz, 1H), 8.02 (d, J = 5.9 Hz, 1H), 7.33 (d, J = 6.0 Hz, 1H), 7.15 (d, J = 5.1 Hz,1H), 4.03 (s, 3H), 3.55 (d, J= 12.3 Hz, 2H), 3.09 - 3.02 (m, 2H), 2.88 (s,3H), 2.85 - 2.76 (m, 2H), 2.46 - 2.13 (m, 2H), 1.92 - 1.84 (m, 2H), 1.81 -1.73 (m, 2H), 1.68 - 1.57 (m, 1H), 1.55 - 1.43 (m, 2H).
[0324] Example 27 Synthesis of cyclopropyl(3-((7-methoxyquinoline-4-yl)oxy)phenyl)-λ6-thionediamine Step 1: 4-(3-(cyclopropylthio)phenoxy)-7-methoxyquinoline Cs₂CO₃ (1.70 g, 5.22 mmol, 2.0 equivalent) was added to a stirred mixture of 3-(cyclopropylthioalkyl)phenol (650 mg, 3.91 mmol, 1.5 equivalent) and 4-chloro-7-methoxyquinoline (500 mg, 2.58 mmol, 100 equivalent) in DMF (10 mL). After stirring at 120 °C for 2 h, the mixture was allowed to cool to room temperature. The reaction mixture was diluted with water and then extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by reversed-phase rapid chromatography using ACN / water (22:78) under the following conditions to give 4-(3-(cyclopropylthioalkyl)phenoxy)-7-methoxyquinoline (700 mg, 82%) as a brown oil.
[0325] Step 2: Cyclopropyl(3-((7-methoxyquinoline-4-yl)oxy)phenyl)-λ4-thionimineonium 2,4,6-trimethylbenzenesulfonate A mixture of 4-(3-(cyclopropylthioalkyl)phenoxy)-7-methoxyquinoline (400 mg, 1.237 mmol, 1 equivalent) and 2,4,6-trimethylbenzenesulfonylhydroxylamine (800 mg, 3.716 mmol, 3.00 equivalent) in DCM (8 mL) was stirred at room temperature for 1 h. The resulting mixture was concentrated under reduced pressure to give cyclopropyl(3-((7-methoxyquinoline-4-yl)oxy)phenyl)-λ4-thionimineonium 2,4,6-trimethylbenzenesulfonate (680 mg, crude) as a brown solid, which was used directly in the next step without further purification.
[0326] Step 3: Cyclopropyl(3-((7-methoxyquinoline-4-yl)oxy)phenyl)-λ6-thionediamine The title compound was synthesized in a manner similar to that described in step 3 of Example 40, except that cyclopropyl(3-((7-methoxyquinoline-4-yl)oxy)phenyl)-λ4-thionimineonium 2,4,6-trimethylbenzenesulfonate (680 mg, crude) was used instead of (4-(((7-methoxyquinoline-4-yl)oxy)methyl)phenyl)(methyl)-λ4-thionimineonium 2,4,6-trimethylbenzenesulfonate). The crude product was purified by reversed-phase rapid chromatography with elution of ACN / H2O (29:61) and then further purified by preparative HPLC under the following conditions (column: XBridge Prep OBD C18 column, 30...). 150 mm, 5 µm; mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; flow rate: 60 mL / min; gradient: 12% B to 27% B over 18 min; wavelength: 254 nm / 220 nm; RT1 (min): 17.5), to obtain cyclopropyl(3-((7-methoxyquinoline-4-yl)oxy)phenyl)-λ6-thionediamine (4 mg, 2%) as a grayish-white solid. MS (ESI, positive ion) m / z: 354.1 (M+1). 1 H NMR (400 MHz, DMSO- d 6) δ 8.67 (d, J = 5.1 Hz, 1H), 8.20 (d, J = 9.1Hz, 1H), 7.93 (d, J = 7.9 Hz, 1H), 7.83 - 7.78 (m, 1H), 7.70 (t, J = 7.9 Hz, 1H),7.53 - 7.42 (m, 2H), 7.35 - 7.29 (m, 1H), 6.57 (d, J = 5.1 Hz, 1H), 3.95 (s,3H), 2.91 (s, 2H), 2.82 - 2.73 (m, 1H), 0.97 - 0.90 (m, 2H), 0.86 - 0.79 (m,2H).
[0327] Example 28 Synthesis of cyclopropyl(3-((7-methoxyquinazoline-4-yl)oxy)phenyl)-λ6-thionediamine Step 1: 3-(cyclopropylthioalkyl)phenol Potassium tert-butoxide (8.00 g, 71.29 mmol, 1 equivalent) was added dropwise to a stirred solution of 3-hydroxythiophenol (5.00 g, 39.62 mmol, 1 equivalent) in DMSO (70 mL) at 0 °C under a nitrogen atmosphere. The resulting mixture was stirred at room temperature for 30 min. Bromocyclopropane (5.72 mL, 71.39 mmol, 1.80 equivalent) was added dropwise to the mixture at room temperature. After stirring overnight at 90 °C, the resulting mixture was cooled to room temperature. The reaction mixture was diluted with water (500 mL) and then extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by reversed-phase rapid chromatography with EtOAc / PE (5:95) to give 3-(cyclopropylthioalkyl)phenol (5.00 g, 74%) as a yellow oil.
[0328] Step 2: 4-(3-(cyclopropylthio)phenoxy)-7-methoxyquinazoline Cs₂CO₃ (1.50 g, 4.60 mmol, 2.0 equivalent) was added to a stirred mixture of 3-(cyclopropylthioalkyl)phenol (580 mg, 3.48 mmol, 1.5 equivalent) and 4-chloro-7-methoxyquinazoline (450 mg, 2.31 mmol, 1.0 equivalent) in DMSO (7 mL). After stirring at 80 °C for 2 h, the mixture was allowed to cool to room temperature. The reaction mixture was diluted with water and then extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by reversed-phase rapid chromatography using ACN / water (61:39) under the following conditions to give 4-(3-(cyclopropylthioalkyl)phenoxy)-7-methoxyquinazoline (680 mg, 87%) as a yellow oil.
[0329] Step 3: Cyclopropyl(3-((7-methoxyquinazoline-4-yl)oxy)phenyl)-λ4-thionimineonium 2,4,6-trimethylbenzenesulfonate A mixture of 4-(3-(cyclopropylthioalkyl)phenoxy)-7-methoxyquinazoline (250 mg, 0.771 mmol, 1 equivalent) and 2,4,6-trimethylbenzenesulfonylhydroxylamine (500 mg, 2.323 mmol, 3.01 equivalent) in DCM (5 mL) was stirred at room temperature for 1 h. The resulting mixture was concentrated under reduced pressure to give cyclopropyl(3-((7-methoxyquinazoline-4-yl)oxy)phenyl)-λ4-thionimineonium 2,4,6-trimethylbenzenesulfonate (530 mg, crude) as a brown solid. The crude product was used directly in the next step without further purification.
[0330] Step 4: Cyclopropyl(3-((7-methoxyquinazoline-4-yl)oxy)phenyl)-λ6-thionediamine The title compound was synthesized in a manner similar to that described in step 3 of Example 40, except that cyclopropyl(3-((7-methoxyquinazolin-4-yl)oxy)phenyl)-λ4-thionimineonium 2,4,6-trimethylbenzenesulfonate (530 mg, crude) was used instead of (4-(((7-methoxyquinazolin-4-yl)oxy)methyl)phenyl)(methyl)-λ4-thionimineonium 2,4,6-trimethylbenzenesulfonate). The crude product was purified by reversed-phase rapid chromatography with elution of ACN / H2O (25:75) and then further purified by preparative HPLC under the following conditions (column: XBridge Prep OBD C18 column, 30...). 150 mm, 5 µm; mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; flow rate: 60 mL / min; gradient: 10% B to 40% B over 7 min; wavelength: 254 nm / 220 nm; RT1 (min): 6.82), to obtain cyclopropyl(3-((7-methoxyquinazoline-4-yl)oxy)phenyl)-λ6-thionediamine (12.2 mg, 2%) as a grayish-white solid. MS (ESI, positive ion) m / z: 355.2 (M+1). 1 H NMR (400 MHz, DMSO- d 6) δ 8.67 (s, 1H), 8.30 (d, J = 9.8Hz, 1H), 7.97 - 7.87 (m, 2H), 7.67 (t, J= 8.0 Hz, 1H), 7.60 - 7.54 (m, 1H), 7.44 - 7.37 (m, 2H), 3.99 (s, 3H), 2.90 (s, 2H), 2.81 - 2.72 (m, 1H), 0.99 -0.93 (m, 2H), 0.86 - 0.79 (m, 2H).
[0331] Example 29 Synthesis of cyclopropyl(4-((6,7-dimethoxyquinazoline-4-yl)oxy)phenyl)-λ6-thionediamine Step 1: 4-(4-(cyclopropylthio)phenoxy)-6,7-dimethoxyquinazoline To a solution of 4-chloro-6,7-dimethoxyquinazoline (500 mg, 2.22 mmol, 1.0 equivalent) in DMSO (10 mL), 4-(cyclopropylthioalkyl)phenol (555 mg, 3.33 mmol, 1.5 equivalent) and Cs₂CO₃ (1450 mg, 4.45 mmol, 2.0 equivalent) were added. The reaction mixture was stirred at 100 °C for 3 h. After cooling to room temperature, the resulting mixture was diluted with EtOAc and washed with H₂O. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography using EtOAc / PE (60:40) elution to give 4-(4-(cyclopropylthioalkyl)phenoxy)-6,7-dimethoxyquinazoline (700 mg, 88%) as a grayish-white solid.
[0332] Step 2: Cyclopropyl(4-((6,7-dimethoxyquinazoline-4-yl)oxy)phenyl)-λ4-thionimineonium 2,4,6-trimethylbenzenesulfonate At 0 °C, 2,4,6-trimethylbenzenesulfonylhydroxylamine (728 mg, 3.38 mmol, 3.0 equivalent) was added to a solution of 4-(4-(cyclopropylthioalkyl)phenoxy)-6,7-dimethoxyquinazoline (400 mg, 1.12 mmol, 1.0 equivalent) in DCM (10 mL). The reaction mixture was stirred at room temperature for 1 h. The resulting mixture was concentrated under reduced pressure to give cyclopropyl(4-((6,7-dimethoxyquinazoline-4-yl)oxy)phenyl)-λ4-thionimineonium 2,4,6-trimethylbenzenesulfonate (600 mg, crude). The crude product was used directly in the next step without further purification.
[0333] Step 3: Cyclopropyl(4-((6,7-dimethoxyquinazoline-4-yl)oxy)phenyl)-λ6-thionediamine The title compound was synthesized in a manner similar to that described in step 3 of Example 40, except that cyclopropyl(4-((6,7-dimethoxyquinazolin-4-yl)oxy)phenyl)-λ4-thionimineonium 2,4,6-trimethylbenzenesulfonate (600 mg, crude) was used instead of (4-(((7-methoxyquinazolin-4-yl)oxy)methyl)phenyl)(methyl)-λ4-thionimineonium 2,4,6-trimethylbenzenesulfonate). The crude product was purified by reversed-phase rapid chromatography with elution of ACN / H2O (45:55) to obtain the crude product, which was then further purified by preparative HPLC under the following conditions (Xbridge Prep OBDC18 column, 30...). 150 mm, 5 μm water (10 mmol / L NH4HCO3); ACN; 60 mL / min; 11% B to 41% B wavelength over 10 min (254 nm / 220 nm, RT1 (min): 8.68) to obtain cyclopropyl(4-((6,7-dimethoxyquinazoline-4-yl)oxy)phenyl)-λ6-thionediamine (29.5 mg, 6%) as a grayish-white solid. MS (ESI, positive ion) m / z: 385.1 (M+1). 1 H NMR (400 MHz, DMSO- d 6, ppm ) δ 8.59 (s, 1H), 8.10 (s, 1H), 8.08 (s, 1H), 7.57 (s, 1H), 7.51 (s, 1H), 7.49 (s, 1H), 7.41 (s, 1H), 3.99 (d, J = 7.2 Hz, 6H), 2.84 (s, 2H), 2.83 - 2.72 (m, 1H), 1.02 - 0.94 (m, 2H), 0.90 - 0.79 (m, 2H).
[0334] Example 30 Synthesis of cyclopropyl(3-(((7-methoxyquinazolin-4-yl)oxy)methyl)phenyl)-λ6-thionediamine Step 1: 4-((3-(cyclopropylthio)phenyl)methoxy)-7-methoxyquinazoline At room temperature, Cs₂CO₃ (1.70 g, 5.20 mmol, 2.0 equivalent) and (3-(cyclopropylthioalkyl)phenyl)-methanol (556 mg, 3.10 mmol, 1.2 equivalent) were added to a solution of 4-chloro-7-methoxyquinazoline (500 mg, 2.50 mmol, 1 equivalent) in DMF (12 mL). The resulting mixture was stirred at 80 °C for 2 h. After cooling to room temperature, water was added, and the mixture was extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography with EtOAc / PE (87 / 13) elution to give 4-((3-(cyclopropylthioalkyl)phenyl)methoxy)-7-methoxyquinazoline (566 mg, 65%) as an orange solid.
[0335] Step 2: Cyclopropyl(3-(((7-methoxyquinazoline-4-yl)oxy)methyl)phenyl)-λ4-thionimineonium 2,4,6-trimethylbenzenesulfonate At 0 °C, 2,4,6-trimethylbenzenesulfonylhydroxylamine (1.20 g, 5.55 mmol, 3 equivalents) was added to a solution of 4-((3-(cyclopropylthioalkyl)phenyl)methoxy)-7-methoxyquinazoline (565 mg, 1.85 mmol, 1 equivalent) in DCM (6 mL). The reaction mixture was stirred at room temperature for 1 h. Half of the DCM was concentrated and Et2O was added. The product was stored at 4 °C for 1 h, then crystallized and collected by filtration and dried under high vacuum to give cyclopropyl(3-(((7-methoxyquinazoline-4-yl)oxy)methyl)phenyl)-λ4-thionimineonium 2,4,6-trimethylbenzenesulfonate (1.00 g, crude) as a yellow solid.
[0336] Step 3: Cyclopropyl(3-(((7-methoxyquinazoline-4-yl)oxy)methyl)phenyl)-λ6-thionediamine The title compound was synthesized in a manner similar to that described in step 3 of Example 40, except that cyclopropyl(3-(((7-methoxyquinazolin-4-yl)oxy)methyl)phenyl)-λ4-thionimineon 2,4,6-trimethylbenzenesulfonate (1.00 g, crude) was used instead of (4-(((7-methoxyquinazolin-4-yl)oxy)methyl)phenyl)(methyl)-λ4-thionimineon 2,4,6-trimethylbenzenesulfonate. The crude product was purified by reversed-phase rapid chromatography with elution using ACN / H2O (28:72) to obtain 100 mg of crude cyclopropyl(3-(((7-methoxyquinazoline-4-yl)oxy)methyl)phenyl)-λ6-thionediamine and 150 mg of crude cyclopropyl(imino)(3-(((7-methoxyquinazoline-4-yl)oxy)methyl)phenyl)-λ6-thionone.
[0337] 100 mg of crude cyclopropyl(3-(((7-methoxyquinazolin-4-yl)oxy)methyl)phenyl)-λ6-thionediamine was further purified by preparative HPLC under the following conditions: Column: Xbridge Prep OBD C18 column, 19 250 mm, 5 µm; Mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: MeOH; Flow rate: 25 mL / min; Gradient: 45% B to 67% B over 10 min; Wavelength: 254 nm / 220 nm; RT1 (min): 8.68. Fractions containing the desired product were combined and lyophilized to give cyclopropyl(3-(((7-methoxyquinazoline-4-yl)oxy)methyl)phenyl)-λ6-thionediamine (12.1 mg, 1%) as a white solid. MS (ESI, positive ion) m / z: 369.1 (M+1). 1 H NMR (400 MHz, DMSO- d 6 , ppm ) δ 8.75 (s, 1H), 8.16 (s, 1H), 8.10 (d, J = 9.0 Hz, 1H), 7.98 (d, J = 7.9, 1.5 Hz, 1H), 7.74 (d, J = 7.6, 1.4 Hz, 1H), 7.59 (t, J = 7.7 Hz, 1H), 7.33 (d, J =2.5 Hz, 1H), 7.29 (q, J= 9.0, 2.5 Hz, 1H), 5.72 (s, 2H), 3.95 (s, 3H), 2.80(s, 2H), 2.75 - 2.66 (m, 1H), 0.97 - 0.89 (m, 2H), 0.80 - 0.72 (m, 2H).
[0338] Example 31 Synthesis of ((2-(7-methoxyquinazoline-4-yl)-2-azaspiro[3.3]hept-6-yl)methyl)(methyl)-λ6-thionediamine Step 1: 7-Methoxy-4-(6-((methylthioalkyl)methyl)-2-azaspiro[3.3]hept-2-yl)quinazolin DIEA (3 mL) and 6-((methylthioalkyl)methyl)-2-azaspiro[3.3]heptane (1.90 g, crude product) were added to a solution of 4-chloro-7-methoxyquinazoline (655 mg, 3.37 mmol) in NMP (10 mL). The resulting mixture was stirred at 100 °C for 2 h. After cooling to room temperature, the crude product was purified by reversed-phase rapid chromatography with elution of ACN / H2O (90:10) to give 7-methoxy-4-(6-((methylthioalkyl)methyl)-2-azaspiro[3.3]hept-2-yl)quinazoline (640 mg, 49%) as a brownish-yellow oil.
[0339] Step 2: ((2-(7-methoxyquinazoline-4-yl)-2-azaspiro[3.3]hept-6-yl)methyl)(methyl)-λ6-thionediamine The title compound was synthesized in a manner similar to that described in step 3 of Example 41, except that 7-methoxy-4-(6-(((methylthioalkyl)methyl)-2-azaspiro[3.3]hept-2-yl)quinazoline (640 mg, 1.75 mmol). The crude product was purified by reversed-phase rapid chromatography with elution of ACN / H2O to give 100 mg of crude ((2-(7-methoxyquinazoline-4-yl)-2-azaspiro[3.3]hept-6-yl)methyl)(methyl)-λ6-thiondiimide and 50 mg of crude imino ((2-(7-methoxyquinazoline-4-yl)-2-azaspiro[3.3]hept-6-yl)methyl)(methyl)-λ6-thionone).
[0340] 100 mg of crude ((2-(7-methoxyquinazoline-4-yl)-2-azaspiro[3.3]hept-6-yl)methyl)(methyl)-λ6-thionediamine) was further purified by preparative HPLC under the following conditions: Column: (XBridge Prep Shield RP18 OBD C18 column, 30 150 mm, 5 µm; Mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; Flow rate: 60 mL / min; Gradient: 2% B to 27% B over 10 min; Wavelength: 254 nm / 220 nm; RT1 (min): 9.92). Fractions containing the desired product were combined and lyophilized to give ((2-(7-methoxyquinazoline-4-yl)-2-azaspiro[3.3]hept-6-yl)methyl)(methyl)-λ6-thionediamine (36.9 mg, 7%) as a white solid. MS (ESI, positive ion) m / z: 346.1 (M+1). 1 H NMR (400 MHz, DMSO- d 6 , ppm ) δ 8.37 (s, 1H), 7.84 (d, J = 9.1 Hz, 1H), 7.09 (d, J = 2.6 Hz, 1H), 7.07 - 7.03 (m, 1H), 4.52 (s, 2H), 4.36 (s, 2H), 3.88 (s, 3H), 3.13 (d, J = 7.0 Hz, 2H), 2.80 (s, 3H), 2.72 (p, J = 7.4 Hz, 1H), 2.50 - 2.43 (m, 2H), 2.27 - 2.23 (m, 2H), 2.20 - 2.10 (m, 2H).
[0341] Example 32 Synthesis of 1-(4-(((8-methoxy-1,7-naphthid-4-yl)oxy)methyl)phenyl)-N,1-dimethyl-λ6-thionediamine Step 1: 5-(((2-methoxypyridin-3-yl)amino)methylene)-2,2-dimethyl-1,3-dioxane-4,6-dione A solution of 2-methoxypyridin-3-amine (3.00 g, 24.2 mmol, 1 equivalent), 2,2-dimethyl-1,3-dioxane-4,6-dione (4.50 g, 31.46 mmol, 1.3 equivalent), and trimethoxymethane (3.60 g, 33.8 mmol, 1.4 equivalent) in acetonitrile (30 mL) was stirred at 80 °C under nitrogen atmosphere for 2 h. After cooling to room temperature, the resulting solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using EA / PE (25:75) elution. Fractions containing the desired product were combined and concentrated under reduced pressure to give 5-(((2-methoxypyridin-3-yl)amino)methylene)-2,2-dimethyl-1,3-dioxane-4,6-dione (6.50 g, 97%) as a yellow solid.
[0342] Step 2: 8-Methoxy-1,7-Naphthyl-4-ol A mixture of 5-(((2-methoxypyridin-3-yl)amino)methylene)-2,2-dimethyl-1,3-dioxane-4,6-dione (1.50 g, 5.4 mmol, 1 equivalent) in phenoxybenzene (38 mL) was stirred at 225 °C for 1.5 h. After cooling to room temperature, PE was added to the reaction mixture. The precipitated solid was collected by filtration, washed with PE (30 mL × 3), and then purified by reversed-phase rapid chromatography with elution of ACN / H2O (26:74) to give 8-methoxy-1,7-naphthidine-4-ol (600 mg, 63%) as a white solid.
[0343] Step 3: 8-Methoxy-4-((4-(methylthioalkyl)phenyl)methoxy)-1,7-naphthidine Add (4-(methylthio)phenyl)methanol (912 mg, 5.92 mmol, 2 equivalents) and 2-(tributyl-) to a mixture of 8-methoxy-1,7-naphthyl-4-ol (550 mg, 2.96 mmol, 1 equivalent) in toluene (8 mL). l^(5)-phosphono)acetonitrile (1.40 g, 5.92 mmol, 2 equivalents). The resulting mixture was stirred at 130 °C for 2 h. After cooling to room temperature, the reaction mixture was concentrated under reduced pressure. The residue was purified by silica gel chromatography with MeOH / DCM (9:91) to give 650 mg of crude product, which was further purified by reversed-phase rapid chromatography with ACN / H2O (45:55) to give 8-methoxy-4-((4-(methylthioalkyl)phenyl)methoxy)-1,7-naphthidine (470 mg, 44%) as a white solid.
[0344] Step 4: ((4-(((8-methoxy-1,7-naphthid-4-yl)oxy)methyl)phenyl)(methyl)-λ4-thionyl)aza-2,4,6-trimethylbenzenesulfonate At room temperature, 2,4,6-trimethylbenzenesulfonylhydroxylamine (620 mg, 2.88 mmol, 3 equivalents) was added to a stirred solution of 8-methoxy-4-((4-(methylthioalkyl)phenyl)methoxy)-1,7-naphthidine (300 mg, 0.96 mmol, 1 equivalent) in DCM (6 mL). The resulting mixture was stirred at room temperature for 1 h. Half of the DCM was evaporated, and diethyl ether was added. The product was stored at 0 °C for 10 min, then crystallized and collected by filtration and dried under vacuum to give ((4-(((8-methoxy-1,7-naphthidine-4-yl)oxy)methyl)phenyl)(methyl)-λ4-thionyl)azainium 2,4,6-trimethylbenzenesulfonate (320 mg, crude) as a yellow solid.
[0345] Step 5: 1-(4-(((8-methoxy-1,7-naphthid-4-yl)oxy)methyl)phenyl)-N,1-dimethyl-λ6-thionediamine At 0 °C, Na₂CO₃ (72 mg, 0.68 mmol, 1.2 equivalence) and NCS (108 mg, 0.68 mmol, 1.2 equivalence) were added to a stirred solution of ((4-(((8-methoxy-1,7-naphthid-4-yl)oxy)methyl)phenyl)-(methyl)-λ4-thionyl)azamonium-2,4,6-trimethylbenzenesulfonate (300 mg, 0.56 mmol, 1 equivalent) in DMF (6 mL). After stirring for 15 min, methylamine hydrochloride (191 mg, 2.84 mmol, 5 equivalent) was added at 0 °C, and the mixture was stirred overnight at room temperature. The resulting mixture was purified by reversed-phase rapid chromatography with elution of ACN / H₂O (28:72) and concentrated under reduced pressure. The crude product was further purified by preparative HPLC (column: Welch Ultimate PFP 30). 250, 10 μm; Mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; flow rate: 60 mL / min; gradient: 6% B to 36% B over 10 min; wavelength: 254 nm / 220 nm; RT1 (min): 7.5). Fractions containing the desired product were combined and lyophilized to give 1-(4-(((8-methoxy-1,7-naphthidin-4-yl)oxy)methyl)phenyl)-N,1-dimethyl-λ6-thionediamine (9.8 mg, 4%) as a white solid. MS (ESI, positive ion) m / z: 357.1 (M+1). 1 H NMR (400 MHz, DMSO- d 6, ppm ) δ8.20 (d, J = 7.8 Hz, 1H), 7.99 (d, J = 5.4 Hz, 1H), 7.94 - 7.87 (m, 2H), 7.63 (d, J = 5.3 Hz, 1H), 7.29 (d, J = 8.2 Hz, 2H), 6.30 (d, J = 7.7 Hz, 1H), 5.82 (s, 2H), 3.82 (s, 3H), 2.97 (s, 3H), 2.57 (s, 1H), 2.45 (s, 3H).
[0346] Example 33 Synthesis of (2-(1-(7-methoxyquinazoline-4-yl)piperidin-4-yl)ethyl)(methyl)-λ6-thionediamine Step 1: 2-(1-(7-methoxyquinazoline-4-yl)piperidin-4-yl)ethanol-1-ol DIEA (1.59 g, 12.33 mmol, 3.0 equivalent) and 4-piperidinol (1.33 g, 10.27 mmol, 2.5 equivalent) were added to a solution of 4-chloro-7-methoxyquinazoline (800 mg, 4.11 mmol, 1.0 equivalent) in NMP (8 mL). The resulting mixture was stirred at 100 °C for 2 h. After cooling to room temperature, the crude product was purified by reversed-phase rapid chromatography with elution using ACN / H2O (44 / 56) to give 2-(1-(7-methoxyquinazoline-4-yl)piperidin-4-yl)ethanol-1-ol (1.15 g, 96%) as a yellow solid.
[0347] Step 2: 2-(1-(7-methoxyquinazoline-4-yl)piperidin-4-yl)ethyl mesylate At room temperature, TEA (788 mg, 7.79 mmol, 2.0 equivalent) and DMAP (47 mg, 0.39 mmol, 0.1 equivalent) were added to a solution of 2-(1-(7-methoxyquinazoline-4-yl)piperidin-4-yl)ethanol-1-ol (1.12 g, 3.89 mmol, 1.0 equivalent) in DCM (10 mL). Then, methanesulfonic anhydride (1.02 g, 5.84 mmol, 1.5 equivalent) was added at 0 °C. The resulting mixture was stirred at room temperature for 2 h. The reaction mixture was then diluted with water (200 mL) and extracted with DCM (3 × 200 mL). The combined organic layers were washed with brine (250 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain 2-(1-(7-methoxyquinazoline-4-yl)piperidin-4-yl)ethyl methanesulfonic acid (1.60 g, 99%), which was a yellow oil.
[0348] Step 3: 7-Methoxy-4-(4-(2-(methylthio)ethyl)piperidin-1-yl)quinazolin Sodium methanethiol (3.01 g, 42.96 mmol, 10.0 equivalent, 20% aqueous solution) was added to a solution of 2-(1-(7-methoxyquinazoline-4-yl)piperidin-4-yl)ethyl methanesulfonic acid (1.57 g, 4.29 mmol, 1.0 equivalent) in EtOH (20 mL). The resulting mixture was stirred at room temperature for 2 h. The solution was concentrated under reduced pressure. The residue was diluted with water and extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure and purified by silica gel column chromatography with MeOH / DCM (7:93) to give 7-methoxy-4-(4-(2-(methylthioalkyl)ethyl)piperidin-1-yl)quinazoline (1.26 g, 85%) as a yellow solid.
[0349] Step 4: (2-(1-(7-methoxyquinazoline-4-yl)piperidin-4-yl)ethyl)(methyl)-λ6-thionediamine The title compound was synthesized as described in step 3 of Example 41, except that 7-methoxy-4-(4-(2-(methylthio)ethyl)piperidin-1-yl)quinazoline (500 mg, 1.57 mmol). The crude product was purified by preparative HPLC under the following conditions: (column: XBridge Prep RP OBD C18 column, 30...) 150 mm, 5 µm; mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; flow rate: 60 mL / min; gradient: 15% B to 26% B over 7 min; wavelength: 254 nm / 220 nm; RT1 (min): 6.5), to obtain (2-(1-(7-methoxyquinazoline-4-yl)piperidin-4-yl)ethyl)(methyl)-λ6-thionediamine (11.8 mg, 2%) as a white solid. MS (ESI, positive ion) m / z: 348.2 (M+1). 1 H NMR (400 MHz, DMSO- d 6 , ppm ) δ 8.52 (s, 1H), 7.85 (d, J = 8.8 Hz, 1H), 7.17 (d, J = 2.8 Hz, 1H), 7.15 - 7.09 (m, 1H), 4.23 (d, J= 13.2 Hz, 2H),3.90 (s, 3H), 3.15 - 3.09 (m, 2H), 3.07 - 2.97 (m, 2H), 2.85 (s, 3H), 2.26(s, 2H), 1.87 - 1.78 (m, 2H), 1.77 - 1.67 (m, 3H), 1.44 - 1.26 (m, 2H).
[0350] Example 34 Synthesis of (4-(((7-methoxyquinazolin-4-yl)oxy)methyl)phenyl)(methyl)-λ6-thionediamine Step 1: 7-Methoxy-4-((4-(methylthio)benzyl)oxy)quinazolin NaH (369 mg, 9.24 mmol, 3.0 equivalent, 60%) was added to a solution of (4-(methylthio)phenyl)methanol (1.19 g, 7.70 mmol, 2.5 equivalents) in DMF (6 mL) at 0 °C. After stirring at 0 °C for 10 min, 4-chloro-7-methoxyquinazoline (600 mg, 3.083 mmol, 1 equivalent) was added. The resulting mixture was stirred at 0 °C for 2 h, and then water was added. The mixture was extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography with EtOAc / PE (30:70) elution to give 7-methoxy-4-((4-(methylthio)benzyl)oxy)quinazoline (472 mg, 47%) as a white solid.
[0351] Step 2: (4-(((7-methoxyquinazoline-4-yl)oxy)methyl)phenyl)(methyl)-λ4-thionimineonium 2,4,6-trimethylbenzenesulfonate To a solution of 7-methoxy-4-((4-(methylthio)benzyl)oxy)quinazoline (272 mg, 0.87 mmol, 1.0 equivalent) in DCM (3 mL), 2,4,6-trimethylbenzenesulfonylhydroxylamine (562 mg, 2.61 mmol, 3.0 equivalent) was added at 0 °C. The resulting mixture was stirred at room temperature for 1 h. The reaction mixture was concentrated under reduced pressure and filtered, and the filter cake was washed with Et2O. The filtrate was concentrated under reduced pressure to give (4-(((7-methoxyquinazoline-4-yl)oxy)methyl)phenyl)(methyl)-λ4-thionimineonium 2,4,6-trimethylbenzenesulfonate (520 mg, crude) as a colorless oil.
[0352] Step 3: (4-(((7-methoxyquinazoline-4-yl)oxy)methyl)phenyl)(methyl)-λ6-thionediamine The title compound was synthesized in a manner similar to that described in step 3 of Example 40, except that (4-(((7-methoxyquinazolin-4-yl)oxy)methyl)phenyl)(methyl)-λ4-thionimineonium 2,4,6-trimethylbenzenesulfonate (520 mg, crude) was used instead of (4-(((7-methoxyquinazolin-4-yl)oxy)methyl)phenyl)(methyl)-λ4-thionimineonium 2,4,6-trimethylbenzenesulfonate). The crude product was purified by reversed-phase rapid chromatography with elution of ACN / H2O (35:65) to obtain the crude product, which was then further purified by preparative HPLC under the following conditions (column: XBridgePrep OBD C18 column, 30...). 150 mm, 5 µm; mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; flow rate: 60 mL / min; gradient: 6% B to 36% B over 10 min; wavelength: 254 nm / 220 nm; RT1 (min): 9.1), to obtain (4-(((7-methoxyquinazoline-4-yl)oxy)methyl)phenyl)(methyl)-λ6-thionediamine (15.1 mg, 3%) as a white solid. MS (ESI, positive ion) m / z: 343.1 (M+1). 1 H NMR (400 MHz, DMSO- d 6 , ppm ) δ8.75 (s, 1H), 8.13 (d, J = 9.2 Hz, 1H), 8.10 - 8.04 (m, 2H), 7.72 (d, J= 8.4 Hz,2H), 7.36 - 7.26 (m, 2H), 5.71 (s, 2H), 3.95 (s, 3H), 3.02 (s, 3H), 2.94 (s,2H).
[0353] Example 35 Synthesis of cyclopropyl(4-((7-methoxyquinazoline-4-yl)oxy)phenyl)-λ6-thionediamine Step 1: 4-(4-(cyclopropylthio)phenoxy)-7-methoxyquinazoline Cs₂CO₃ (2.0 g, 6.20 mmol, 2 equivalents) and 4-(cyclopropylthioalkyl)phenol (768 mg, 4.62 mmol, 1.5 equivalents) were added to a stirred mixture of 4-chloro-7-methoxyquinazoline (600 mg, 3.08 mmol, 1 equivalent) in DMF (12 mL). The resulting mixture was stirred at 80 °C for 2 h. After cooling to room temperature, the mixture was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography with EtOAc / PE (24:76) to give 4-(4-(cyclopropylthioalkyl)phenoxy)-7-methoxyquinazoline (1.00 g, 83%) as a grayish-white solid.
[0354] Step 2: Cyclopropyl(4-((7-methoxyquinazoline-4-yl)oxy)phenyl)-λ4-thionimineonium 2,4,6-trimethylbenzenesulfonate At 0 °C, 2,4,6-trimethylbenzenesulfonylhydroxylamine (540 mg, 2.50 mmol, 2.70 equivalent) was added to a solution of 4-(4-(cyclopropylthioalkyl)phenoxy)-7-methoxyquinazoline (300 mg, 0.93 mmol, 1 equivalent) in DCM (6 mL). The reaction mixture was stirred at room temperature for 1 h. Half of the DCM was concentrated and Et2O (10 mL) was added. The product was stored at 4 °C overnight, crystallized, collected by filtration, and dried under high vacuum to give cyclopropyl(4-((7-methoxyquinazoline-4-yl)oxy)phenyl)-λ4-thionimineonium 2,4,6-trimethylbenzenesulfonate (500 mg, crude) as a yellow solid.
[0355] Step 3: Cyclopropyl(4-((7-methoxyquinazoline-4-yl)oxy)phenyl)-λ6-thionediamine The title compound was synthesized as described in step 3 of Example 40, except that cyclopropyl(4-((7-methoxyquinazoline-4-yl)oxy)phenyl)-λ4-thionimineon 2,4,6-trimethylbenzenesulfonate (500 g, crude) was used instead of (4-(((7-methoxyquinazoline-4-yl)oxy)methyl)phenyl)(methyl)-λ4-thionimineon 2,4,6-trimethylbenzenesulfonate. The crude product was purified by reversed-phase rapid chromatography with elution of ACN / H2O (28:72) to give 50 mg of crude cyclopropyl(4-((7-methoxyquinazoline-4-yl)oxy)phenyl)-λ6-thionimine and 50 mg of crude cyclopropyl(imino)(4-((7-methoxyquinazoline-4-yl)oxy)phenyl)-λ6-thionone.
[0356] 50 mg of crude cyclopropyl(4-((7-methoxyquinazolin-4-yl)oxy)phenyl)-λ6-thionediamine was further purified by preparative HPLC under the following conditions: column: Xbridge Prep OBD C18 column, 30 °C. 150 mm, 5 µm; Mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; Flow rate: 60 mL / min; Gradient: 11% B to 36% B over 10 min; Wavelength: 254 nm / 220 nm; RT1 (min): 8.68. Fractions containing the desired product were combined and lyophilized to give cyclopropyl(4-((7-methoxyquinazoline-4-yl)oxy)phenyl)-λ6-thionediamine (11.1 mg, 3%) as a white solid. MS (ESI, positive ion) m / z: 355.1 (M+1). 1 H NMR (400 MHz, DMSO- d 6 , ppm ) δ8.67 (s, 1H), 8.32 - 8.25 (m, 1H), 8.10 (d, J = 2.0 Hz, 1H), 8.08 (d, J = 2.0 Hz, 1H), 7.52 (d, J = 2.0 Hz, 1H), 7.50 (d, J = 2.0 Hz, 1H), 7.40 (d, J= 7.7 Hz, 2H), 3.99 (s, 3H), 2.85 (s, 2H), 2.81 - 2.74 (m, 1H), 1.02 - 0.94 (m, 2H), 0.90 -0.79 (m, 2H).
[0357] Example 36 Synthesis of (3-fluoro-5-(((7-methoxyquinazolin-4-yl)oxy)methyl)phenyl)(methyl)-λ6-thionediamine Step 1: 4-((3-fluoro-5-(methylthioalkyl)phenyl)methoxy)-7-methoxyquinazoline Cs₂CO₃ (2.08 g, 6.16 mmol, 2.0 equivalent) and (3-fluoro-5-(methylthioalkyl)phenyl)methanol (796 mg, 4.62 mmol, 1.5 equivalent) were added to a solution of 4-chloro-7-methoxyquinazoline (600 mg, 3.08 mmol, 1.0 equivalent) in DMF (10 mL). The reaction mixture was stirred at 80 °C for 2 h. After cooling to room temperature, the reaction mixture was quenched with water and extracted with dichloromethane. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with EtOAc / PE (30:70) as elution to give 4-((3-fluoro-5-(methylthioalkyl)phenyl)methoxy)-7-methoxyquinazoline (800 mg, 78%) as a pale yellow solid.
[0358] Step 2: (3-Fluoro-5-(((7-methoxyquinazoline-4-yl)oxy)methyl)phenyl)(methyl)-λ4-thionimineonium 2,4,6-trimethylbenzenesulfonate At 0 °C, 2,4,6-trimethylbenzenesulfonylhydroxylamine (1.17 g, 5.44 mmol, 3.0 equivalent) was added to a solution of 4-((3-fluoro-5-(methylthioalkyl)phenyl)methoxy)-7-methoxyquinazoline (600 mg, 1.81 mmol, 1.0 equivalent) in DCM. The reaction mixture was stirred at room temperature for 1 h. The resulting mixture was concentrated under reduced pressure to give (3-fluoro-5-(((7-methoxyquinazoline-4-yl)oxy)methyl)phenyl)(methyl)-λ4-thionimineonium 2,4,6-trimethylbenzenesulfonate (850 mg, crude). The crude product was used directly in the next step without further purification.
[0359] Step 3: (3-Fluoro-5-(((7-methoxyquinazoline-4-yl)oxy)methyl)phenyl)(methyl)-λ6-thionediamine The title compound was synthesized in a manner similar to that described in step 3 of Example 40, except that (3-fluoro-5-(((7-methoxyquinazolin-4-yl)oxy)methyl)phenyl)(methyl)-λ4-thionimineonium 2,4,6-trimethylbenzenesulfonate (800 mg, crude) was used instead of (4-(((7-methoxyquinazolin-4-yl)oxy)methyl)phenyl)(methyl)-λ4-thionimineonium 2,4,6-trimethylbenzenesulfonate). The crude product was purified by reversed-phase rapid chromatography with elution of ACN / H2O (30:70) and then further purified by preparative HPLC under the following conditions (column: Xselect CSHPrep OBD C18 column, 30 °C). 150 mm, 5 µm; mobile phase A: water (0.1% FA), mobile phase B: ACN; flow rate: 60 mL / min; gradient: 2% B to 24% B over 10 min; wavelength: 254 nm / 220 nm; RT1 (min): 8.68), to obtain (3-fluoro-5-(((7-methoxyquinazoline-4-yl)oxy)methyl)phenyl)(methyl)-λ6-thionediamine (17.6 mg, 5%) as a grayish-white solid. MS (ESI, positive ion) m / z: 361.1 (M+1). 1 H NMR (400 MHz, DMSO- d 6, ppm )δ 8.77 (s, 1H), 8.14 (d, J = 8.8 Hz, 1H), 8.07 (d, J = 1.2 Hz, 1H), 7.88 - 7.78 (m, 1H), 7.69 - 7.62 (m, 1H), 7.37 - 7.27 (m, 2H), 5.72 (s, 2H), 3.96 (s, 3H), 3.15(s, 2H), 3.07 (s, 3H). 19 F NMR (376 MHz, DMSO- d 6 ) δ -111.43 (s, 1 F).
[0360] Example 37 Synthesis of (3-(((7-methoxyquinazolin-4-yl)oxy)methyl)phenyl)(methyl)-λ6-thionediamine Step 1: 4-Chloro-7-methoxyquinazoline At room temperature, 0.5 mL of DMF was added to a solution of 7-methoxy-3H-quinazolin-4-one (5.00 g, 28.38 mmol, 1 equivalent) in 60 mL of SOCl2. After stirring at 80 °C for 2 h, the reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was dissolved in a saturated solution of sodium bicarbonate at 0 °C and extracted with DCM. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography with EtOAc / PE (26:74) as elution to give 4-chloro-7-methoxyquinazolin (4.90 g, 88%) as a yellow solid.
[0361] Step 2: 7-Methoxy-4-((3-(methylthioalkyl)phenyl)methoxy)quinazolin At 0 °C, NaH (221 mg, 9.24 mmol, 3 equivalents) was added to a solution of (3-(methylthioalkyl)phenyl)methanol (713 mg, 4.62 mmol, 1.5 equivalents) in DMF (12 mL). After stirring for 10 min, 4-chloro-7-methoxyquinazoline (600 mg, 3.08 mmol, 1 equivalent) was added. After stirring at 0 °C for 2 h, the resulting mixture was quenched with water (100 mL) and extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was concentrated under reduced pressure and purified by silica gel column chromatography with EtOAc / PE (30:70) to give 7-methoxy-4-((3-(methylthioalkyl)phenyl)methoxy)quinazoline (710 mg, 73%) as a yellow solid.
[0362] Step 3: (3-(((7-methoxyquinazoline-4-yl)oxy)methyl)phenyl)(methyl)-λ6-thionediamine The title compound was synthesized as described in step 3 of Example 41, except that 7-methoxy-4-((3-(methylthioalkyl)phenyl)methoxy)quinazoline (600 mg, 1.92 mmol) was used. The crude product was purified by preparative HPLC under the following conditions: (column: Welch Ultimate XB-C18 50) 250, 10 μm; Mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; Flow rate: 60 mL / min; Gradient: 17% B to 47% B over 10 min; Wavelength: 254 nm / 220 nm; RT1 (min): 18.38). Fractions containing the desired product were combined and lyophilized to give (3-(((7-methoxyquinazoline-4-yl)oxy)methyl)phenyl)(methyl)-λ6-thionediamine (47.4 mg, 7%) as a white solid. MS (ESI, positive ion) m / z: 343.1 (M+1). 1 H NMR (400 MHz, DMSO- d 6, ppm ) δ8.76 (s, 1H), 8.23 (t, J = 1.8 Hz, 1H), 8.10 (d, J = 9.0 Hz, 1H), 8.07 - 8.01 (m,1H), 7.80 - 7.73 (m, 1H), 7.61 (t, J = 7.7 Hz, 1H), 7.34 - 7.27 (m, 2H), 5.72(s, 2H), 3.95 (s, 3H), 3.03 (s, 3H), 2.95 (s, 2H).
[0363] Example 38 Synthesis of N-isopropyl-1-(3-(((8-methoxy-1,7-naphthid-4-yl)oxy)methyl)phenyl)-1-methyl-λ6-thionediamine Step 1: 8-Methoxy-4-((3-(methylthioalkyl)phenyl)methoxy)-1,7-naphthidine Under a nitrogen atmosphere, a solution of 8-methoxy-1,7-naphthyl-4-ol (4.50 g, 25.54 mmol, 1 equivalent) in toluene (5 mL) was added with (3-(methylthioalkyl)phenyl)methanol (5.91 g, 38.31 mmol, 1.5 equivalent) and 2-(tributyl- l^(5)-phosphono)acetonitrile (12.33 g, 51.08 mmol, 2 equivalents). After cooling to room temperature, the resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with EA / PE (65:35) elution to give a crude product (7.0 g). The crude product was further purified by reversed-phase rapid chromatography with ACN / water (55:45) elution to give 8-methoxy-4-((3-(methylthioalkyl)phenyl)methoxy)-1,7-naphthidine (2.80 g, 34%) as a yellow solid.
[0364] Step 2: ((3-(((8-methoxy-1,7-naphthidin-4-yl)oxy)methyl)phenyl)(methyl)-λ4-thionyl)azannium 2,4,6-trimethylbenzenesulfonate At room temperature, 2,4,6-trimethylbenzenesulfonylhydroxylamine (620 mg, 2.88 mmol, 3 equivalents) was added to a solution of 8-methoxy-4-((3-(methylthioalkyl)phenyl)methoxy)-1,7-naphthidine (300 mg, 0.96 mmol, 1 equivalent) in DCM (6 mL). The resulting mixture was stirred at room temperature for 1 h, then half of the DCM was evaporated and diethyl ether was added. The product was stored at 0 °C for 10 min and then crystallized by filtration and dried under reduced pressure to give (3-((((8-methoxy-1,7-naphthidine-4-yl)oxy)methyl)phenyl)-(methyl)-λ4-thionyl)azainium 2,4,6-trimethylbenzenesulfonate (220 mg, crude) as a yellow solid.
[0365] Step 2: (3-(((7-methoxyquinazoline-4-yl)oxy)methyl)phenyl)(methyl)-λ6-thionediamine At 0 °C, Na₂CO₃ (158 mg, 1.49 mmol, 5 equivalents) and NCS (57 mg, 0.35 mmol, 1.2 equivalents) were added to a stirred solution of ((3-(((8-methoxy-1,7-naphthid-4-yl)oxy)methyl)phenyl)-(methyl)-λ4-thionyl)azainium 2,4,6-trimethylbenzenesulfonate (157 mg, 0.34 mmol, 1 equivalent) in DMF (3 mL). After stirring for 15 min, isopropylamine (21 mg, 0.35 mmol, 1.2 equivalents) was added at 0 °C, and the mixture was stirred overnight at room temperature. The resulting mixture was purified by reversed-phase rapid chromatography with elution of ACN / H₂O (28:72) and concentrated under reduced pressure. The crude product was further purified by preparative HPLC (column: XBridge Prep Shield RP18 OBD C18 column, 30 150 mm, 5 μm; Mobile phase A: water (10 mmol / L NH4HCO3), Mobile phase B: ACN; Flow rate: 60 mL / min; Gradient: 7% B to 37% B over 10 min; Wavelength: 254 nm / 220 nm; RT1 (min): 9.23). Fractions containing the desired product were combined and lyophilized to give N-isopropyl-1-(3-(((8-methoxy-1,7-naphthidin-4-yl)oxy)methyl)phenyl)-1-methyl-λ6-thionediamine (4.6 mg, 3.9%) as a grayish-white solid. MS (ESI, positive ion) m / z: 385.1 (M+1). 1 H NMR (400 MHz, DMSO-) d 6 , ppm ) δ 8.78 (d, J = 5.2 Hz, 1H), 8.21 (t, J = 1.8 Hz, 1H), 8.07 (d, J = 5.8 Hz, 1H), 8.09 - 8.00 (m, 1H), 7.79 - 7.73 (m, 1H), 7.64 (t, J =7.7 Hz, 1H), 7.55 (d, J = 5.8 Hz, 1H), 7.38 (d, J = 5.3 Hz, 1H), 5.52 (s, 2H), 4.05 (s, 3H), 3.33 -3.26 (m, 1H), 3.01 (s, 3H), 2.68 (s, 1H), 1.08 (d, J= 6.3Hz, 3H), 0.88 (d, J = 6.3 Hz, 3H).
[0366] Example 39 Synthesis of ((2-(7-methoxyquinoline-4-yl)-2-azaspiro[3.3]hept-6-yl)methyl)(methyl)-λ6-thionediamine Step 1: 7-Methoxy-4-(6-((methylthioalkyl)methyl)-2-azaspiro[3.3]hept-2-yl)quinoline DIEA (3 mL) and 6-((methylthioalkyl)methyl)-2-azaspiro[3.3]heptane (1.22 g, crude) were added to a solution of 4-chloro-7-methoxyquinoline (500 mg, 2.58 mmol, 1 equivalent) in NMP (8 mL). The resulting mixture was stirred at 130 °C for 2 h. After cooling to room temperature, the crude product was purified by reversed-phase rapid chromatography with elution of ACN / H2O (95:5) to give 7-methoxy-4-(6-((methylthioalkyl)-methyl)-2-azaspiro[3.3]hept-2-yl)quinoline (1.00 g, crude) as a brownish-yellow oil.
[0367] Step 2: ((2-(7-methoxyquinoline-4-yl)-2-azaspiro[3.3]hept-6-yl)methyl)(methyl)-λ6-thionediamine The title compound was synthesized as described in step 3 of Example 41, except that 7-methoxy-4-(6-(((methylthioalkyl)methyl)-2-azaspiro[3.3]hept-2-yl)quinoline (1.00 g, crude). The crude product was purified by silica gel column chromatography with MeOH / DCM (1:10) elution to give 100 mg of crude ((2-(7-methoxyquinoline-4-yl)-2-azaspiro[3.3]hept-6-yl)methyl)(methyl)-λ6-thiondiimide and 100 mg of crude imino ((2-(7-methoxyquinoline-4-yl)-2-azaspiro[3.3]hept-6-yl)methyl)(methyl)-λ6-thionone).
[0368] 100 mg of crude ((2-(7-methoxyquinoline-4-yl)-2-azaspiro[3.3]hept-6-yl)methyl)(methyl)-λ6-thionediamine) was further purified by preparative HPLC under the following conditions: (column: SHIMADZU Shim-pack Scepter C18-120, 30) 150 mm, 5 μm; Mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; Flow rate: 60 mL / min; Gradient: 2% B to 23% B over 10 min; Wavelength: 254 nm / 220 nm; RT1 (min): 7.92). Fractions containing the desired product were combined and lyophilized to give ((2-(7-methoxyquinoline-4-yl)-2-azaspiro[3.3]hept-6-yl)methyl)(methyl)-λ6-thionediamine (28.4 mg, 2.3%) as a white solid. MS (ESI, positive ion) m / z: 345.1 (M+1). 1 H NMR (400 MHz, DMSO- d 6 , ppm ) δ 8.31 (d, J = 5.3 Hz, 1H), 7.86 (d, J = 9.3 Hz, 1H), 7.19 (d, J = 2.8 Hz, 1H), 7.00 (dd, J = 9.3, 2.7 Hz, 1H), 6.13 (d, J = 5.4 Hz, 1H), 4.37 (s, 2H), 4.22 (s, 2H), 3.86 (s, 3H), 3.13 (d, J = 7.0 Hz, 2H), 2.81 (s, 3H), 2.79 - 2.67 (m, 1H), 2.52 - 2.41 (m, 2H), 2.23 (s, 2H), 2.20 - 2.10 (m, 2H).
[0369] Example 40 Synthesis of (4-(((7-methoxyquinoline-4-yl)oxy)methyl)phenyl)(methyl)-λ6-thionediamine Step 1: 7-Methoxy-4-((4-(methylthio)phenyl)methoxy)quinoline Cs₂CO₃ (2019 mg, 6.19 mmol, 2.0 equivalent) and (4-(methylthioalkyl)phenyl)methoxy)quinoline (600 mg, 3.09 mmol, 1.0 equivalent) were added to a solution of 4-chloro-7-methoxyquinoline (600 mg, 3.09 mmol, 1.0 equivalent) in DMSO (10 mL). The reaction mixture was stirred at 100 °C for 3 h. After cooling to room temperature, the resulting mixture was diluted with DCM (100 mL) and washed with H₂O. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography with EtOAc / PE (88:12) as elution to give 7-methoxy-4-((4-(methylthioalkyl)phenyl)methoxy)quinoline (600 mg, 62%) as a pale yellow solid.
[0370] Step 2: (4-(((7-methoxyquinoline-4-yl)oxy)methyl)phenyl)(methyl)-λ4-thionimineonium 2,4,6-trimethylbenzenesulfonate At 0 °C, 2,4,6-trimethylbenzenesulfonylhydroxylamine (868 mg, 4.03 mmol, 3.0 equivalent) was added to a solution of 7-methoxy-4-((4-(methylthioalkyl)phenyl)methoxy)quinoline (400 mg, 1.34 mmol, 1.0 equivalent) in DCM (10 mL). The reaction mixture was stirred at room temperature for 1 h. The reaction mixture was concentrated under reduced pressure to give (4-(((7-methoxyquinoline-4-yl)oxy)methyl)phenyl)(methyl)-λ4-thionimineonium 2,4,6-trimethylbenzenesulfonate (650 mg, crude) as a grayish-white solid. The crude product was used directly in the next step without further purification.
[0371] Step 3: (4-(((7-methoxyquinoline-4-yl)oxy)methyl)phenyl)(methyl)-λ6-thionediamine Na₂CO₃ (109 mg, 1.03 mmol, 1.2 equivalence) and NCS (165 mg, 1.03 mmol, 1.2 equivalence) were added to a solution of (4-(((7-methoxyquinoline-4-yl)oxy)methyl)phenyl)(methyl)-λ4-thionimineonium 2,4,6-trimethylbenzenesulfonate (400 mg, crude) in DMF (10 mL) at 0 °C under a nitrogen atmosphere. The reaction mixture was stirred at 0 °C for 15 min, and NH₃ (0.37 mL, 2.59 mmol, 3.0 equivalence, 7 M in MeOH) was added. The resulting mixture was stirred at room temperature for 12 h. The mixture was purified by reversed-phase rapid chromatography with elution of ACN / H₂O (35:65) to give crude product, which was further purified by preparative HPLC under the following conditions (column: XBridge Prep RP OBD C18 column, 30 °C). 150 mm, 5 µm; mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; flow rate: 60 mL / min; gradient: 6% B to 36% B over 10 min; wavelength: 254 nm / 220 nm; RT1 (min): 9.2), to obtain (4-(((7-methoxyquinoline-4-yl)oxy)methyl)phenyl)(methyl)-λ6-thionediamine (22.5 mg, 7%) as a grayish-white solid. MS (ESI, positive ion) m / z: 342.1 (M+1). 1 H NMR (400 MHz, DMSO- d 6, ppm ) δ 8.66 (d, J = 5.2 Hz, 1H),8.15 - 8.06 (m, 3H), 7.74 (s, 1H), 7.72 (s, 1H), 7.34 (d, J = 2.4 Hz, 1H), 7.21(d, J = 9.2 Hz, 1H), 6.99 (d, J = 5.2 Hz, 1H), 5.48 (s, 2H), 3.91 (s, 3H), 3.03 (s, 3H), 2.92 (s, 2H).
[0372] Example 41 Synthesis of (3-fluoro-5-(((7-methoxyquinoline-4-yl)oxy)methyl)phenyl)(methyl)-λ6-thionediamine Step 1: (3-Fluoro-5-(methylthio)phenyl)methanol Sodium methanethiol (3.16 g, 45.10 mmol, 1.3 equivalents) was added to a solution of (3,5-difluorophenyl)methanol (5.00 g, 34.69 mmol, 1.0 equivalent) in DMF (50 mL). The reaction mixture was stirred at 110 °C for 2 h. After cooling to room temperature, the resulting mixture was diluted with DCM and washed with H2O. The organic layer was washed with brine and dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography with EtOAc / PE (18:82) to give (3-fluoro-5-(methylthioalkyl)phenyl)methanol (4.50 g, 75%) as a colorless oil.
[0373] Step 2: 4-((3-fluoro-5-(methylthio)benzyl)oxy)-7-methoxyquinoline At 0 °C, NaH (371 mg, 9.29 mmol, 2.0 equivalent, 60%) was added to a solution of (3-fluoro-5-(methylthio)phenyl)methanol (800 mg, 4.64 mmol, 1.0 equivalent) in DMF (10 mL). After stirring for 15 min, 4-chloro-7-methoxyquinoline (1.35 g, 6.96 mmol, 1.5 equivalent) was added at the same temperature. The resulting mixture was heated to room temperature and stirred for 2 h. The reaction mixture was quenched with water and extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with EtOAc / PE (87:13) elution to give 4-((3-fluoro-5-(methylthio)benzyl)oxy)-7-methoxyquinoline (800 mg, 39%) as a grayish-white solid.
[0374] Step 3: (3-Fluoro-5-(((7-methoxyquinoline-4-yl)oxy)methyl)phenyl)(methyl)-λ6-thionediamine NH3-H2O (2.48 g, 25% (v / v)) was added to a solution of 4-((3-fluoro-5-(methylthio)benzyl)oxy)-7-methoxyquinoline (600 mg, 1.82 mmol, 1.0 equivalent) in ACN (20 mL) at -15 °C under a nitrogen atmosphere. The reaction mixture was stirred for 1 h at the same temperature. Tert-butyl hypochlorite (988 mg, 9.11 mmol, 5.0 equivalent) was added, and the mixture was stirred again at -15 °C for 1 h. NH3-H2O (2.48 g, 25% (v / v)) was added. After stirring overnight at room temperature, the resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with elution of MeOH / DCM (8:92) to give a crude product, which was further purified by preparative HPLC under the following conditions (column: XBridge Prep RPOBD C18 column, 30...). 150 mm, 5 µm; mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; flow rate: 60 mL / min; gradient: 10% B to 40% B over 10 min; wavelength: 254 nm / 220 nm; RT1 (min): 9.2), to obtain (3-fluoro-5-(((7-methoxyquinoline-4-yl)oxy)methyl)phenyl)(methyl)-λ6-thionediamine (8.5 mg, 1%) as a grayish-white solid. MS (ESI, positive ion) m / z: 360.1 (M+1). 1 H NMR (400 MHz, DMSO- d 6, ppm ) δ 8.68 (d, J = 5.2 Hz, 1H), 8.12 (d, J = 9.2 Hz, 1H), 8.11 - 8.08 (m, 1H), 7.87 - 7.79 (m,1H), 7.69 - 7.61 (m, 1H), 7.35 (d, J = 2.4 Hz, 1H), 7.26 - 7.18 (m, 1H), 7.01(d, J = 5.2 Hz, 1H), 5.48 (s, 2H), 3.91 (s, 3H), 3.13 (s, 2H), 3.07 (s, 3H). 19 FNMR (377 MHz, DMSO- d 6 ) δ -111.26 (s, 1 F).
[0375] Examples 45 and 42 Synthesis of 1-(3-(((8-methoxy-1,7-naphthid-4-yl)oxy)methyl)phenyl)-N,N,1-trimethyl-λ6-thionediamine and 1-(3-(((8-methoxy-1,7-naphthid-4-yl)oxy)methyl)phenyl)-N,1-dimethyl-λ6-thionediamine At 0 °C, NaH (4 mg, 0.20 mmol, 2 equivalents) was added to a stirred solution of (3-(((8-methoxy-1,7-naphthid-4-yl)oxy)methyl)phenyl)-(methyl)-λ6-thionediamine 7 (35 mg, 0.10 mmol, 1 equivalent) in DMF (1 mL). After stirring for 10 min, iodomethane (21 mg, 0.15 mmol, 1.5 equivalents) was added and the reaction mixture was stirred at room temperature for 2 h. The resulting mixture was quenched with water (2 mL) at 0 °C and concentrated under reduced pressure. The crude product was purified by preparative HPLC (column: XBridge Prep RP OBD C18 column, 30). 150 mm, 5 µm; Mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; Flow rate: 60 mL / min; Gradient: 4% B to 34% B over 10 min; Wavelength: 254 nm / 220 nm; RT1 (min): 8.7, 9.3 min). Fractions containing the desired product were combined and lyophilized to give... Fraction 1: 1-(3-(((8-methoxy-1,7-naphthidin-4-yl)oxy)methyl)phenyl)-N,N,1-trimethyl-λ6-thionediamine (6.0 mg, 15%), white solid. MS (ESI, positive ion) m / z: 371.1 (M+1). 1 H NMR (400MHz, DMSO- d 6 , ppm ) δ 8.79 (d, J = 5.2 Hz, 1H), 8.13 (d, J = 1.8 Hz, 1H), 8.09 (d, J = 5.8 Hz, 1H), 7.98 - 7.91(m, 1H), 7.84 - 7.79 (m, 1H), 7.67 (t, J = 7.7 Hz, 1H), 7.55 (d, J = 5.8 Hz, 1H), 7.38 (d, J= 5.3 Hz, 1H), 5.53 (s, 2H), 4.06 (s, 3H), 3.01 (s, 3H), 2.53 (s, 6H).
[0376] Fraction 2: 1-(3-(((8-methoxy-1,7-naphthidin-4-yl)oxy)methyl)phenyl)-N,1-dimethyl-λ6-thionediamine (2.0 mg, 5%), yellow solid. MS (ESI, positive ion) m / z: 357.1 (M+1). 1 H NMR (400MHz, DMSO- d 6 , ppm ) δ 8.79 (d, J = 5.2 Hz, 1H), 8.16 (t, J = 1.9 Hz, 1H), 8.11 -8.05 (m, 1H), 8.00 - 7.93 (m, 1H), 7.82 - 7.77 (m, 1H), 7.66 (t, J = 7.7 Hz,1H), 7.59 - 7.53 (m, 1H), 7.39 (d, J = 5.2 Hz, 1H), 5.52 (s, 2H), 4.06 (s, 3H), 3.04 (s, 3H), 2.70 (s, 1H), 2.50 (s, 3H).
[0377] Examples 43 and 44 Synthesis of diethyl-1-(3-(((8-methoxy-1,7-naphthid-4-yl)oxy)methyl)phenyl)-1-methyl-λ6-thionediamine and N-ethyl-1-(3-(((8-methoxy-1,7-naphthid-4-yl)oxy)methyl)phenyl)-1-methyl-λ6-thionediamine.
[0378] At 0 °C, NaH (21 mg, 0.87 mmol, 2 equivalents) was added to a stirred solution of (3-(((8-methoxy-1,7-naphthid-4-yl)oxy)methyl)phenyl)-(methyl)-λ6-thionediamine (150 mg, 0.43 mmol, 1 equivalent) in DMF (3 mL). After stirring for 10 min, iodoethane (102 mg, 0.65 mmol, 1.5 equivalents) was added and the mixture was stirred at room temperature for 2 h. The resulting mixture was quenched with water (2 mL) at 0 °C and concentrated under reduced pressure. The residue was purified by reversed-phase rapid chromatography with elution of ACN / H2O (26:74) and concentrated under reduced pressure. The crude product was further purified by preparative HPLC (column: XBridge Prep RP OBD C18 column, 30). 150 mm, 5 µm; Mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; Flow rate: 60 mL / min; Gradient: 4% B to 34% B over 10 min; Wavelength: 254 nm / 220 nm; RT1 (min): 9.1, 9.4). Fractions containing the desired product were combined and lyophilized to give: Fraction 1: N-ethyl-1-(3-(((8-methoxy-1,7-naphthidin-4-yl)oxy)methyl)phenyl)-1-methyl-λ6-thionediamine (26.3 mg, 15%), yellow solid. MS (ESI, positive ion) m / z: 371.1 (M+1). 1 H NMR (400 MHz, DMSO-) d 6 , ppm ) δ 8.79 (d, J = 5.2 Hz, 1H), 8.18 (t, J = 1.9 Hz, 1H), 8.08 (d, J = 5.8 Hz, 1H), 8.03 - 7.96 (m, 1H), 7.82 - 7.75 (m, 1H), 7.66 (t, J =7.7 Hz, 1H), 7.56 (d, J = 5.8 Hz, 1H), 7.38 (d, J = 5.2 Hz, 1H), 5.53 (s, 2H), 4.06 (s, 3H), 3.04 (s, 3H), 2.98 - 2.86 (m, 1H), 2.79 - .67 (m, 2H), 1.02 (t, J = 7.2 Hz, 3H).
[0379] Fraction 2: Diethyl-1-(3-(((8-methoxy-1,7-naphthidin-4-yl)oxy)methyl)phenyl)-1-methyl-λ6-thionediamine (6.2 mg, 3%), yellow solid. MS (ESI, positive ion) m / z: 399.2 (M+1). 1 H NMR (400MHz, DMSO- d 6 , ppm ) δ 8.78 (d, J = 5.2 Hz, 1H), 8.17 (s, 1H), 8.07 (d, J = 5.8 Hz, 1H), 7.98 (d, J = 7.8 Hz, 1H), 7.79 (d, J = 7.6 Hz, 1H), 7.66 (t, J = 7.7 Hz, 1H), 7.54 (d, J = 5.8 Hz, 1H), 7.36 (d, J = 5.2 Hz, 1H), 5.53 (s, 2H), 4.05 (s, 3H), 3.01 (s, 3H), 2.97 - 2.87 (m, 2H), 2.86 - 2.76 (m, 2H), 1.06 (t, J = 7.2 Hz, 6H).
[0380] Example 46 Synthesis of (2-(1-(6,7-dimethoxyquinazolin-4-yl)piperidin-4-yl)ethyl)(methyl)-λ6-thionediamine Step 1: 2-(1-(6,7-dimethoxyquinazoline-4-yl)piperidin-4-yl)ethanol DIEA (1.40 g, 10.70 mmol, 3 equivalents) and 4-piperidinol (920 mg, 7.10 mmol, 2 equivalents) were added to a solution of 4-chloro-6,7-dimethoxyquinazoline (800 mg, 3.55 mmol, 1 equivalent) in NMP (10 mL). The resulting mixture was stirred at 100 °C for 2 h. After cooling to room temperature, the crude product was purified by reversed-phase rapid chromatography with elution using ACN / H2O (58:42) to give 2-(1-(6,7-dimethoxyquinazoline-4-yl)piperidin-4-yl)ethanol (970 mg, 85%) as a brownish-yellow oil.
[0381] Step 2: 2-(1-(6,7-dimethoxyquinazoline-4-yl)piperidin-4-yl)ethyl mesylate At 0 °C, methanesulfonic anhydride (1.60 g, 9.50 mmol, 3 equivalents), TEA (637 mg, 6.3 mmol, 2.00 equivalents), and DMAP (50 mg, 0.5 mmol, 0.15 equivalents) were added to a solution of 2-(1-(6,7-dimethoxyquinazoline-4-yl)piperidin-4-yl)ethanol (970 mg, 3.10 mmol, 1 equivalent) in DCM (15 mL). After stirring at room temperature for 2 h, the reaction mixture was diluted with water and extracted with DCM. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give 2-(1-(6,7-dimethoxyquinazoline-4-yl)piperidin-4-yl)ethyl methanesulfonic acid (1.60 g, crude) as a pale yellow oil, which was used directly in the next step without further purification.
[0382] Step 3: 6,7-Dimethoxy-4-(4-(2-(methylthio)ethyl)piperidin-1-yl)quinazolin Sodium methanethiol (16.13 g, 46.10 mmol, 10 equivalences, 20% aqueous solution) was added to a stirred solution of 2-(1-(6,7-dimethoxyquinazoline-4-yl)piperidin-4-yl)ethyl methanesulfonic acid (1.60 g, crude) in EtOH (15 mL). After stirring for 2 h, the reaction mixture was concentrated under reduced pressure. The residue was diluted with water and extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure and purified by silica gel column chromatography with EA / PE (56:44) elution to give 6,7-dimethoxy-4-(4-(2-(methylthioalkyl)ethyl)piperidin-1-yl)quinazoline (762 mg, 55%) as a yellow solid.
[0383] Step 4: (2-(1-(6,7-dimethoxyquinazoline-4-yl)piperidin-4-yl)ethyl)(methyl)-λ6-thionediamine The title compound was synthesized as described in step 3 of Example 41, except that 6,7-dimethoxy-4-(4-(2-(methylthioalkyl)ethyl)piperidin-1-yl)quinazoline (762 mg, 2.20 mmol). The crude product was purified by preparative HPLC under the following conditions: purification by silica gel column chromatography with EtOAc / PE (1:1) elution to give 150 mg of crude (2-(1-(6,7-dimethoxyquinazoline-4-yl)piperidin-4-yl)ethyl)(methyl)-λ6-thionediamine and 150 mg of crude (2-(1-(6,7-dimethoxyquinazoline-4-yl)piperidin-4-yl)ethyl)(imino)(methyl)-λ6-thionone).
[0384] 150 mg of crude (2-(1-(6,7-dimethoxyquinazolin-4-yl)piperidin-4-yl)ethyl)(methyl)-λ6-thionediamine) was further purified by preparative HPLC under the following conditions (column: XBridge Prep RP OBD C18 column, 30 °C). 150 mm, 5 µm; Mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; Flow rate: 60 mL / min; Gradient: 2% B to 28% B over 10 min; Wavelength: 254 nm / 220 nm; RT1 (min): 9.4). Fractions containing the desired product were combined and lyophilized to give (2-(1-(6,7-dimethoxyquinazoline-4-yl)piperidin-4-yl)ethyl)(methyl)-λ6-thionediamine (65.2 mg, 8%) as a white solid. MS (ESI, positive ion) m / z: 378.1 (M+1). 1 H NMR (400MHz, DMSO- d 6 , ppm ) δ 8.52 (s, 1H), 7.20 (s, 1H), 7.11 (s, 1H), 4.15 (d, J =13.1 Hz, 2H), 3.92 (d, J = 7.0 Hz, 6H), 3.09 - 2.98 (m, 4H), 2.86 (s, 3H), 2.26(s, 2H), 1.84 (d, J = 12.4 Hz, 2H), 1.79 - 1.62 (m, 3H), 1.48 - 1.35 (m, 2H).
[0385] Example 47 Synthesis of (2-(1-(6,7-dimethoxyquinoline-4-yl)piperidin-4-yl)ethyl)(methyl)-λ6-thionediamine Step 1: 2-(1-(6,7-dimethoxyquinoline-4-yl)piperidin-4-yl)ethanol DIEA (1.40 g, 10.70 mmol, 3.00 equivalent) and 4-piperidinol (1.40 g, 10.70 mmol, 3.00 equivalent) were added to a solution of 4-chloro-6,7-dimethoxyquinoline (800 mg, 3.50 mmol, 1 equivalent) in NMP (15 mL). The resulting mixture was stirred at 130 °C for 2 h. After cooling to room temperature, the crude product was purified by reversed-phase rapid chromatography with elution using ACN / H2O (86:14) to give 2-(1-(6,7-dimethoxyquinoline-4-yl)piperidin-4-yl)ethanol (900 mg, 80%) as a brownish-yellow oil.
[0386] Step 2: 2-(1-(6,7-dimethoxyquinoline-4-yl)piperidin-4-yl)ethyl mesylate At 0 °C, methanesulfonic anhydride (2.50 g, 13.10 mmol, 3 equivalents), TEA (895 mg, 8.85 mmol, 2.00 equivalents), and DMAP (55 mg, 0.50 mmol, 0.10 equivalents) were added to a solution of 2-(1-(6,7-dimethoxyquinoline-4-yl)piperidin-4-yl)ethanol (900 mg, 4.45 mmol, 1 equivalent) in DCM (15 mL). After stirring at room temperature for 2 h, the resulting mixture was quenched with H2O and extracted with DCM. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give 2-(1-(6,7-dimethoxyquinoline-4-yl)piperidin-4-yl)ethyl methanesulfonate (1.30 g, crude), which was used directly in the next step without further purification.
[0387] Step 3: 6,7-Dimethoxy-4-(4-(2-(methylthio)ethyl)piperidin-1-yl)quinoline At room temperature, sodium methanethiol (13.15 g, 37.57 mmol, 10 equivalences, 20% aqueous solution) was added to a solution of 2-(1-(6,7-dimethoxyquinoline-4-yl)piperidin-4-yl)ethyl methanesulfonic acid (1.30 g, crude) in EtOH (15 mL). After stirring for 2 h, the reaction mixture was concentrated under reduced pressure. The residue was diluted with water and extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure and purified by silica gel column chromatography with EA / PE (67:33) elution to give 6,7-dimethoxy-4-(4-(2-(methylthioalkyl)ethyl)piperidin-1-yl)quinoline (250 mg, 25% (two steps)) as a yellow solid.
[0388] Step 4: (2-(1-(6,7-dimethoxyquinoline-4-yl)piperidin-4-yl)ethyl)(methyl)-λ6-thionediamine The title compound was synthesized as described in step 3 of Example 41, except that 6,7-dimethoxy-4-(4-(2-(methylthioalkyl)ethyl)piperidin-1-yl)quinoline (250 mg, 0.72 mmol). The crude product was purified by preparative HPLC under the following conditions: purification by silica gel column chromatography with EtOAc / PE elution to give 100 mg of crude (2-(1-(6,7-dimethoxyquinoline-4-yl)piperidin-4-yl)ethyl)(methyl)-λ6-thionediamine and 80 mg of crude (2-(1-(6,7-dimethoxyquinoline-4-yl)piperidin-4-yl)ethyl)(imino)(methyl)-λ6-thionone).
[0389] 100 mg of crude (2-(1-(6,7-dimethoxyquinoline-4-yl)piperidin-4-yl)ethyl)(methyl)-λ6-thionediamine) was further purified by preparative HPLC under the following conditions: column: XBridge Prep OBD C18 column, 30 150 mm, 5 µm; Mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; Flow rate: 60 mL / min; Gradient: 2% B to 9% B over 10 min; Wavelength: 254 nm / 220 nm; RT1 (min): 9.2. The fractions containing the desired product were combined and lyophilized to give (2-(1-(6,7-dimethoxyquinoline-4-yl)piperidin-4-yl)ethyl)(methyl)-λ6-thionediamine (28.3 mg, 10%) as a white solid. MS (ESI, positive ion) m / z: 377.1 (M+1). 1 H NMR (400 MHz, DMSO- d 6 , ppm ) δ 8.48 (d, J = 5.0 Hz, 1H), 7.30 (s, 1H), 7.18 (s, 1H), 6.85 (d, J = 5.1 Hz,1H), 3.91 (s, 6H), 3.49 (d, J = 11.8 Hz, 2H), 3.10 - 3.01 (m, 2H), 2.87 (s,3H), 2.75 (t, J = 11.6 Hz, 2H), 2.28 (s, 2H), 1.89 (d, J= 12.1 Hz, 2H), 1.83 -1.73 (m, 2H), 1.65 - 1.42 (m, 3H).
[0390] Example 48 Synthesis of (2-(1-(7-methoxyquinoline-4-yl)piperidin-4-yl)ethyl)(methyl)-λ6-thionediamine Step 1: 2-(1-(7-methoxyquinoline-4-yl)piperidin-4-yl)ethanol DIEA (1.60 g, 12.39 mmol, 3 equivalents) and 4-piperidinol (1.33 g, 10.33 mmol, 2.5 equivalents) were added to a solution of 4-chloro-7-methoxyquinoline (800 mg, 4.13 mmol, 1 equivalent) in NMP (8 mL). The resulting mixture was stirred at 130 °C for 2 h. After cooling to room temperature, the mixture was diluted with H2O and extracted with DCM. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by reversed-phase rapid chromatography with elution of ACN / H2O (89:11) to give 2-(1-(7-methoxyquinoline-4-yl)piperidin-4-yl)ethanol (1.11 g, 90%) as a yellow solid.
[0391] Step 2: 2-(1-(7-methoxyquinoline-4-yl)piperidin-4-yl)ethyl mesylate At room temperature, TEA (763 mg, 7.54 mmol, 2 equivalents) and DMAP (46 mg, 0.37 mmol, 0.1 equivalents) were added to a solution of 2-(1-(7-methoxyquinoline-4-yl)piperidin-4-yl)ethanol (1.08 g, 3.77 mmol, 1 equivalent) in DCM (15 mL). Then, mesylate anhydride (985 mg, 5.65 mmol, 1.5 equivalents) was added at 0 °C. After stirring at room temperature for 2 h, the resulting mixture was quenched with H₂O and extracted with DCM. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was concentrated under reduced pressure to give 2-(1-(7-methoxyquinoline-4-yl)piperidin-4-yl)ethyl mesylate (1.45 g, 98%) as a yellow solid.
[0392] Step 3: 7-Methoxy-4-(4-(2-(methylthio)ethyl)piperidin-1-yl)quinoline Sodium methanethiol (13.65 g, 38.96 mmol, 1 equivalent) was added to a solution of 2-(1-(7-methoxyquinoline-4-yl)piperidin-4-yl)ethyl methanesulfonic acid (1.42 g, 3.89 mmol, 1 equivalent) in EtOH (10 mL). After stirring at room temperature for 2 h, the resulting mixture was concentrated under reduced pressure. The residue was diluted with water and extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure and purified by silica gel column chromatography with MeOH / DCM (6:94) to give 7-methoxy-4-(4-(2-(methylthioalkyl)ethyl)piperidin-1-yl)quinoline (1.03 g, 80%) as a yellow solid.
[0393] Step 4: (2-(1-(7-methoxyquinoline-4-yl)piperidin-4-yl)ethyl)(methyl)-λ6-thionediamine The title compound was synthesized as described in step 3 of Example 41, except that 7-methoxy-4-(4-(2-(methylthio)ethyl)piperidin-1-yl)quinoline (400 mg, 1.26 mmol). The crude product was purified by preparative HPLC under the following conditions: (column: XBridge Prep OBD C18 column, 30...). 150 mm, 5 µm; Mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; Flow rate: 60 mL / min; Gradient: 2% B to 31% B over 10 min; Wavelength: 254 nm / 220 nm; RT1 (min): 9.2). Fractions containing the desired product were combined and lyophilized to give (2-(1-(7-methoxyquinoline-4-yl)piperidin-4-yl)ethyl)(methyl)-λ6-thionediamine (37.8 mg, 8%) as a yellow solid. MS (ESI, positive ion) m / z: 347.2 (M+1). 1 H NMR (400 MHz, DMSO- d 6, ppm ) δ 8.58 (d, J = 5.0 Hz, 1H), 7.88 (d, J = 9.2 Hz, 1H), 7.31 (d, J = 2.6 Hz, 1H), 7.18 (dd, J=9.2, 2.7 Hz, 1H), 6.84 (d, J = 5.1 Hz, 1H), 3.90 (s, 3H), 3.51 (d, J = 12.0 Hz,2H), 3.10 - 3.01 (m, 2H), 2.87 (s, 3H), 2.84 - 2.73 (m, 2H), 2.36 - 2.30 (m,2H), 1.90 - 1.82 (m, 2H), 1.82 - 1.72 (m, 2H), 1.50 (m, 2H), 1.39 (s, 1H).
[0394] Example 49 Synthesis of cyclopropyl(4-((7-methoxyquinoline-4-yl)oxy)phenyl)-λ6-thionediamine Step 1: Cyclopropyl(4-methoxyphenyl)thion At room temperature, K₂CO₃ (9.86 g, 71.32 mmol, 2.0 equivalent) and bromocyclopropane (8.63 g, 71.32 mmol, 2.0 equivalent) were added to a solution of 4-methoxyphenylthiophenol (5.00 g, 35.66 mmol, 1.0 equivalent) in DMF (50 mL). After stirring overnight at 120 °C, the reaction mixture was cooled to room temperature and quenched with water. The resulting mixture was extracted with dichloromethane. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with EtOAc / PE (1:4) to give cyclopropyl(4-methoxyphenyl)thione (5.40 g, 83%) as a colorless oil.
[0395] Step 2: 4-(cyclopropylthio)phenol At 0 °C, BBr3 (50 mL, 50.00 mmol, 1 M in DCM) was added to a solution of cyclopropyl(4-methoxyphenyl)thione (5.40 g, 29.95 mmol, 1.0 equivalent) in DCM (50 mL). After stirring at room temperature for 24 h, the resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with EtOAc / PE (1:1) elution to give 4-(cyclopropylthio)phenol (4.00 g, 80%) as a pale yellow oil.
[0396] Step 3: 4-(4-(cyclopropylthio)phenoxy)-7-methoxyquinoline Cs₂CO₃ (3.53 g, 10.84 mmol, 3 equivalents) and 4-(cyclopropylthio)phenol (901 mg, 5.42 mmol, 1.5 equivalents) were added to a mixture of 4-chloro-7-methoxyquinoline (700 mg, 3.61 mmol, 1 equivalent) in DMSO (15 mL). After stirring at 120 °C for 3 h, the resulting mixture was cooled to room temperature, diluted with water, and extracted with EA. The combined organic layers were washed with brine and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The crude product was purified by reversed-phase rapid chromatography with elution of ACN / H₂O (92:8) to give 4-(4-(cyclopropylthio)phenoxy)-7-methoxyquinoline (880 mg, 71%) as a grayish-white solid.
[0397] Step 4: Cyclopropyl(4-((7-methoxyquinoline-4-yl)oxy)phenyl)-λ6-thionediamine The title compound was synthesized as described in step 3 of Example 41, except that 4-(4-(cyclopropylthio)phenoxy)-7-methoxyquinoline (750 mg, 2.31 mmol) was used. The crude product was purified by preparative HPLC under the following conditions: (column: Xbridge Prep OBD C18 column, 30...). 150 mm, 5 µm; Mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; Flow rate: 60 mL / min; Gradient: 11% B to 38% B over 10 min; Wavelength: 254 nm / 220 nm; RT1 (min): 8.68). Fractions containing the desired product were combined and lyophilized to give cyclopropyl(4-((7-methoxyquinoline-4-yl)oxy)phenyl)-λ6-thionediamine (6.0 mg, 0.7%) as a grayish-white solid. MS (ESI, positive ion) m / z: 354.1 (M+1). 1 H NMR (400 MHz, DMSO-d 6 , ppm ) δ 8.70 (d, J = 5.2Hz, 1H), 8.15 - 8.07 (m, 3H), 7.45 (d, J= 2.4 Hz, 1H), 7.41 - 7.38 (m, 2H), 7.32 - 7.29 (m, 1H), 6.66 (d, J = 5.2 Hz, 1H), 3.95 (s, 3H), 2.84 (s, 2H), 2.77- 2.73 (m, 1H), 0.97 - 0.94 (m, 2H), 0.85 (d, J = 1.2 Hz, 2H).
[0398] Example 50 Synthesis of cyclopropyl(3-(((7-methoxyquinoline-4-yl)oxy)methyl)phenyl)-λ6-thionediamine Step 1: 3-(cyclopropylthioalkyl)benzoic acid A mixture of 3-thioalkylbenzoic acid (20.00 g, 129.72 mmol, 1.0 equivalent) in DMSO (200 mL) was supplemented with bromocyclopropane (23.54 g, 194.57 mmol, 1.5 equivalent) and potassium tert-butoxide (36.39 g, 324.29 mmol, 2.5 equivalent). The reaction mixture was stirred at 80 °C for 24 h. After cooling to room temperature, the reaction mixture was diluted with water, the pH was adjusted to 5 with 1 NHCl (aqueous solution), and extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with EtOAc / PE (40:60) elution to give 3-(cyclopropylthioalkyl)benzoic acid (20.00 g, 69%) as a colorless oil.
[0399] Step 2: (3-(cyclopropylthio)phenyl)methanol At 0 °C, lithium aluminum hydride (110 mL, 2 equivalents, 2 M in THF) was added to a solution of 24.0 g (117.37 mmol, 1 equivalent) of 3-(cyclopropylthioalkyl)benzoic acid in 250 mL of THF. The resulting mixture was stirred overnight at room temperature under a nitrogen atmosphere. The reaction mixture was quenched at 0 °C with saturated ammonium bicarbonate solution and extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with EtOAc / PE (10:90) as elution to give (3-(cyclopropylthioalkyl)phenyl)methanol (20.0 g, 86%) as a yellow oil.
[0400] Step 3: 4-((3-(cyclopropylthio)phenyl)methoxy)-7-methoxyquinoline At 0 °C, NaH (223 mg, 9.29 mmol, 3 equivalents) was added to a solution of (3-(cyclopropylthioalkyl)phenyl)methanol (837 mg, 4.64 mmol, 1.5 equivalents) in DMF (12 mL). After stirring for 10 min, 4-chloro-7-methoxyquinoline (600 mg, 3.09 mmol, 1 equivalent) was added at the same temperature. The reaction mixture was stirred at 80 °C for 2 h. The resulting mixture was then quenched with water at 0 °C and extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography with EtOAc / PE (62:38) as elution to give 4-((3-(cyclopropylthioalkyl)phenyl)-methoxy)-7-methoxyquinoline (620 mg, 43%) as a yellow solid.
[0401] Step 4: Cyclopropyl(3-(((7-methoxyquinoline-4-yl)oxy)methyl)phenyl)-λ6-thionediamine The title compound was synthesized as described in step 3 of Example 41, except that 4-((3-(cyclopropylthio)phenyl)methoxy)-7-methoxyquinoline (500 mg, 1.48 mmol) was used. The crude product was purified by preparative HPLC under the following conditions: (column: Xbridge Prep OBD C18 column, 30...) 150 mm, 5 µm; Mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; Flow rate: 60 mL / min; Gradient: 11% B to 41% B over 10 min; Wavelength: 254 nm / 220 nm; RT1 (min): 8.68. Fractions containing the desired product were combined and lyophilized to give cyclopropyl(3-(((7-methoxyquinoline-4-yl)oxy)methyl)phenyl)-λ6-thionediamine (3.7 mg, 0.7%) as a white solid. MS (ESI, positive ion) m / z: 368.1 (M+1). 1 H NMR (400 MHz, DMSO- d 6 , ppm ) δ 8.67(d, J = 5.3 Hz, 1H), 8.19 (s, 1H), 8.09 (d, J = 9.1 Hz, 1H), 8.00 (d, J = 7.8 Hz, 1H), 7.76 (d, J = 7.6 Hz, 1H), 7.62 (t, J = 7.7 Hz, 1H), 7.35 (d, J = 2.6 Hz, 1H),7.26 - 7.16 (m, 1H), 7.01 (d, J = 5.3 Hz, 1H), 5.48 (s, 2H), 3.91 (s, 3H), 2.82(s, 2H), 2.76 - 2.66 (m, 1H), 1.01 - 0.88 (m, 2H), 0.84 - 0.73 (m, 2H).
[0402] Example 51 Synthesis of 1-cyclopropyl-1-(3-(((8-methoxy-1,7-naphthidin-4-yl)oxy)methyl)phenyl)-N-methyl-λ6-thionediamine At 0 °C, NaH (11 mg, 0.46 mmol, 2.0 equivalent) was added to a solution of cyclopropyl(3-(((8-methoxy-1,7-naphthidin-4-yl)oxy)methyl)phenyl)-λ6-thionediamine (85 mg, 0.23 mmol, 1.0 equivalent) in DMF (3 mL). After stirring at 0 °C for 0.5 h, iodomethane (104 mg, 0.73 mmol, 3.2 equivalent) was added. The reaction mixture was stirred at room temperature for 1 h, quenched with water, and extracted with dichloromethane. The combined organic layers were washed with water and brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure and purified by preparative HPLC under the following conditions (column: Welch Ultimate PFP-C18 30). 250, 10 μm; Mobile phase A: water (10 mmol / L NH4HCO3), Mobile phase B: ACN; Flow rate: 60 mL / min; Gradient: 2% B to 32% B over 10 min; Wavelength: 254 nm / 220 nm; RT1 (min): 7.47, 8.25 (min): , to obtain the crude product, which was then purified by chiral SFC under the following conditions (column: CHIRALPAKIG3; Mobile phase A: hexane (0.1% DEA): (MeOH: DCM = 1: 1) = 40: 60; Flow rate: 1 mL / min; Gradient: isocratic; Injection volume: 1 μ mL) to obtain 1-cyclopropyl-1-(3-((((8-methoxy-1,7-naphthidin-4-yl)oxy)methyl)phenyl)-N-methyl-λ6-thionediamine (6.3 mg, 7%) as a grayish-white solid. MS (ESI, positive ion) m / z: 383.0 (M+1). 1 H NMR (400 MHz, DMSO- d 6, ppm )δ 8.78 (d, J = 5.2 Hz, 1H), 8.13 -8.05 (m, 2H), 7.94 - 7.87 (m, 1H), 7.81 - 7.73 (m, 1H), 7.68 - 7.60 (m, 1H),7.54 (d, J = 5.6 Hz, 1H), 7.37 (d, J= 5.2 Hz, 1H), 5.52 (s, 2H), 4.05 (s, 3H), 2.77 - 2.67 (m, 1H), 2.47 (s, 3H), 2.37 (s, 1H), 1.26 - 1.14 (m, 1H), 0.96 -0.83 (m, 1H), 0.73 - 0.60 (m, 2H).
[0403] Biological examples Example 1 pNP-TMP hydrolysis was measured using ENPP1. p-Nitrophenylthymidine 5'-monophosphate (pNP-TMP) is the substrate for the synthesis of ENPP1. The ENPP1 enzyme activity assay using pNP-TMP as a substrate was performed as follows: First, 7.5 ng of purified ENPP1 was mixed with a compound of formula (I) (test compound) ranging from 13.7 pM to 10 μM in a 60 μl reaction mixture. The incubation of ENPP1 and the compound was set at 25 °C for 10 min. The reaction containing only DMSO (ENPP1 but no compound) yielded the fastest reaction (maximum activity). For each compound dilution, a control containing only assay buffer (50 mM Tris-HCl, pH 8.8, 250 mM NaCl, 0.1 mg / ml BSA, 1% DMSO) but without ENPP1 was used to subtract the absorbance produced by the test compound at 405 nm.
[0404] Next, after incubating ENPP1 and the test compound for 10 minutes, the assay was initiated by transferring 50 μl of the above ENPP1 / test compound reaction to 50 μl of 1 mM pNP-TMP in buffer, resulting in a total reaction of 100 μl in a clear-bottom 96-well plate. The absorbance at 405 nm was immediately recorded in kinetic mode using a PerkinElmer 2300 Enspire multimode plate reader.
[0405] For each inhibitor, the specific ENPP1 activity is calculated using the following equation: ENPP1 activity (pmol / min / µg) = Adjusted Vmax (OD405 nm / min) X Conversion factor (pmol / OD405 nm) / Enzyme amount (µg) The adjusted Vmax = V0 × (Km + (S)) / (S). In this measurement, Km = 232 µM, (S) = 500 µM. The adjusted Vmax = 1.464 × V0.
[0406] V0 = (OD405 nm with ENPP1 - OD405 nm with ENPP1 blank) / minutes. The initial linear rate is V0 when plotting OD405 nm relative to time (minutes) after removing the blank. The initial linear rate is V0 after removing the blank and plotting relative to time (minutes).
[0407] The conversion factor (pmol / OD405 nm) was determined by plotting the amount of the standard 4-nitrophenol (Sigma-Aldrich, catalog #241326) relative to the absorbance at 405 nm. The slope is the conversion factor. The percentage of ENPP1 activity for each sample was calculated using the following equation: Enzyme activity % = Sample enzyme activity / Maximum activity x 100%.
[0408] To determine the IC50 of each compound 50 Compound concentration values and enzyme activity percentage values were interpolated into GraphPad Prism (GraphPad Prism version 7.0 for Windows, GraphPad software, La Jolla, California, USA, www.graphpad.com), and Prism's transformation analysis was used to convert the x-axis values (compound concentrations) to logarithms. Inverted variable slope nonlinear regression analysis was performed using the following equation: Y = bottom + (top - bottom) / (1 + 10^(LogIC) 50 - X) Hill slope).
[0409] IC observed in GraphPad analysis 50 K was calculated for each compound using the Cheng-Prusoff equation. i Value: K i = IC 50 / (1+(S) / K M Here, (S) is 500 µM and K M It was determined to be 232 µM.
[0410] Table 2 below provides the Ki of representative compounds of formula (I) disclosed in Tables 1A and 1B above: Example 2 Measurement of ENPP1-catalyzed 2'3'-cGAMP hydrolysis ENPP1 catalyzes the hydrolysis of 2'3'-cGAMP to 5'-AMP and 5'-GMP, and therefore the enzyme activity of ENPP1 in the presence of 2'3'-cGAMP as a substrate is monitored by measuring the product 5'-AMP. The yield of 5'-AMP was measured using the AMP-Glo assay kit (catalog number V5012) from Promega.
[0411] First, ENPP1 and the test compounds were incubated in assay buffer (50 mM Tris-HCl, pH 8.8, 250 mM NaCl, 0.1 mg / ml BSA, 1% DMSO) under the following conditions: ENPP1 concentration: 1.25 nM; test compound concentration range: 68 pM to 20 μM. The incubation was performed at 25 °C for 10 min.
[0412] Next, after incubating ENPP1 and the test compound for 10 minutes, 15 µl of the substrate 2'3'-cGAMP was prepared in assay buffer at 200 µM on a separate plate. Then, 15 µl of the ENPP1 / compound incubation solution was transferred to 200 µM 2'3'-cGAMP solution to initiate the reaction. 30 µl of the mixture was incubated at 25 °C for 30 min. In all these assays, a DMSO control without the compound was included, which gave the maximum 5'-AMP yield (maximum RLU). After 30 min, the reaction was stopped by heating at 90 °C for 3 min.
[0413] Furthermore, the Promega AMP-Glo kit was used to detect 5'-AMP production as a measure of ENPP1 enzyme activity. For this purpose, 10 µl of the total 30 µl reaction solution for each sample was transferred to a 384-well white solid-bottom assay plate to measure 5'-AMP production. For each well, 10 μl of AMP Glo reagent I was added, thoroughly mixed, and incubated at 25°C for 1 h. Meanwhile, the AMP assay solution was prepared, and 20 μl was added to each well, and the resulting solution was incubated at 25°C for 1 h. Repeats were performed for each inhibitor concentration. The luminescence signal (relative luminescence units, RLU) was recorded using a PerkinElmer 2300 Enspire multimode plate reader.
[0414] The inhibition rate % is calculated using the following equation: Inhibition rate % = (Maximum RLU - Sample RLU) / Maximum RLU x 100%.
[0415] IC of the compound 50The values were determined by loading the compound concentration data and the percentage inhibition rate values into GraphPad Prism (GraphPad Prism version 7.0 for Windows, GraphPad Software, La Jolla, CA, www.graphpad.com) and fitting them with an sigmoid variable slope nonlinear regression.
[0416] Based on IC observed in GraphPad analysis 50 K was calculated for each compound using the Cheng-Prusoff equation. i Value: K i = IC 50 / (1+(S) / K M Here, (S) is 100 µM and K M It is 32 µM.
[0417] Examples of preparations The following are representative pharmaceutical formulations containing the compounds disclosed herein.
[0418] Tablet formulations Mix the following ingredients closely and compress them into single-score tablets.
[0419] Capsule formulations Mix the following ingredients closely and load them into hard-shell gelatin capsules.
[0420] Injectable formulations The disclosed compound (e.g., compound 1) in 2% HPMC, in 1% Tween 80 in DI water, pH 2.2 (using MSA), is supplemented to a minimum of 20 mg / mL.
[0421] Inhalation Composition To prepare a pharmaceutical composition for inhalation delivery, 20 mg of the compound disclosed herein was mixed with 50 mg of anhydrous citric acid and 100 mL of 0.9% sodium chloride solution. The mixture was then incorporated into an inhalation delivery unit (such as a nebulizer) suitable for inhalation administration.
[0422] Topical gel composition To prepare the pharmaceutically acceptable topical gel composition, 100 mg of the compound disclosed herein was mixed with 1.75 g hydroxypropyl cellulose, 10 mL propylene glycol, 10 mL isopropyl myristate, and 100 mL purified ethanol USP. The resulting gel mixture was then incorporated into a container (e.g., a tube) suitable for topical application.
[0423] Ophthalmic solution composition To prepare the pharmaceutical ophthalmic solution composition, 100 mg of the compound disclosed herein was mixed with 0.9 g NaCl in 100 mL of purified water and filtered using a 0.2-micron filter. The resulting isotonic solution was then incorporated into an ophthalmic delivery device (such as an eye drop container) suitable for ocular application.
[0424] Nasal spray solution To prepare the pharmaceutical nasal spray solution, 10 g of the compound disclosed herein was mixed with 30 mL of 0.05 M phosphate buffer solution (pH 4.4). The solution was placed in a nasal applicator designed to deliver 100 μL of spray per application.
Claims
1. A compound having formula (I), or a pharmaceutically acceptable salt thereof: (I) in: X is N, CH, or when attached to R 1 When, it is C; a, b, d, and e are each independently CH, or when attached to R. 4 R 5 or R 6 If any of the following is true, then it is C; or one or two of a, b, d, and e are N, and the remaining terms of a, b, d, and e are each independently CH, or when attached to R 4 R 5 or R 6 For any one of the options, it is C; Z represents a bond, NH, O, S, SO, or SO2; m and n are each 0 or 1 independently; alk is an alkylene group substituted with 0 to 3 halogroups; alk 1 It is an alkylene group, wherein one carbon atom in the alkylene chain is optionally replaced by oxygen, and further wherein the alkylene group is replaced by 0 to 3 halogroups; Ar is an arylene, heteroarylene, cycloalkyl, cyclic amino, fused cyclic amino, bridged cyclic amino, or spirocyclic cyclic amino. R 1 It does not exist; alkyl, alkoxy, halogroup, haloalkyl, haloalkoxy, amino, alkylamino, dialkylamino, hydroxyalkyl, alkoxyalkyl, hydroxyalkoxy, alkoxyalkoxy, hydroxyalkylamino, alkoxyalkylamino, aminoalkyl, aminoalkoxy, aminoalkylamino, diaminoalkyl, diaminoalkoxy, diaminoalkylamino, or cyano. R 2 and R 3 Each of the following is independent of the following: methyl, ethyl, methoxy, fluorine, trifluoromethyl, trifluoromethoxy, or cyano. R 4 R 5 and R 6 One of them is absent, alkyl, hydroxy, alkoxy, halogroup, haloalkyl, haloalkoxy, cyano, amino, alkylamino, dialkylamino, alkylsulfonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, carboxyl, or alkoxycarbonyl; and R 4 R 5 and R 6 The remaining two are independently absent: alkyl, alkoxy, hydroxy, halogroup, haloalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, hydroxyalkoxy, alkoxyalkoxy, hydroxyalkylamino, alkoxyalkylamino, aminoalkyl, aminoalkoxy, aminoalkylamino, heterocyclic, heterocyclic oxy, heterocyclic amino (wherein the heterocyclic group is substituted by 0 to 3 substituents alone or as part of the heterocyclic oxy and heterocyclic amino groups, each independently selected from alkyl, halogroup, hydroxy, alkoxy, hydroxyalkyl, alkoxyalkyl, and aminoalkyl). Heterocyclic alkyl, heterocyclic alkyloxy, heterocyclic alkylamino (wherein the heterocyclic ring in the heterocyclic alkyl, heterocyclic alkyloxy, and heterocyclic alkylamino is substituted by 0 to 3 substituents, each independently selected from alkyl, haloyl, hydroxy, alkoxy, hydroxyalkyl, alkoxyalkyl, and aminoalkyl), cycloalkyloxy, phenyloxy, or heteroaryloxy (wherein the phenyl in the phenyloxy and the heteroaryl in the heteroaryloxy are substituted by 0 to 3 substituents, each independently selected from alkyl, hydroxy, alkoxy, haloyl, haloalkyl, haloalkoxy, and cyano); R 7 It is an alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, aminocarbonylalkyl, carbonylaminoalkyl, carboxyaminoalkyl, cyanoalkyl, cycloalkyl, cycloalkylalkyl, aryl, fused aryl, heteroaryl, fused heteroaryl, heterocyclic, aralkyl, heteroarylalkyl, aryloxyalkyl, heteroaryloxyalkyl, fused arylalkyl, fused heteroarylalkyl, or heterocyclic alkyl, wherein the cyclic portion of the cycloalkyl, aryl, fused aryl, heteroaryl, fused heteroaryl, heterocyclic and cycloalkylalkyl, arylalkyl, heteroarylalkyl, aryloxyalkyl, heteroaryloxyalkyl, fused arylalkyl, fused heteroarylalkyl, or heterocyclic alkyl is substituted with one, two or three substituents, each independently selected from hydrogen, alkyl, haloalkyl, haloalkyl, haloalkoxy, hydroxyl, alkoxy, cyano, alkylcarbonyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocyclic; R 8 and R 9 Each is independently selected from hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, aminocarbonylalkyl, carbonylaminoalkyl, carboxyaminoalkyl, cyanoalkyl, cycloalkyl, cycloalkylalkyl, aryl, fused aryl, heteroaryl, fused heteroaryl, heterocyclic, aralkyl, heteroarylalkyl, aryloxyalkyl, heteroaryloxyalkyl, fused arylalkyl, fused heteroarylalkyl, or heterocyclic alkyl, wherein the cyclic portion of the cycloalkyl, aryl, fused aryl, heteroaryl, fused heteroaryl, heterocyclic and cycloalkylalkyl, arylalkyl, heteroarylalkyl, aryloxyalkyl, heteroaryloxyalkyl, fused arylalkyl, fused heteroarylalkyl, or heterocyclic alkyl is substituted with one, two or three substituents, each independently selected from hydrogen, alkyl, haloalkyl, haloalkyl, haloalkoxy, hydroxyl, alkoxy, cyano, alkylcarbonyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocyclic.
2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein, Z is a key.
3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein, Z can be NH, O, S, or SO2.
4. The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein, The compound having formula (I) is based on formula (Ia), (Ib), (Ic), (Id), (If), (Ig), or (Ih): In compounds having formulas (Ia) to (Id), Z is a bond, and in compounds having formulas (Ie) to (Ih), Z is NH, O, S, SO, or SO2.
5. The compound of any one of claims 1, 2 and 4, or a pharmaceutically acceptable salt thereof, wherein the compound has formula (Ia).
6. The compound of any one of claims 1, 2 and 4, or a pharmaceutically acceptable salt thereof, having formula (Ib).
7. The compound of any one of claims 1, 3 and 4, or a pharmaceutically acceptable salt thereof, having the formula (Ig).
8. The compound of any one of claims 1, 3, 4 and 7, or a pharmaceutically acceptable salt thereof, wherein, Z is O.
9. The compound of any one of claims 1, 3, 4 and 7, or a pharmaceutically acceptable salt thereof, wherein, Z stands for bond or O.
10. The compound of any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein, X is N.
11. The compound of any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein, X is CH, or when attached to R 1 At that time, it was C.
12. The compound of any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein, X is N or CH.
13. The compound of any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, wherein, a, b, d, and e are each independently CH, or when attached to R. 4 R 5 and R 6 For any of the options, it is C.
14. The compound of any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, wherein, d is N and a, b, and e are each independently CH, or when attached to R 4 R 5 and R 6 For any of the options, it is C.
15. The compound of any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, wherein, a is CH; b is CH, or when attached to R 4 R 5 or R 6 For any one of the options, it is C; d is N, or when attached to R 4 R 5 or R 6 For any one of them, it is C; and e is N, CH, or when attached to R 4 R 5 or R 6 For any of the options, it is C.
16. The compound of any one of claims 1, 2, 3 and 8 to 15, or a pharmaceutically acceptable salt thereof, wherein, n and m are 0.
17. The compound of any one of claims 1, 2, 3 and 8 to 15, or a pharmaceutically acceptable salt thereof, wherein, n is 1 and m is 0.
18. The compound of any one of claims 1 to 15 and 17, or a pharmaceutically acceptable salt thereof, wherein, alk and / or alk 1 When present, each is independently selected from methylene, ethylene, or propylene.
19. The compound of any one of claims 1 to 15 and 17, or a pharmaceutically acceptable salt thereof, wherein, alk and / or alk 1 When present, each is independently selected from methylene.
20. The compound of any one of claims 1 to 15 and 17, or a pharmaceutically acceptable salt thereof, wherein, alk and / or alk 1 When present, each is an alkylene group independently.
21. The compound of any one of claims 1 to 15 and 17, or a pharmaceutically acceptable salt thereof, wherein, alk, when present, is methylene.
22. The compound of any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, wherein, alk 1 When present, it is either methylene or ethylene.
23. The compound of any one of claims 1 to 22, or a pharmaceutically acceptable salt thereof, wherein, Ar is a phenylene or a 5- or 6-membered heteroaryl group, with each ring being R 2 and R 3 replace.
24. The compound of any one of claims 1 to 23, or a pharmaceutically acceptable salt thereof, wherein, Ar was R 2 and R 3 Substituted phenylene.
25. The compound of any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof, wherein, -(alk 1 ) m -S(=NR 8 (=NR) 9 )R 7 The carbon attached to the phenylene ring is located at the meta position of the carbon that attaches the phenylene ring to the remaining portion of the compound having formulas (I) and (Ia) to (Ih).
26. The compound of any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof, wherein, -(alk 1 ) m -S(=NR 8 (=NR) 9 )R 7 The carbon attached to the phenylene ring is located at the para position of the carbon that attaches the phenylene ring to the remaining portion of the compound having formulas (I) and (Ia) to (Ih).
27. The compound of any one of claims 1 to 19, or a pharmaceutically acceptable salt thereof, wherein, Ar is a cyclic amino group, a spirocyclic cyclic amino group, or a bridged cyclic amino group, and each ring is divided by R. 2 and R 3 replace.
28. The compound of any one of claims 1 to 22 and 27, or a pharmaceutically acceptable salt thereof, wherein, Ar is a cyclic amino group selected from divalent pyrrolidine, piperidine, or homopiperidine, each ring being R 2 and R 3 replace.
29. The compound of any one of claims 1 to 22 and 27, or a pharmaceutically acceptable salt thereof, wherein, Ar is a spirocyclic cyclic amino group or a bridged cyclic amino group, and each ring is divided by R. 2 and R 3 replace.
30. The compound of any one of claims 1 to 22 and 27 to 29, or a pharmaceutically acceptable salt thereof, wherein, The cyclic amino group, spirocyclic cyclic amino group, and bridging cyclic amino group are selected from: Each ring is R 2 and R 3 Replace, and among them Is with -(alk) 1 ) m -S(=NR 8 (=NR) 9 )R 7 The attachment point, and It is the attachment point with the rest of the compound having formulas (I) to (Ih).
31. The compound of any one of claims 1 to 22, or a pharmaceutically acceptable salt thereof, wherein, Ar is an arylene, a cyclic amino group, or a spirocyclic cyclic amino group, and each ring is divided by R. 2 and R 3 replace.
32. The compound of any one of claims 1 to 22 and 32, or a pharmaceutically acceptable salt thereof, wherein, Ar is Each ring is R 2 and R 3 Replace, and among them Is with -(alk) 1 ) m -S(=NR 8 (=NR) 9 )R 7 The attachment point, and It is the attachment point to the rest of the compound having formulas (I) to (Ih).
33. The compound of any one of claims 1 to 32, or a pharmaceutically acceptable salt thereof, wherein, R 1 It does not exist; it is an alkyl, alkoxy, halogroup, haloalkyl, or haloalkoxy group.
34. The compound of any one of claims 1 to 33, or a pharmaceutically acceptable salt thereof, wherein, R 1 It does not exist.
35. The compound of any one of claims 1 to 34, or a pharmaceutically acceptable salt thereof, wherein, R 2 and R 3 Each of these groups is independent of the following: methyl, methoxy, fluorine, trifluoromethyl, trifluoromethoxy, or cyano.
36. The compound of any one of claims 1 to 35, or a pharmaceutically acceptable salt thereof, wherein, R 2 and R 3 It does not exist.
37. The compound of any one of claims 1 to 34, or a pharmaceutically acceptable salt thereof, wherein, R 2 and R 3 They do not exist independently, or they are fluorine.
38. The compound of any one of claims 1 to 37, or a pharmaceutically acceptable salt thereof, wherein, R 4 It does not exist; it is alkyl, alkoxy, alkylsulfonyl, halogroup, haloalkyl, haloalkoxy, cyano, carboxyl, alkoxycarbonyl, hydroxyl, aminocarbonyl, alkylaminocarbonyl, or dialkylaminocarbonyl.
39. The compound of any one of claims 1 to 38, or a pharmaceutically acceptable salt thereof, wherein, R 4 It does not exist; it is methyl, methoxy, ethoxy, fluorine, chlorine, trifluoromethyl, hydroxy, cyano, or trifluoromethyloxy.
40. The compound of any one of claims 1 to 39, or a pharmaceutically acceptable salt thereof, wherein, R 4 It does not exist; it is either methoxy or ethoxy.
41. The compound of any one of claims 1 to 40, or a pharmaceutically acceptable salt thereof, wherein, R 4 It is methoxy or ethoxy.
42. The compound of any one of claims 1 to 38, or a pharmaceutically acceptable salt thereof, wherein, R 4 It is an alkoxy or haloalkoxy group.
43. The compound of any one of claims 1 to 38 and 42, or a pharmaceutically acceptable salt thereof, wherein, R 4 It is methoxy or fluoromethoxy.
44. The compound of any one of claims 1 to 43, or a pharmaceutically acceptable salt thereof, wherein, R 4 Attach a six-membered ring containing a, b, d, and e of formulas (I) to (Ih) to any of the carbons shown in formulas (a) to (c): The wavy lines represent the attachment points to the rest of the molecule.
45. The compound of any one of claims 1 to 44, or a pharmaceutically acceptable salt thereof, wherein, R 5 and R 6 It does not exist.
46. The compound of any one of claims 1 to 44, or a pharmaceutically acceptable salt thereof, wherein, R 5 and R 6 Each of the following is independent of the following: alkyl, alkoxy, hydroxy, amino, halogenated, haloalkyl, or haloalkoxy.
47. The compound of any one of claims 1 to 44 and 46, or a pharmaceutically acceptable salt thereof, wherein, R 5 and R 6 Each of the following is independent of the following: methyl, methoxy, ethoxy, propoxy, hydroxy, fluorine, difluoromethyl, trifluoromethyl, difluoromethoxy, or trifluoromethoxy.
48. The compound of any one of claims 1 to 44, 46 and 47, or a pharmaceutically acceptable salt thereof, wherein, R 5 and R 6 Each of these is independent of the following: methyl, methoxy, ethoxy, hydroxy, fluorine, difluoromethoxy, or trifluoromethoxy.
49. The compound of any one of claims 1 to 44 and 46 to 48, or a pharmaceutically acceptable salt thereof, wherein, R 5 and R 6 Each of these substances, independently, does not exist; they are methoxy, ethoxy, propoxy, or fluorine.
50. The compound of any one of claims 1 to 44 and 46 to 49, or a pharmaceutically acceptable salt thereof, wherein, R 5 and R 6 Each of these is independent of the following: alkoxy, halogenated, or haloalkoxy groups.
51. The compound of any one of claims 1 to 44 and 46 to 50, or a pharmaceutically acceptable salt thereof, wherein, R 5 and R 6 Each of these is independent of the presence of methoxy, fluorine, or fluoromethoxy.
52. The compound of any one of claims 1 to 40, 50 and 51, or a pharmaceutically acceptable salt thereof, wherein, R 5 and R 6 As shown below, attach to the six-membered ring containing a, b, d, and e of equations I to (Ih). The wavy lines represent the attachment points to the rest of the molecule.
53. The compound of any one of claims 1 to 52, or a pharmaceutically acceptable salt thereof, wherein, R 7 It is an alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, aminocarbonylalkyl, carbonylaminoalkyl, cyanoalkyl, cycloalkyl, cycloalkylalkyl, aryl, fused aryl, heteroaryl, fused heteroaryl, heterocyclic, aralkyl, heteroarylalkyl, aryloxyalkyl, heteroaryloxyalkyl, fused aralkyl, fused heteroarylalkyl, or heterocyclic alkyl, wherein the cyclic portion of the cycloalkyl, aryl, fused aryl, heteroaryl, fused heteroaryl, heterocyclic, and cycloalkylalkyl, arylalkyl, heteroarylalkyl, aryloxyalkyl, heteroaryloxyalkyl, fused aralkyl, fused heteroarylalkyl, or heterocyclic alkyl is substituted with one, two, or three substituents, each independently selected from hydrogen, alkyl, haloalkyl, haloalkyl, haloalkoxy, hydroxyl, alkoxy, cyano, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocyclic; and R 8 and R 9 Each of the following is independently selected from hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, aminocarbonylalkyl, carbonylaminoalkyl, carboxyaminoalkyl, cyanoalkyl, cycloalkyl, cycloalkylalkyl, aryl, fused aryl, heteroaryl, fused heteroaryl, heterocyclic, aralkyl, heteroarylalkyl, aryloxyalkyl, heteroaryloxyalkyl, fused arylalkyl, fused heteroarylalkyl, or heterocyclic alkyl, wherein the cyclic portion of the cycloalkyl, aryl, fused aryl, heteroaryl, fused heteroaryl, heterocyclic, and cycloalkylalkyl, arylalkyl, heteroarylalkyl, aryloxyalkyl, heteroaryloxyalkyl, fused arylalkyl, fused heteroarylalkyl, or heterocyclic alkyl is substituted with one, two, or three substituents, each independently selected from hydrogen, alkyl, haloalkyl, haloalkyl, haloalkoxy, hydroxyl, alkoxy, cyano, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocyclic.
54. The compound of any one of claims 1 to 52, or a pharmaceutically acceptable salt thereof, wherein, R 7 It is an alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, aminocarbonylalkyl, carbonylaminoalkyl, carboxyaminoalkyl, cyanoalkyl, cycloalkyl, cycloalkylalkyl, aryl, fused aryl, heteroaryl, fused heteroaryl, heterocyclic, aralkyl, heteroarylalkyl, aryloxyalkyl, heteroaryloxyalkyl, fused aralkyl, fused heteroarylalkyl, or heterocyclic alkyl, wherein the cyclic portion of the cycloalkyl, aryl, fused aryl, heteroaryl, fused heteroaryl, heterocyclic, and cycloalkylalkyl, arylalkyl, heteroarylalkyl, aryloxyalkyl, heteroaryloxyalkyl, fused aralkyl, fused heteroarylalkyl, or heterocyclic alkyl is substituted with one, two, or three substituents, each independently selected from hydrogen, alkyl, haloyl, haloalkyl, haloalkoxy, hydroxy, alkoxy, cyano, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocyclic, and R 8 and R 9 It is hydrogen.
55. The compound of any one of claims 1 to 52, or a pharmaceutically acceptable salt thereof, wherein, R 7 and R 8 Each of the following groups is independently alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, aminocarbonylalkyl, carbonylaminoalkyl, carboxyaminoalkyl, cyanoalkyl, cycloalkyl, cycloalkylalkyl, aryl, fused aryl, heteroaryl, fused heteroaryl, heterocyclic, aralkyl, heteroarylalkyl, aryloxyalkyl, heteroaryloxyalkyl, fused aralkyl, fused heteroarylalkyl, or heterocyclic alkyl, wherein the cyclic portion of the cycloalkyl, aryl, fused aryl, heteroaryl, fused heteroaryl, heterocyclic, and cycloalkylalkyl, arylalkyl, heteroarylalkyl, aryloxyalkyl, heteroaryloxyalkyl, fused aralkyl, fused heteroarylalkyl, or heterocyclic alkyl is substituted with one, two, or three substituents, each independently selected from hydrogen, alkyl, haloalkyl, haloalkyl, haloalkoxy, hydroxy, alkoxy, cyano, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocyclic, and R 9 It is hydrogen.
56. The compound of any one of claims 1 to 52, or a pharmaceutically acceptable salt thereof, wherein, R 7 R 8 and R 9 Each is independently an alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, aminocarbonylalkyl, carbonylaminoalkyl, carboxyaminoalkyl, cyanoalkyl, cycloalkyl, cycloalkylalkyl, aryl, fused aryl, heteroaryl, fused heteroaryl, heterocyclic, aralkyl, heteroarylalkyl, aryloxyalkyl, heteroaryloxyalkyl, fused arylalkyl, fused heteroarylalkyl, or heterocyclic alkyl, wherein the cyclic portion of the cycloalkyl, aryl, fused aryl, heteroaryl, fused heteroaryl, heterocyclic, and cycloalkylalkyl, arylalkyl, heteroarylalkyl, aryloxyalkyl, heteroaryloxyalkyl, fused arylalkyl, fused heteroarylalkyl, or heterocyclic alkyl is substituted with one, two, or three substituents, each independently selected from hydrogen, alkyl, haloalkyl, haloalkyl, haloalkoxy, hydroxyl, alkoxy, cyano, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocyclic.
57. The compound of any one of claims 1 to 52, or a pharmaceutically acceptable salt thereof, wherein, R 7 It is an alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, cycloalkyl, cycloalkylalkyl, or heterocyclic group, wherein the cycloalkyl and heterocyclic groups are substituted by one, two, or three substituents, each independently selected from hydrogen, alkyl, haloyl, haloalkyl, haloalkoxy, hydroxyl, alkoxy, cyano, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocyclic group.
58. The compound of any one of claims 1 to 57, or a pharmaceutically acceptable salt thereof, wherein, Unless otherwise stated, R 8 and R 9 Each is independently hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocyclic, aralkyl, heteroaryl, aryloxyalkyl, heteroaryloxyalkyl, or heterocyclic alkyl, wherein the cyclic portion of the cycloalkyl, aryl, heteroaryl, heterocyclic and cycloalkylalkyl, arylalkyl, heteroarylalkyl, aryloxyalkyl, heteroaryloxyalkyl, or heterocyclic alkyl is substituted with one, two or three substituents, each independently selected from hydrogen, alkyl, haloyl, haloalkyl, haloalkoxy, hydroxyl, alkoxy, cyano, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocyclic.
59. The compound of any one of claims 1 to 57, or a pharmaceutically acceptable salt thereof, wherein, Unless otherwise stated, R 7 It includes methyl, ethyl, cyclopropyl, cyclopropylmethyl, 1-cyclopropylethyl, 1-hydroxycyclopropyl-1-ylmethyl, 3,3-difluorobutylmethyl, cyclobutylmethyl, -CH2CH2NH2, -CH2CH2NH(COCH3), -CH2CH2NH(COphenyl), 2,2,2-trifluoroethyl, 2-hydroxyethyl, 2-hydroxy-2-methylpropyl, 2,3-dihydroxypropyl, 1-hydroxymethylethyl, 2-hydroxymethyl, 2-hydroxypropyl, carboxymethyl, morpholino-4-yl, Pyrroloalkyl-1-methyl, phenyl, phenylmethyl, 2-phenylethyl, 1-phenylethyl, 2-phenoxyethyl, 4-pyridin-4-ylphenylmethyl, 4-pyridin-4-ylphenyl, 2-oxazol-2-ylmethyl, 2-thiazol-2-ylmethyl, 1-methylimidazol-2-ylmethyl, pyridin-2-ylmethyl, pyridin-3-ylmethyl, pyridin-4-ylmethyl, 2-pyridin-2-yloxyethyl, 2-pyridin-3-yloxyethyl, or 2-pyridin-4-yloxyethyl, and R 8 and R 9 Each of these components independently is hydrogen, methyl, ethyl, cyclopropyl, cyclopropylmethyl, 1-cyclopropylethyl, 1-hydroxycyclopropyl-1-ylmethyl, 3,3-difluorobutylmethyl, cyclobutylmethyl, -CH2CH2NH2, -CH2CH2NH(COCH3), -CH2CH2NH(COphenyl), 2,22-trifluoroethyl, 2-hydroxyethyl, 2-hydroxy-2-methylpropyl, 2,3-dihydroxypropyl, 1-hydroxymethylethyl, 2-hydroxymethyl, 2-hydroxypropyl, carboxymethyl, morpholine- 4-yl, pyrrolyl-1-methyl, phenyl, phenylmethyl, 2-phenylethyl, 1-phenylethyl, 2-phenoxyethyl, 4-pyridin-4-ylphenylmethyl, 4-pyridin-4-ylphenyl, 2-oxazol-2-ylmethyl, 2-thiazol-2-ylmethyl, 1-methylimidazol-2-ylmethyl, pyridin-2-ylmethyl, pyridin-3-ylmethyl, pyridin-4-ylmethyl, 2-pyridin-2-yloxyethyl, 2-pyridin-3-yloxyethyl, or 2-pyridin-4-yloxyethyl.
60. The compound of any one of claims 1 to 59, or a pharmaceutically acceptable salt thereof, wherein, R 7 It is an alkyl group.
61. The compound of any one of claims 1 to 59, or a pharmaceutically acceptable salt thereof, wherein, R 7 It is hydroxyalkyl, aminoalkyl, or alkoxyalkyl.
62. The compound of any one of claims 1 to 59, or a pharmaceutically acceptable salt thereof, wherein, R 7 It is a haloalkyl group.
63. The compound of any one of claims 1 to 59, or a pharmaceutically acceptable salt thereof, wherein, R 7 It is cycloalkyl or cycloalkylalkyl.
64. The compound of any one of claims 1 to 59, or a pharmaceutically acceptable salt thereof, wherein, R 7 It is a heterocyclic group substituted with 0 to 3 substituents.
65. The compound of any one of claims 1 to 59, or a pharmaceutically acceptable salt thereof, wherein, R 7 It is an alkyl or cycloalkyl group.
66. The compound of any one of claims 1 to 59, or a pharmaceutically acceptable salt thereof, wherein, R 7 It is methyl or cyclopropyl.
67. The compound of any one of claims 1 to 53 and 57 to 66, or a pharmaceutically acceptable salt thereof, wherein, R 8 and R 9 Each is either hydrogen or alkyl.
68. The compound of any one of claims 1 to 53, 57, 58 and 60 to 67, or a pharmaceutically acceptable salt thereof, wherein, R 8 and R 9 Each can be hydrogen, methyl, ethyl, or isopropyl.
69. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein, X is N or CH; a is CH; b is CH, or when attached to R 4 R 5 or R 6 For any one of the options, it is C; d is N, or when attached to R 4 R 5 or R 6 For any one of the options, it is C; e is N, CH, or when attached to R 4 R 5 or R 6 For any one of the options, it is C; Z represents a bond or an O; m and n are each independently 0 or 1; alk is an alkylene group; alk 1 It is an alkylene group; Ar is an arylene, a cyclic amino group, or a spirocyclic cyclic amino group, and each ring is divided by R. 2 and R 3 replace; R 1 It does not exist; R 2 and R 3 They do not exist independently, or are fluorine; R 4 R 5 and R 6 One of them is an alkoxy or a haloalkoxy; and R 4 R 5 and R 6 The remaining two are independently absent: alkoxy, halogroup, or haloalkoxy. R 7 It is an alkyl or cycloalkyl group; and R 8 and R 9 Each is either hydrogen or alkyl.
70. The compound of claim 1 or 69, or a pharmaceutically acceptable salt thereof, wherein, X is N or CH; a is CH; b is CH, or when attached to R 4 R 5 or R 6 For any one of the options, it is C; d is N, or when attached to R 4 R 5 or R 6 For any one of the options, it is C; e is N, CH, or when attached to R 4 R 5 or R 6 For any one of the options, it is C; Z represents a bond or an O; m and n are each 0 or 1 independently; alk is methylene; alk 1 It is methylene or ethylene; Ar is Each ring is R 2 and R 3 Replace, and among them Is with -(alk) 1 ) m -S(=NR 8 (=NR) 9 )R 7 The attachment point, and It is the attachment point to the rest of the compound having formula (I); R 1 It does not exist; R 2 and R 3 They do not exist independently, or are fluorine; R 4 R 5 and R 6 One of them is methoxy or fluoromethoxy; and R 4 R 5 and R 6 The remaining two are independently non-existent: methoxy, fluorine, or fluoromethoxy. R 7 It is methyl or cyclopropyl; and R 8 and R 9 Each can be hydrogen, methyl, ethyl, or isopropyl.
71. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from Tables 1A and 1B.
72. A pharmaceutical composition comprising the compound as described in any one of claims 1 to 71 and a pharmaceutically acceptable excipient.
73. A method of treating a patient with an ENPP1-mediated disease or condition, the method comprising administering to the patient a therapeutically effective amount of the compound as claimed in any one of claims 1 to 71, or the pharmaceutical composition as claimed in claim 72, optionally together with at least one other anticancer agent.
74. The method of claim 73, wherein, The disease or condition is cancer, an inflammatory disease, a metabolic disease, or a viral disease.
75. The method of claim 73 or 74, wherein, The disease or condition is cancer.
76. The method of claim 75, wherein, The disease or condition is cancer, specifically hepatocellular carcinoma, glioblastoma, melanoma, testicular cancer, pancreatic cancer, thyroid cancer, or breast cancer.
Citation Information
Patent Citations
Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US4107288A
Surface modified drug nanoparticles
US5145684A
